# EDGAR Filing Document

**Accession Number:** 0001610590
**File Stem:** 0001213900-26-010363
**Filing Date:** 2026-1
**Character Count:** 280456
**Document Hash:** 3a21108f7710b9cf2d50b7d8d817a607
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-010363.hdr.sgml**: 20260130

**ACCESSION NUMBER**: 0001213900-26-010363

**CONFORMED SUBMISSION TYPE**: F-1

**PUBLIC DOCUMENT COUNT**: 26

**FILED AS OF DATE**: 20260130

**DATE AS OF CHANGE**: 20260130

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Check-Cap Ltd
- **CENTRAL INDEX KEY:** 0001610590
- **STANDARD INDUSTRIAL CLASSIFICATION:** X-RAY APPARATUS & TUBES & RELATED IRRADIATION APPARATUS [3844]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** L3

**FILING VALUES:**
- **FORM TYPE:** F-1
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-293109
- **FILM NUMBER:** 26584665

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** ABBA HUSHI AVENUE
- **STREET 2:** P.O. BOX 1271
- **CITY:** ISFIYA
- **NON US STATE TERRITORY:** ISRAEL
- **PROVINCE COUNTRY:** L3
- **ZIP:** 000000
- **BUSINESS PHONE:** 972-4-8303400

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** ABBA HUSHI AVENUE
- **STREET 2:** P.O. BOX 1271
- **CITY:** ISFIYA
- **NON US STATE TERRITORY:** ISRAEL
- **PROVINCE COUNTRY:** L3
- **ZIP:** 000000

#### As filed with the Securities and Exchange Commission on January 30, 2026

#### Registration No. 333-

#### UNITED STATES<br>SECURITIES AND EXCHANGE COMMISSION<br> Washington, D.C. 20549
____________________

#### Form F-1<br> REGISTRATION STATEMENT <br>UNDER <br>THE SECURITIES ACT OF 1933
____________________

#### CHECK-CAP LTD. <br> (Exact name of registrant as specified in its charter)
____________________

---

| | | |
|:---|:---|:---|
|  **Israel** | **3844** | **Not Applicable** |
|  *(State or other jurisdiction of<br>incorporation or organization)* | *(Primary Standard Industrial<br>Classification Code Number)* | *(I.R.S. Employer<br>Identification Number)* |

---

---

| | |
|:---|:---|
|  **29 Abba Hushi Avenue<br>P.O. Box 1271<br>Isfiya, 3009000 Mount Carmel, Israel<br>Tel: +1 (647) 892-9516** | **Puglisi & Associates<br>850 Library Ave., Suite 204<br>Newark, DE 19711<br>Tel: (302) 738-6680** |
|  *(Address, including zip code, and telephone number,<br>including area code, of Registrant's principal executive offices)* | *(Name, address, including zip code, and telephone number,<br>including area code, of agent for service)* |

---

#### ____________________

#### Copies to:

---

| | |
|:---|:---|
|  **Sean M. Donahue<br>Paul Hastings LLP<br>2050 M St NW<br>Washington, DC 20036<br>Tel: (202) 551**-1704 | **Carl M. Sherer**<br> **RIMÔN PC**<br> **400 Madison Ave, Suite 11D<br>New York, NY 10017**<br> **Tel:** (**800) 930**-7271 |

---

#### ____________________
**Approximate date of commencement of proposed sale to the public:** As soon as practicable after the effective date hereof.

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. ☒

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933.

Emerging growth company ☐

If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards † provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

____________

† The term "new or revised financial accounting standard" refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012.

**The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the registration statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine.**

------

[**Table of Contents**](#TOC001)

**The information in this prospectus is not complete and may be changed. The Selling Shareholder may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.**

---

| | | |
|:---|:---|:---|
|  **PRELIMINARY PROSPECTUS** | **SUBJECT TO COMPLETION** | **DATED JANUARY 30, 2026** |

---

#### Up to 2,267,857 Ordinary Shares
![](tcheckcap_logo.jpg)

#### Check-Cap Ltd.
This prospectus relates to the offer and sale, from time to time, by ARC Group International Ltd. ("ARC Group" or the "Selling Shareholder"), of ordinary shares, par value NIS 48.00 per share (the "Ordinary Shares), of Check-Cap Ltd. ("Check-Cap" or the "Company") consisting of (i) Ordinary Shares that may be issued by the Company from time to time pursuant to advances (the "Advance Shares") under a purchase agreement, dated December 17, 2025 (the "Purchase Agreement"), by and between the Company and the Selling Shareholder, and (ii) the Commitment Fee Shares (defined below) issued to the Selling Shareholder by the Company pursuant to the Purchase Agreement.

Pursuant to the Purchase Agreement, the Company has the right, but not the obligation, to sell and issue to the Selling Shareholder up to $30.0 million of Ordinary Shares over a three-year period (the "Total Commitment Amount"), subject to the terms and conditions of the Purchase Agreement, applicable securities laws, and Nasdaq listing rules.

As consideration for the Selling Shareholder's Total Commitment Amount, the Company issued to the Selling Shareholder 267,857 Ordinary Shares (the "Commitment Fee Shares") upon the signing of the Purchase Agreement. The Commitment Fee Shares have an aggregate dollar value equal to 1.5% of the Total Commitment Amount, calculated using the lowest one-day volume-weighted average price ("VWAP") of the Ordinary Shares during the five trading days immediately preceding the execution date of the Purchase Agreement. No cash consideration was paid by the Selling Shareholder for the Commitment Fee Shares.

For the purposes of this prospectus, we are registering for resale a total of 2,267,857 Ordinary Shares, which includes (i) 2,000,000 Ordinary Shares at an assumed offering price of $1.89 per Ordinary Share, which was the closing price of the Ordinary Shares on The Nasdaq Capital Market ("Nasdaq") on January 29, 2026, and (ii) all of the Commitment Fee Shares.

Pursuant to the Purchase Agreement, we may request advances in a written notice, (each an "Advance Notice") delivered to the Selling Shareholder at any time during the three-year period following the execution date of the Purchase Agreement. Each Advance Notice directs the Selling Shareholder to purchase Ordinary Shares in an amount up to the lesser of (i) 75% of the average of the daily value traded of the Ordinary Shares on the ten trading days immediately preceding the date an Advance Notice is delivered, and (ii) $5.0 million, or an Advance, subject to satisfaction of the conditions in the Purchase Agreement.

The Advance Shares that may be offered pursuant to this prospectus would be purchased by the Selling Shareholder from time to time at a purchase price equal to 95% of the lowest closing VWAP of the Ordinary Shares during the pricing period specified in the Purchase Agreement following delivery of an Advance Notice and are subject to certain limitations. While any Advance is pending, subject to the Terms of the Purchase Agreement, we may deliver a second Advance Notice specifying a number of Ordinary Shares mutually agreed upon which will begin another Advance. The purchase price of the Ordinary Shares in such Advance will be equal to 100% of the lowest intraday sale price of the Ordinary Shares on the same day the second Advance Notice is received, or the immediately following trading day if the second Advance Notice is received after 8:30 am Eastern Time, subject to mutual consent between the Selling Shareholder and us.

Any sale of Ordinary Shares pursuant to the Purchase Agreement is subject to certain limitations, including that the Selling Shareholder is not permitted to purchase any Ordinary Shares that would result in the Selling Shareholder and its affiliates owning more than 9.99% of the then outstanding Ordinary Shares. In addition, the aggregate number of Ordinary Shares that we can issue to the Selling Shareholder under the Purchase Agreement may in no case exceed 19.99% of the Ordinary Shares outstanding as of the date of the Purchase Agreement (the "Exchange Cap"), unless and until (i) the Company obtains the requisite shareholder approval to issue Advance Shares above the Exchange Cap, or

------

[**Table of Contents**](#TOC001)

(ii) Nasdaq grants an exception to permit Ordinary Shares to be sold in excess of the Exchange Cap pursuant to Nasdaq Listing Rule 5635(f) without shareholder approval. Given that the Company as a foreign private issuer follows home country practice, the Exchange Cap does not apply because there is no requisite shareholder approval required.

The Ordinary Shares being offered by the Selling Shareholder pursuant to this prospectus may be issued pursuant to the Purchase Agreement. We are not selling any securities under this prospectus and will not receive any of the proceeds from the sale of our Ordinary Shares by the Selling Shareholder. However, we may receive up to $30.0 million in aggregate gross proceeds from sales of our Ordinary Shares to the Selling Shareholder that we may make under the Purchase Agreement, from time to time after the date of this prospectus.

The Selling Shareholder may sell the Ordinary Shares included in this prospectus in a number of different ways and at varying prices. We provide more information about how the Selling Shareholder may sell the shares in the section entitled "*Plan of Distribution*." The Selling Shareholder is an "underwriter" within the meaning of Section 2(a)(11) of the Securities Act of 1933, as amended, (the "Securities Act").

The Selling Shareholder will pay all brokerage fees and commissions and similar expenses in connection with the offer and sale of the Ordinary Shares by the Selling Shareholder pursuant to this prospectus. We have paid the Selling Shareholder's legal fees in an amount of $50,000 related to the offer and sale of such Ordinary Shares.

Our Ordinary Shares are listed on Nasdaq under the symbol "MBAI." On January 29, 2026, the last reported sale price of our Ordinary Shares on Nasdaq was $1.89 per share.

**Investing in our securities involves risk. See "Risk Factors" beginning on page 6 of this prospectus and "Item 3. — Key Information — D. Risk Factors" in our Annual Report on Form 20-F for the year ended December 31, 2024, or the 2024 Annual Report, incorporated by reference in this prospectus for a discussion of the factors you should consider carefully before deciding to purchase these securities.**

**Neither the SEC nor any state or other foreign securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.**

The date of this prospectus is , 2026

------

[**Table of Contents**](#TOC001)

#### **TABLE OF CONTENTS**

---

| | |
|:---|:---|
|  | **Page** |
|  [Prospectus Summary](#T13) | 1 |
|  [The Offering](#T12) | 5 |
|  [Risk Factors](#T11) | 6 |
|  [Cautionary Note Regarding Forward-Looking Statements](#T10) | 13 |
|  [Use of Proceeds](#T9) | 15 |
|  [Selling Shareholder](#T8) | 16 |
|  [Description of Share Capital](#T99502) | 17 |
|  [Plan of Distribution](#T7) | 23 |
|  [Expenses](#T6) | 25 |
|  [Legal Matters](#T5) | 26 |
|  [Experts](#T4) | 26 |
|  [Enforceability of Civil Liabilities](#T3) | 27 |
|  [Where You Can Find Additional Information](#T2) | 28 |
|  [Incorporation of Certain Information by Reference](#T1) | 29 |
|  [Part II Information Not Required in Prospectus](#T14) | II-1 |

---

You should rely only on the information contained in this prospectus, including information incorporated by reference herein, and any free writing prospectus prepared by or on behalf of us or to which we have referred you. Neither we nor the Selling Shareholder have authorized anyone to provide you with information that is different. The Selling Shareholder is offering to sell the securities, and seeking offers to buy the securities, only in jurisdictions where offers and sales are permitted. The information in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or any sale of the securities.

For investors outside of the United States: Neither we nor the Selling Shareholder have done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. You are required to inform yourselves about and to observe any restrictions relating to this offering and the distribution of this prospectus.

In this prospectus, "we," "us," "our," the "Company" and "Check-Cap" refer to Check-Cap Ltd. and its consolidated subsidiaries.

All trademarks or trade names referred to in this prospectus are the property of their respective owners. Solely for convenience, the trademarks and trade names in this prospectus are referred to without the<sup>®</sup> and<sup>™</sup> symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.

Our reporting currency and functional currency is the U.S. dollar. Unless otherwise expressly stated or the context otherwise requires, references in this prospectus to "NIS" are to New Israeli Shekels, and references to "dollars" or "$" mean U.S. dollars.

This prospectus includes statistical, market and industry data and forecasts which we obtained from publicly available information and independent industry publications and reports that we believe to be reliable sources. These publicly available industry publications and reports generally state that they obtain their information from sources that they believe to be reliable, but they do not guarantee the accuracy or completeness of the information.

i

[**Table of Contents**](#TOC001)

#### Prospectus Summary
*This summary highlights information contained elsewhere in this prospectus. This summary does not contain all of the information you should consider before investing in our Ordinary Shares. Before you decide to invest in our Ordinary Shares, you should read the entire prospectus carefully, including the "Risk Factors" section, and the financial statements and related notes thereto and the other information incorporated by reference herein.*

#### The Company
Check-Cap is a clinical stage medical diagnostics company with a limited operating history. On June 6, 2023, the Company announced that after further review of additional data and interaction with the Food and Drug Administration on a revised pivotal study protocol together with the anticipated time and investment necessary to further develop the technology, Check-Cap was reducing its workforce significantly to reduce cash burn, concentrating its resources on essential research activities, discontinuing its calibration studies, and evaluating and pursuing strategic options. As a result of its evaluation and pursuit of strategic options, on August 16, 2023, the Company entered into a business combination agreement (the "Keystone BCA"), with Keystone Dental Holdings, Inc. ("Keystone"), Capstone Dental PubCo, Inc ("PubCo"), and other direct, wholly owned subsidiaries of PubCo. At the Company's 2023 annual general meeting of shareholders, such business combination transactions did not receive the requisite majority required for approval under Section 320 of the Israeli Companies Law 5759-1999. On December 24, 2023, the Company received a notice on behalf of Keystone, terminating the Keystone BCA in light of the results. On March 25, 2024, the Company entered into a business combination agreement with Apollo Technology Capital Corporation (formerly known as Nobul AI Corp. ("Nobul"), a private Ontario corporation) (the "Nobul BCA"). On September 12, 2025, the Company entered into an Agreement and Plan of Merger (the "Merger Agreement", and such transaction the "Merger"), with MBody AI Corp, a Nevada corporation, ("MBody AI"), and CC Merger Sub Inc., a Nevada corporation and a direct, wholly owned subsidiary of Check-Cap (the "Merger Sub"). At the annual general meeting of shareholders of the Company held on November 14, 2025, the Company's shareholders approved, among other things, the Merger Agreement and the Merger. The Merger is expected to consummate in the first half of 2026; however, the timing of the completion of the Merger is subject to various conditions and uncertainties, including the availability of sufficient capital to satisfy Nasdaq listing requirements and the completion of regulatory and exchange review processes, and there can be no assurance that the Merger will be completed within this timeframe or at all. Upon the closing of the Merger, Merger Sub will merge with and into MBody AI, with MBody AI surviving as a wholly-owned subsidiary of Check-Cap. Immediately after the Merger, former MBody AI equityholders are expected to own approximately 90% of the issued and outstanding Ordinary Shares of the combined company on a fully diluted basis, and former Check-Cap equityholders are expected to own approximately 10% of the issued and outstanding Ordinary Shares of the combined company on a fully diluted basis. The combined company will change its name from "Check-Cap Ltd." to "MBody AI Ltd." On December 1, 2025, the Company changed its ticker symbol from "CHEK" to "MBAI" effective at the opening of trading on December 2, 2025.

At the effective time of the closing of the Merger, the Nobul BCA will be terminated by mutual consent of the parties such that no termination fee will be due to Nobul or the Company, so long as the Company continues to be open to future integration with Nobul. Upon the closing of the Merger, the loans made by the Company to Nobul that are currently outstanding will be converted into a 7.5% equity position in Nobul that will be owned by the Company, and each of the related loan agreements between the Company and Nobul will be cancelled for no further consideration.

#### Purchase Agreement with the Selling Shareholder
On December 17, 2025, the Company entered into the Purchase Agreement with the Selling Shareholder. Pursuant to the Purchase Agreement, the Company has the right, but not the obligation, to sell and issue to the Selling Shareholder up to $30.0 million of its Ordinary Shares over a three-year period, subject to the terms and conditions of the Purchase Agreement. As consideration for the Selling Shareholder's purchase commitment, the Company agreed to issue Commitment Fee Shares having an aggregate value equal to 1.5% of the Total Commitment Amount.

Any sale of Ordinary Shares pursuant to the Purchase Agreement is subject to certain limitations, including that the Selling Shareholder is not permitted to purchase any Ordinary Shares that would result in it and its affiliates owning more than 9.99% of the then outstanding Ordinary Shares. In addition, the aggregate number of Ordinary Shares that the Company may issue under the Purchase Agreement may not exceed 19.99% of the Ordinary Shares outstanding

[**Table of Contents**](#TOC001)

as of the date of the Purchase Agreement unless the requisite stockholder approval is obtained or Nasdaq grants an exception pursuant to Nasdaq Listing Rule 5635(f). Given that the Company as a foreign private issuer follows the home country practice and rules, the Exchange Cap does not apply because there is no requisite shareholder approval required.

Pursuant to the Purchase Agreement, the Company may deliver Advance Notices to the Selling Shareholder from time to time during the three-year term, subject to specified conditions. The purchase price for Ordinary Shares issued pursuant to an Advance Notice is determined based on a discount to the market price of the Ordinary Shares as provided in the Purchase Agreement, and the Company may, in certain circumstances, deliver a second Advance Notice during an ongoing Advance.

Pursuant to the Purchase Agreement, the Company is required to register for resale the Ordinary Shares that may be sold under the Purchase Agreement and the Commitment Fee Shares. The Company may not request any Advances under the Purchase Agreement unless and until the registration statement of which this prospectus forms a part is declared effective by the SEC.

#### The Merger Agreement and the Merger
On September 12, 2025, the Company entered into the Merger Agreement with MBody AI and Merger Sub. At the annual general meeting of shareholders of the Company held on November 14, 2025, the Company's shareholders approved, among other things, the Merger Agreement and the Merger. The Merger is expected to consummate in the first half of 2026. Upon the closing of the Merger, Merger Sub will merge with and into MBody AI, with MBody AI surviving as a wholly-owned subsidiary of Check-Cap. Immediately after the Merger, former MBody AI equityholders will own 90% of the issued and outstanding Ordinary Shares of the combined company on a fully diluted basis, and former Check-Cap equityholders will own 10% of the issued and outstanding Ordinary Shares of the combined company on a fully diluted basis. The combined company will change its name from "Check-Cap Ltd." to "MBody AI Ltd." Upon the closing of the Merger, the Nobul BCA will be terminated, and the loans made by Check-Cap to Nobul that are outstanding will convert into a 7.5% equity position in Nobul that is owned by Check-Cap, and each of the related loan agreements between Check-Cap and Nobul will be cancelled for no further consideration.

Following and as a result of the Merger, certain business of the Company will be conducted through MBody AI. The Company expects that it will continue to conduct its legacy business as part of the combined company, that its legacy business will continue research and development activities, and that it will continue to hold the Company's legacy assets, consisting primarily of patents and proprietary medical equipment.

#### MBody AI's Business
*Overview*

MBody AI, incorporated in the State of Nevada in October 2024, is an artificial intelligence company focused on developing embodied AI software platforms designed to enable autonomous systems to operate and learn in real time. Rather than manufacturing robots, MBody AI develops a proprietary AI software stack intended to serve as the intelligence layer for robotic and autonomous systems deployed by third parties. MBody AI's initial commercial focus has been on the hospitality industry, with potential applications across other labor-intensive sectors, including warehousing, office management, and healthcare.

*Mission of MBody AI that Drives Transformation*

MBody AI's mission is to simplify the adoption of embodied AI technologies by developing software platforms designed to enable autonomous systems to operate with increasing levels of intelligence over time. The Company's platform is designed to incorporate adaptive learning capabilities intended to improve operational efficiency and effectiveness while reducing the need for ongoing human supervision. MBody AI's deployments are intended to generate operational data that may be used to further refine and enhance the performance of its platform over time.

[**Table of Contents**](#TOC001)

*Proprietary AI Stack*

MBody AI's platform is designed as a full-stack embodied AI software system that integrates multiple functional components intended to support autonomous operation and fleet-level coordination. The platform includes the following primary modules:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Perception AI, which is designed to enable machines to interpret and understand their operating environments through technologies such as semantic mapping, sensor integration, and situational awareness;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Cognitive AI, which is designed to support decision-making and coordination across fleets of autonomous systems by allocating tasks and managing operations based on real-time inputs; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Learning AI, which is designed to analyze operational data over time to support ongoing refinement and improvement of system performance.

MBody AI's platform is designed to be hardware-agnostic, enabling integration with a range of third-party robotic and autonomous systems. The platform is designed to include features such as real-time management of heterogeneous robotic fleets, a unified control environment and user interface, customized fleet-level reporting, and proprietary AI-based analytics tools that are intended to analyze real-time operational data and generate insights to support operational decision-making. Certain features of the platform are in various stages of development and may be refined or modified over time.

*Competitive Ecosystem*

MBody AI's development and commercialization efforts are supported by an ecosystem of technology development, customer deployments, and operational feedback. As part of these efforts, MBody AI has filed provisional patent applications covering aspects of navigation, predictive maintenance, fleet optimization, and safety. MBody AI has also entered into commercial arrangements with two Fortune 500 hospitality companies and other enterprise customers. In addition, MBody AI collaborates with deployment partners to conduct operational testing of its platform in live environments, which is intended to inform ongoing development and refinement of its software

*Business Model*

MBody AI operates an AI-as-a-Service business model, generating revenue primarily through recurring subscription arrangements related to the deployment and use of its software platform, rather than through one-time hardware sales. MBody AI has entered into agreements with multiple enterprise customers, and its future revenues are expected to depend on the scope and duration of customer deployments and adoption of its platform.

*Market Opportunities*

MBody AI believes that the increasing adoption of artificial intelligence and automation technologies across labor-intensive industries reflects a significant market opportunity for embodied AI solutions. Many organizations continue to face rising labor costs, workforce availability challenges, and operational complexity across distributed physical environments, driving demand for technologies that can improve consistency, efficiency, and scalability.

MBody AI's software platform is designed to address these challenges by enabling autonomous systems to be deployed and managed across a range of environments without requiring customers to commit to a single hardware provider. The Company believes that embodied AI solutions have potential applications across multiple large and diverse industries, including hospitality, warehousing, office facilities, and healthcare, and that adoption of such technologies remains at an early stage in many markets.

MBody AI is focused on developing and commercializing embodied AI software platforms designed to support the deployment and management of autonomous systems across physical environments. Following the completion of the Merger, the combined company intends to continue advancing MBody AI's platform while leveraging its existing public company infrastructure to support future development and commercialization efforts. The Company believes that continued innovation in artificial intelligence and automation technologies is expected to influence a wide range of industries over time, and MBody AI intends to participate in this evolving market through the expansion of its software platform and customer deployments.

[**Table of Contents**](#TOC001)

***Company Information***

Check-Cap's legal and commercial name is Check-Cap Ltd. Check-Cap was formed as a company in Israel on April 5, 2009. On May 31, 2009, Check-Cap acquired all of the business operations and substantially all of the assets of Check-Cap LLC, a Delaware limited liability company formed in December 2004. On February 24, 2015, the Company successfully completed an initial public offering in the United States and the listing of its securities on Nasdaq. The Ordinary Shares are listed on Nasdaq under the symbol "MBAI."

On May 15, 2015, the Company formed its wholly-owned subsidiary Check-Cap US, Inc., a Delaware corporation. On April 9, 2024, the Company formed its wholly-owned subsidiary Check-Cap Canada, Inc., an Ontario corporation. On September 9, 2025, the Company formed CC Merger Sub Inc., a Nevada corporation and a direct, wholly owned subsidiary of Check-Cap, in connection with the proposed Merger. On December 1, 2025, the Company changed its Nasdaq ticker symbol from "CHEK" to "MBAI", effective at the opening of trading on December 2, 2025.

The Company is subject to the provisions of the Israeli Companies Law. The Company's principal executive offices are located at Check-Cap Building, 29 Abba Hushi Avenue, P.O. Box 1271, Isfiya, 3009000, Israel. The Company's telephone number is +1 (647) 892-9516 and its website is www.check-cap.com (the information contained therein or linked thereto shall not be considered incorporated by reference in the registration statement of which this prospectus forms a part). The Company's U.S. agent is Puglisi & Associates, located at 850 Library Avenue, Suite 204, Newark, Delaware 19711.

[**Table of Contents**](#TOC001)

#### The Offering

---

| | |
|:---|:---|
|  Ordinary Shares currently outstanding | 7,288,359 Ordinary Shares. |
|  Ordinary Shares offered by the Selling Shareholder | <br>Up to 2,000,000 Ordinary Shares issuable to the Selling Shareholder under the Purchase Agreement from time to time and 267,857 Commitment Fee Shares. |
|  Ordinary Shares to be outstanding after this offering<sup>(1)</sup> | <br>9,288,359 Ordinary Shares, assuming the issuance of a total of 2,267,857 Ordinary Shares to the Selling Shareholder pursuant to the Purchase Agreement (at an assumed price per share of $1.89, which is the last reported sales price of our Ordinary Shares on Nasdaq on January 29, 2026). |
|  Use of proceeds | We will not receive any proceeds from the sale of the Ordinary Shares included in this prospectus by the Selling Shareholder. We may receive up to $30.0 million aggregate gross proceeds under the Purchase Agreement from sales of the Ordinary Shares that we elect to make to the Selling Shareholder pursuant to the Purchase Agreement, if any, from time to time in our sole discretion, The actual amount of proceeds, if any, that we may receive will depend on the number of Ordinary Shares sold under the Purchase Agreement to the Selling Shareholder and market prices at the times of such sales. Any proceeds that we receive from sales of our Ordinary Shares to the Selling Shareholder under the Purchase Agreement will be used for working capital and other general corporate purposes. See "*Use of Proceeds*." |
|  Risk factors | Investing in our securities involves a high degree of risk. You should read the "*Risk Factors*" section starting on page 6 of this prospectus, and "Item 3. — Key Information — D. Risk Factors" in our Annual Report on Form 20-F for the year ended December 31, 2024, or the 2024 Annual Report, which is incorporated by reference herein, and other information included or incorporated by reference in this prospectus for a discussion of factors to consider carefully before deciding to invest in the Ordinary Shares. |
|  Listing | Our Ordinary Shares are listed on Nasdaq under the symbol "MBAI." |

---

____________

(1) The number of the Ordinary Shares to be outstanding immediately after this offering as shown above assumes that all of the Ordinary Shares offered hereby are sold and is based on 7,288,359 Ordinary Shares outstanding as of January 29, 2026. This number excludes Ordinary Shares issuable upon the exercise of outstanding warrants, Ordinary Shares issuable upon the exercise of outstanding options granted under our option and equity incentive plans, and restricted stock units issued to employees, consultants and directors.

[**Table of Contents**](#TOC001)

#### Risk Factors
*Investing in our securities involves risks. Please carefully consider the risk factors described below and in our periodic reports filed with the SEC, including those set forth under the caption "Item 3. Key Information — D. Risk Factors" in our 2024 Annual Report, which is incorporated by reference in this prospectus. Before making an investment decision, you should carefully consider these risks as well as other information we include or incorporate by reference in this prospectus. You should be able to bear a complete loss of your investment.*

#### Risks Related to an Investment in Our Securities and this Offering
***It is not possible to predict the actual number of shares we will sell under the Purchase Agreement to the Selling Shareholder, or the actual gross proceeds resulting from those sales.***

On December 17, 2025, we entered into the Purchase Agreement with the Selling Shareholder, pursuant to which the Selling Shareholder has committed to purchase up to $30.0 million of our Ordinary Shares, subject to certain limitations and conditions set forth in the Purchase Agreement. The Ordinary Shares that may be issued under the Purchase Agreement may be sold by us to the Selling Shareholder at our discretion from time to time over a three-year period commencing on the date of the Purchase Agreement.

We generally have the right to control the timing and amount of any sales of our Ordinary Shares to the Selling Shareholder under the Purchase Agreement. Sales of our Ordinary Shares, if any, to the Selling Shareholder under the Purchase Agreement will depend upon market conditions and other factors. We may ultimately decide to sell to the Selling Shareholder all, some or none of the Ordinary Shares that may be available for us to sell to the Selling Shareholder pursuant to the Purchase Agreement.

Because the purchase price per share to be paid by the Selling Shareholder for the Ordinary Shares that we may elect to sell to the Selling Shareholder under the Purchase Agreement, if any, will fluctuate based on the market prices of Ordinary Shares during the applicable purchase valuation period for each purchase made pursuant to the Purchase Agreement, it is not possible for us to predict, as of the date of this prospectus and prior to any such sales, the total number of Ordinary Shares that we will sell to the Selling Shareholder under the Purchase Agreement, the purchase price per share that the Selling Shareholder will pay for shares purchased from us under the Purchase Agreement, or the aggregate gross proceeds that we will receive from those purchases by the Selling Shareholder under the Purchase Agreement.

Moreover, although the Purchase Agreement provides that we may sell up to an aggregate of $30.0 million of our Ordinary Shares to the Selling Shareholder, other than the Commitment Fee Shares, only an aggregate of 2,000,000 Ordinary Shares are being registered under this registration statement that we may elect to sell to the Selling Shareholder, in our sole discretion, from time to time from and after the date of, and pursuant to, the Purchase Agreement. Even if we elect to sell and issue to the Selling Shareholder all of the Ordinary Shares being registered for resale under this prospectus, depending on the market prices of our Ordinary Shares at the time of such sales, the actual gross proceeds from the sale of all such shares may be substantially less than the $30.0 million Total Commitment Amount under the Purchase Agreement, which could materially adversely affect our liquidity.

If we desire to issue and sell to the Selling Shareholder under the Purchase Agreement more than the 2,000,000 Ordinary Shares offered for resale under this prospectus, we would be required to file with the SEC one or more additional registration statements to register under the Securities Act, the resale by the Selling Shareholder of any such additional Ordinary Shares and such registration statement or statements must be effective before we could sell additional shares.

Any issuance and sale by us under the Purchase Agreement of a substantial number of Ordinary Shares in addition to the Ordinary Shares being registered for resale by the Selling Shareholder under this prospectus could cause additional substantial dilution to our shareholders. The number of Ordinary Shares ultimately offered for sale by the Selling Shareholder is dependent upon the number of Ordinary Shares, if any, we ultimately sell to the Selling Shareholder under the Purchase Agreement.

Further, the resale by the Selling Shareholder of a significant number of shares registered for resale in this offering at any given time, or the perception that these sales may occur, could cause the market price of our Ordinary Shares to decline and to be highly volatile.

[**Table of Contents**](#TOC001)

#### Investors who buy shares at different times will likely pay different prices.
Pursuant to the Purchase Agreement, we will have discretion, subject to market demand, to vary the timing, prices, and numbers of shares sold to the Selling Shareholder. If and when we do elect to sell Ordinary Shares to the Selling Shareholder pursuant to the Purchase Agreement, the Selling Shareholder may resell all, some or none of such shares at any time or from time to time in its discretion and at different prices. As a result, investors who purchase shares from the Selling Shareholder in this offering at different times will likely pay different prices for those shares, and therefore, may experience different levels of dilution and in some cases substantial dilution and different outcomes in their investment results. In addition, investors may experience a decline in the value of the shares they purchase from the Selling Shareholder in this offering as a result of future sales made by us to the Selling Shareholder at prices lower than the prices such investors paid for their shares in this offering.

#### We may require additional financing to sustain our operations, and such financing may not be available on acceptable terms, or at all.
The extent to which we rely on the Selling Shareholder as a source of funding will depend on a number of factors, including the prevailing market price of our Ordinary Shares, our ability to meet the conditions necessary to deliver Advance Notices under the Purchase Agreement and the extent to which we are able to secure funding from other sources. Regardless of the amount of funds we ultimately raise under the Purchase Agreement, if any, we may continue to seek other sources of funding. Even if we were to sell to the Selling Shareholder the total commitment of $30.0 million under the Purchase Agreement, we may still need additional capital to fully implement our business plan. There can be no assurance that additional financing will be available on acceptable terms, or at all, and any inability to obtain such financing could materially adversely affect our business, financial condition, and results of operations.

***Future sales and issuances of our Ordinary Shares or other securities might result in significant dilution and could cause the price of our Ordinary Shares to decline.***

To raise capital, including pursuant to the Purchase Agreement, we may sell Ordinary Shares, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. We may sell shares or other securities in any other offering at a price per share that is less than the price per share paid by investors in this offering, and investors purchasing shares or other securities in the future could have rights superior to existing shareholders. The price per share at which we sell additional Ordinary Shares, or securities convertible or exchangeable into Ordinary Shares, in future transactions may be higher or lower than the price per share paid by investors in this offering. Any sales of additional shares will dilute our shareholders.

Sales of a substantial number of Ordinary Shares in the public market or the perception that these sales might occur could depress the market price of our Ordinary Shares and could impair our ability to raise capital through the sale of additional equity securities. We are unable to predict the effect that sales may have on the prevailing market price of our Ordinary Shares. In addition, the sale of substantial numbers of our Ordinary Shares could adversely impact their price.

***Management will have broad discretion as to the use of the proceeds from the Purchase Agreement and such uses may not improve our financial condition or market value.***

Because we have not designated the amount of net proceeds from the Purchase Agreement to be used for any specific purpose, our management will have broad discretion as to the application of such proceeds. We expect our management to use any proceeds received for working capital and other general corporate purposes; however, these uses may not improve our financial condition, results of operations, or market value, and may not advance our business objectives.

#### We undertake to seek shareholder approval to re-designate our Ordinary Shares as no-par value, and there can be no assurance that such re-designation will be completed.
The Ordinary Shares in this offering are non-assessable (except as such non-assessability may be affected by Section 181 of the Israeli Companies Law and by Articles 14 and 16 of our amended articles of association). Our Ordinary Shares currently have a nominal value of NIS 48.0 per share. Our board of directors undertakes that it will not seek to make calls on or forfeit the shares offered in this offering at any time if the nominal amount per share has not been paid. We also undertake to include on the agenda for our next annual general meeting of shareholders

[**Table of Contents**](#TOC001)

a proposal to amend our amended articles of association to re-designate the Ordinary Shares as no-par value shares, subject to applicable law and shareholder approval. Any delay or failure to complete the re-designation could limit our flexibility to issue Ordinary Shares, including under the Purchase Agreement, and could adversely affect our ability to raise capital.

#### Risks Related to the Ownership of our Ordinary Shares

#### We may be unable to maintain compliance with Nasdaq's continued listing requirements, which could result in the delisting of our Ordinary Shares from Nasdaq.
Nasdaq has established certain standards for the continued listing of a security on Nasdaq. On September 3, 2025, we received a deficiency letter from the Nasdaq Listing Qualifications Department notifying us that we were not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires us to maintain a minimum of $2,500,000 in shareholders' equity. The letter further stated that we had 45 calendar days, or by October 20, 2025, to submit a plan to regain compliance with respect to the deficiency identified in the letter. We submitted the plan on October 20, 2025. If Nasdaq accepts the plan, it may grant an extension of up to 180 calendar days from the date of the letter for us to evidence compliance. If Nasdaq does not accept the plan, we will have the opportunity to appeal the decision to a Nasdaq Hearings Panel.

There can be no assurance that Nasdaq will accept our plan, grant an extension, or that we will be able to regain or maintain compliance with Nasdaq's continued listing requirements in the future. If we are delisted from Nasdaq, our Ordinary Shares may be eligible for trading on an over-the-counter market in the United States. In the event that we are not able to obtain a listing on another U.S. stock exchange or quotation service for our Ordinary Shares, it may be extremely difficult or impossible for shareholders to sell their Ordinary Shares in the United States. Moreover, if we are delisted from Nasdaq, but obtain a substitute listing for our Ordinary Shares in the United States, it will likely be on a market with less liquidity, and therefore, experience potentially more price volatility than experienced on Nasdaq. Shareholders may not be able to sell their Ordinary Shares on any such substitute U.S. market in the quantities, at the times, or at the prices that could potentially be available on a more liquid trading market. As a result of these factors, if our Ordinary Shares are delisted from Nasdaq, the price of our Ordinary Shares is likely to decline. A delisting of our Ordinary Shares from Nasdaq could also adversely affect our ability to obtain financing for our operations and/or result in a loss of confidence by investors, or employees.

#### Risks Related to the Merger
***The issuance of Ordinary Shares in connection with the Merger will substantially dilute the relative voting power of shareholders of Check-Cap prior to the closing of the Merger, and, as a result, such shareholders prior to the closing of the Merger will exercise substantially less influence over the management of the Company following the consummation of the Merger.***

Following the closing of the Merger, shareholders of Check-Cap prior to the closing of the Merger, or the Previous Shareholders, are expected to own approximately 10% of the Company's outstanding share capital, on a fully diluted and as-converted basis, and the MBody AI shareholders are expected to own approximately 90% of the Company's outstanding share capital, on a fully-diluted and as-converted basis.

Accordingly, the issuance of Ordinary Shares to MBody AI's shareholders pursuant to the Merger Agreement will significantly reduce the relative voting power of each Ordinary Share held by the Previous Shareholders. Consequently, the Previous Shareholders exercise substantially less influence over the management and policies of the Company than they did prior to the consummation of the Merger.

#### The Company has incurred and expects to continue to incur substantial transaction-related costs in connection with the Merger.
The Company has incurred, and expects to continue to incur, a number of non-recurring transaction-related costs associated with the Merger and the related transactions, which cannot be accurately estimated at this time. These fees and costs have been, and will continue to be, substantial. Non-recurring transaction costs include, but are not limited to, fees paid to legal and other advisors, SEC filing costs and printing costs. Additional unanticipated costs may be incurred in the Company's business, which may be higher than expected and could have a material adverse effect on the Company's financial condition and operating results.

[**Table of Contents**](#TOC001)

#### The Company may fail to realize the anticipated benefits of the Merger.
The success of the Merger and the related transactions will depend on the Company's ability to achieve its business objectives and raise the necessary capital to fund its operations. If the Company is not able to achieve these objectives, the anticipated benefits of the Merger and the related transactions may not be realized fully, may take longer to realize than expected, or may not be realized at all.

***The Company may become involved in securities litigation or shareholder derivative litigation in connection with the Merger, and this could divert the attention of management and harm the Company's business.***

Securities litigation or shareholder derivative litigation frequently follows the announcement of certain significant business transactions. The Company may become involved in this type of litigation in connection with the Merger and is currently involved in shareholder derivative litigation relating to the Nobul BCA. Litigation often is expensive and diverts management's attention and resources, which could adversely affect the business of the Company.

#### Risks Related to MBody AI's Business and Operations

#### MBody AI has a limited operating history and an evolving business model, which makes it difficult to evaluate its future prospects.
MBody AI was incorporated in October 2024 and has a limited operating history as an embodied AI software and service company. As a result, there is limited historical information upon which investors can evaluate its business, operating results, or future prospects. MBody AI's business model, technology platform, and go-to-market strategy continue to evolve, and there can be no assurance that its current approach will result in sustainable growth or profitability.

***MBody AI currently relies on a limited number of customers, and the loss or reduction of business from any customer could materially adversely affect its results of operations.***

MBody AI currently derives a significant portion of its revenue from a small number of enterprise customers. While certain customer arrangements have multi-year terms, some customer agreements may be terminable under certain circumstances. The loss of a customer, a reduction in deployment scope, delays in implementation, or a failure to expand existing deployments could materially adversely affect MBody AI's revenue, operating results, and business prospects.

#### MBody AI's platform is deployed through a phased and evolving feature set, which may affect the timing and scope of customer adoption
MBody AI's platform is deployed through a staged rollout of features, with certain capabilities delivered incrementally or provided to customers through asynchronous analysis and reporting rather than fully integrated real-time operation. While this approach is intended to support ongoing refinement and optimization of the platform, there can be no assurance that all planned features will be completed on schedule, fully integrated, or deliver the anticipated operational benefits. Delays in development, integration challenges, or performance limitations could affect customer satisfaction, the pace of deployment expansion, or the renewal of customer arrangements. MBody AI relies in part on asynchronous deployment, data collection, and analysis, which in certain circumstances may limit customer adoption, expansion, or perceived value of the platform.

#### MBody AI's operations depend on third-party vendors, deployment partners, and hardware suppliers .
MBody AI does not manufacture robots or autonomous hardware and relies on third-party vendors, integrators, and partners for hardware procurement, deployment, financing, and maintenance. This comprehensive service model involves customized deployments and coordination with customer personnel. As a result, MBody AI's operations are subject to several material risks related to these third-party dependencies:

*Procurement and Inventory Risk:* MBody AI is responsible for the procurement of third-party hardware to fulfill turnkey customer orders. Any failure by its suppliers to deliver units on schedule, in sufficient quantities, or at anticipated price points could delay customer implementations, increase deployment costs, or impair our ability to meet its revenue targets.

[**Table of Contents**](#TOC001)

*Integration and Technical Compatibility:* MBody AI's proprietary AI Orchestrator™ must integrate with various types of third-party hardware to deliver a "unified command layer". Disruptions in technical relationships, changes to Original Equipment Manufacturer (OEM) firmware, or lack of access to critical APIs could cause service failures, limit platform functionality, or hinder its ability to coordinate heterogeneous robot fleets.

*Geopolitical and Supply Chain Sensitivity:* Certain components or systems may be sourced from vendors located outside the United States, including in jurisdictions subject to evolving trade policies, export controls, or geopolitical tensions. These factors could increase MBody AI's deployment costs, compress hardware margins, or result in supply chain delays that materially adversely affect its results of operations.

*Dependence on Financing and Maintenance Partners:* MBody AI's business involves complex implementation and ongoing operational support. MBody AI relies on third-party partners for hardware, parts and software updates. Any failure by these partners to perform could result in increased costs, contractual disputes, reputational harm, or reduced demand for MBody AI's offerings causing a material adverse effect on its business.

#### MBody AI's business involves complex implementation and service delivery, which may expose it to operational risks.
MBody AI's services often involve customized deployments across customer facilities, coordination with customer personnel, and ongoing operational support. These activities may involve unforeseen technical, logistical, or operational challenges. Failure to effectively manage deployments, services, or customer expectations could result in increased costs, contractual disputes, reputational harm, or reduced demand for MBody AI's offerings.

#### Customer Adoption, ROI, and Budget Cycles could adversely affect MBody AI's revenue, growth, and operating results.
Customer adoption, expansion, and renewal of MBody AI's platform may depend on customers achieving expected operational benefits and on customer budget cycles. MBody AI's customers may evaluate continued or expanded deployment of the Company's platform based on perceived operational savings, efficiency improvements, or return on investment. These evaluations may be influenced by customer-specific factors, including budget cycles, capital allocation priorities, labor conditions, macroeconomic factors, and internal approval processes. Even if customers are satisfied with MBody AI's platform, delays in expansion decisions, reductions in deployment scope, or changes in customer priorities could adversely affect MBody AI's revenue, growth, and operating results.

#### Dependence on Customer Facilities and Operating Environments could delay deployments, increase costs, or affect the performance or scalability of MBody AI's platform.
MBody AI's deployments depend on customer-controlled facilities and operating environments, which are outside of its control. MBody AI's platform is deployed within customer facilities and physical environments that are owned and operated by customers. Deployment timelines, system performance, and operational outcomes may be affected by factors outside of MBody AI's control, including facility layout, network infrastructure, physical access constraints, operational schedules, and coordination with customer personnel. Limitations or changes in customer-controlled environments could delay deployments, increase costs, or affect the performance or scalability of MBody AI's platform.

#### Integration with Third-Party Software and Systems could increase deployment costs, delay implementations, or reduce customer satisfaction.
MBody AI's platform may require integration with third-party software systems used by customers, which may present technical and operational challenges. Customer deployments of MBody AI's platform may require integration with third-party software systems, including facility management, scheduling, or reporting systems. Such integrations may involve technical complexity, reliance on third-party interfaces or application programming interfaces, and coordination with customer or third-party vendors. Changes to third-party systems, integration delays, or compatibility issues could increase deployment costs, delay implementations, or reduce customer satisfaction.

[**Table of Contents**](#TOC001)

#### Risks Related to MBody AI's Regulatory Matters

#### MBody AI operates in regulated environments and may be subject to regulatory requirements that could increase costs or limit growth.
MBody AI's customers operate in regulated industries, including hospitality, gaming, and potentially healthcare and data centres. In certain jurisdictions, deployment of autonomous systems may require regulatory approvals, licenses, or compliance with industry-specific rules, including gaming or safety regulations. Regulatory requirements may change over time, differ by jurisdiction, or impose additional compliance costs, which could adversely affect MBody AI's ability to deploy its platform or expand into new markets.

#### MBody AI may face liability or compliance exposure related to the operation of autonomous systems.
Although MBody AI does not manufacture hardware, it sells, procures, finances, and/or supports the deployment of third-party autonomous hardware in connection with its software platform. MBody AI's software influences the operation and coordination of autonomous systems deployed in customer environments, and its involvement in hardware procurement, deployment, or ongoing services may increase its exposure to claims, investigations, or regulatory scrutiny related to system performance, safety incidents, or operational failures, whether or not caused by its software. Such matters could result in litigation, regulatory action, reputational harm, or increased insurance, indemnification, or compliance costs.

#### The regulatory landscape for artificial intelligence, robotics, and autonomous systems is evolving and may adversely affect our business.
Laws and regulations governing artificial intelligence, robotics, and autonomous systems are evolving in the United States and internationally. New or modified requirements related to safety, accountability, transparency, data use, or deployment of AI-enabled systems could impose additional compliance obligations, restrict certain applications, or increase regulatory oversight. Because MBody AI's platform influences the operation and coordination of autonomous systems deployed in physical environments, regulatory changes may require modifications to its technology, deployment practices, or business model, increase operating costs, delay deployments, or limit market opportunities. Failure to comply with applicable or future regulations could result in fines, penalties, litigation, or reputational harm, any of which could materially adversely affect our business, financial condition, and results of operations.

#### Risks Related to MBody AI's Financing

#### MBody AI has a history of operating losses and may not achieve or sustain profitability.
MBody AI has incurred operating losses since inception and expects to continue to incur expenses as it grows its operations, develops its platform, and expands customer deployments. Although MBody AI may achieve profitability in future periods, there can be no assurance that it will do so or that profitability, if achieved, will be sustainable.

#### MBody AI will require additional capital to execute its business plan, and such capital may not be available on acceptable terms.
MBody AI expects to require additional financing to fund its operations, growth initiatives, and platform development. There can be no assurance that additional capital will be available when needed, on acceptable terms, or at all. Failure to obtain additional financing could materially adversely affect MBody AI's ability to continue operations or execute its business strategy.

#### Future financings may result in dilution and could adversely affect shareholders.
MBody AI may raise capital through equity issuances, convertible securities, debt financings, or other structured transactions. Such financings may result in significant dilution to existing shareholders, impose restrictive covenants, or grant preferential rights to new investors. Market conditions, stock price volatility, and Nasdaq compliance considerations may further limit financing alternatives.

[**Table of Contents**](#TOC001)

#### MBody AI's General Risk Factors

#### MBody AI operates in a rapidly evolving and competitive market.
The markets for artificial intelligence, automation, and autonomous systems are rapidly evolving and highly competitive. New technologies, business models, and competitors may emerge that could reduce demand for MBody AI's platform or render its offerings less competitive.

#### MBody AI's success depends on its ability to attract and retain key personnel.
MBody AI's future success depends on the continued services of its management team and technical personnel. Competition for qualified employees is intense, and the loss of key personnel or inability to attract additional talent could materially adversely affect its business.

***As a foreign private issuer, the combined company will be permitted to follow certain home country corporate governance practices instead of otherwise applicable Nasdaq requirements, which may result in less protection than is accorded to investors under rules applicable to domestic U.S. issuers.***

As a foreign private issuer, the combined company will be permitted to follow certain home country corporate governance practices instead of those otherwise required under the listing rules of the Nasdaq for domestic U.S. issuers. For instance, the combined company will be permitted to follow home country practice in Israel with regard to, among other things, director nomination procedures, the approval of compensation of officers and quorum requirements at general meetings of shareholders. In addition, the combined company will be permitted to follow home country practice instead of the listing rules of Nasdaq that would require the combined company to obtain shareholder approval for certain dilutive events, such as the establishment or amendment of certain equity based compensation plans, an issuance that will result in a change of control of the combined company, certain transactions other than a public offering involving issuances of a 20% or greater interest in the combined company, and certain acquisitions of the stock or assets of another company. Following home country governance practices as opposed to the requirements that would otherwise apply to a United States company listed on Nasdaq may provide less protection to investors than what is accorded to investors under the listing rules of the Nasdaq Stock Market applicable to domestic U.S. issuers.

[**Table of Contents**](#TOC001)

#### Cautionary Note Regarding Forward-Looking Statements
Some of the statements made under "Prospectus Summary," "Risk Factors," "Use of Proceeds," and elsewhere in this prospectus, including in our 2024 Annual Report, incorporated by reference herein, and other information included or incorporated by reference in this prospectus, constitute forward-looking statements. Forward-looking statements are often characterized by the use of forward-looking terminology such as "may," "will," "expect," "anticipate," "estimate," "continue," "believe," "should," "intend," "project" or other similar words, but are not the only way these statements are identified.

These forward-looking statements may include, but are not limited to, statements about the offer and sale of Ordinary Shares under the Purchase Agreement and expected benefits of the offering; our expectations, beliefs or intentions regarding, among other things, our belief with respect to the benefits of the Merger; our financial performance following the Merger; the timing of, and our ability to make, regulatory filings and obtain and maintain regulatory approvals; our intellectual property position; the degree of clinical utility of our products, particularly in specific patient populations; our ability to develop commercial functions; our results of operations; cash needs; financial condition, liquidity, prospects, growth and strategies; the industry in which we operate; and the trends that may affect the industry or us.

Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. We have based these forward-looking statements on assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate.

Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements include, among other things:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to recognize the anticipated benefits of the Merger;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to successfully integrate and operate the combined business following the Merger;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to execute MBody AI's business strategy, scale customer deployments, and expand adoption of its platform;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Our customers' demand for embodied AI solutions and our customers' ability to achieve expected operational benefits from MBody AI's platform;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the timing, development, integration, and performance of MBody AI's platform features and capabilities;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• MBody AI's reliance on third-party hardware vendors, software integrations, and deployment partners;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the performance of MBody AI's platform in customer-controlled environments and facilities;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• regulatory requirements applicable to autonomous systems, artificial intelligence, robotics, and customer operating environments;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• changes in laws, regulations, trade policies, tariffs, or geopolitical conditions affecting hardware procurement or deployments;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• MBody AI's liquidity, capital requirements, and ability to obtain additional financing on acceptable terms;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our failure to maintain compliance with Nasdaq continued listing requirements;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our history of losses;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• changes in personnel and availability of qualified personnel;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our needs for additional capital to fund our operations and our inability to obtain additional capital on acceptable terms, or at all;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to continue as a going concern;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the initiation, timing, progress and results of our clinical trials and other product development efforts;

[**Table of Contents**](#TOC001)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our reliance on one product;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the clinical development, commercialization and market acceptance of C-Scan;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to receive de novo classification or premarket approval and other regulatory approvals for C-Scan;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to successfully complete clinical trials and obtain desired performance.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our reliance on single-source suppliers;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to achieve an acceptable cost of goods;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our reliance on third parties, such as for purposes of our clinical trials and clinical development and the manufacturing, marketing and distribution of C-Scan;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to establish and maintain strategic partnerships and other corporate collaborations;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to achieve reimbursement and coverage from government and private third-party payors;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the implementation of our business model and strategic plans for our business;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the scope of protection we are able to establish and maintain for intellectual property rights covering C-Scan and our ability to operate our business without infringing the intellectual property rights of others;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• competitive companies, technologies and our industry;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• current or future adverse developments with respect to financial institutions and associated liquidity risk;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• unfavorable economic and market conditions, including uncertainties around the impact of inflation, cost of capital and the impact from the changes in economic policies and regulations, such as trade policies and tariffs and the recent U.S. federal government shutdown;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• those factors discussed in the section "*Risk Factors*" beginning on page 6 of this prospectus; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• those factors referred to in "Item 3. Key Information — D. Risk Factors," "Item 4. Information on the Company," and "Item 5. Operating and Financial Review and Prospects", as well as in the 2024 Annual Report generally.

These statements are only current predictions and are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from those anticipated by the forward-looking statements. We discuss many of these risks in "Item 3. — Key Information — D. Risk Factors" in our 2024 Annual Report and in this prospectus in greater detail under the heading "*Risk Factors*" on page 6 of the prospectus. You should not rely upon forward-looking statements as predictions of future events.

Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements. Except as required by law, we are under no duty to update or revise any of the forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this prospectus.

[**Table of Contents**](#TOC001)

#### Use of Proceeds
This prospectus relates to our Ordinary Shares that may be offered and sold from time to time by the Selling Shareholder. All of the Ordinary Shares offered by the Selling Shareholder pursuant to this prospectus will be sold by the Selling Shareholder for its own account. We will not receive any of the proceeds from the sale of Ordinary Shares by the Selling Shareholder.

We may receive up to $30.0 million aggregate gross proceeds under the Purchase Agreement from any sales we make to the Selling Shareholder pursuant to the Purchase Agreement.

We are unable to estimate the total amount of proceeds that we may receive, as it will depend on the number of shares that we choose to sell, our ability to meet the conditions to purchases set forth in the Purchase Agreement, market conditions and the price of our Ordinary Shares, among other factors.

We expect to use any proceeds that we receive under the Purchase Agreement for working capital and other general corporate purposes. As of the date of this prospectus, we cannot specify with certainty all of the particular uses, and the respective amounts we may allocate to those uses, for any net proceeds we receive. Accordingly, we will retain broad discretion over the use of these proceeds.

[**Table of Contents**](#TOC001)

#### Selling Shareholder
This prospectus relates to the possible resale from time to time by the Selling Shareholder of any or all of the Ordinary Shares that may be issued by us to the Selling Shareholder under the Purchase Agreement and the Commitment Fee Shares. For additional information regarding the issuance of Ordinary Shares covered by this prospectus, see the section titled "Prospectus Summary — Purchase Agreement with the Selling Shareholder" above. Except for the transactions contemplated by the Purchase Agreement, the Selling Shareholder does not, and has not had, any material relationship with us.

The table below presents information regarding the Selling Shareholder and the Ordinary Shares that it may offer from time to time under this prospectus. This table is prepared based on information supplied to us by the Selling Shareholder. The number of shares in the column "Maximum Number of Ordinary Shares to be Offered Pursuant to this Prospectus" represents all of the Ordinary Shares that the Selling Shareholder may offer under this prospectus. The Selling Shareholder may sell some, all or none of its shares in this offering. We do not know how long the Selling Shareholder will hold the shares before selling them, and we currently have no agreements, arrangements or understandings with the Selling Shareholder regarding the sale of any of the shares. The registration of these Ordinary Shares does not necessarily mean that the Selling Shareholder will sell any or all of the shares registered hereby.

Beneficial ownership is determined in accordance with Rule 13d-3(d) promulgated by the SEC under the Exchange Act and includes Ordinary Shares with respect to which the Selling Shareholder has voting and investment power. The percentage of Ordinary Shares beneficially owned by the Selling Shareholder prior to the offering shown in the table below is based on an aggregate of 7,288,359 of our Ordinary Shares outstanding on January 29, 2026. The number of shares that may actually be sold by us under the Purchase Agreement may be fewer than the number of shares being offered by this prospectus. The fourth column assumes the sale of all of the shares offered by the Selling Shareholder pursuant to this prospectus.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Number of Shares of<br> Ordinary Shares Owned<br> Prior to Offering** | **Number of Shares of<br> Ordinary Shares Owned<br> Prior to Offering** | **Maximum Number of<br>Ordinary Shares to be<br>Offered Pursuant<br>to this Prospectus** | **Number of Ordinary<br> Shares Owned After<br> Offering** | **Number of Ordinary<br> Shares Owned After<br> Offering** |
|  **Name of Selling Shareholder** | **Number<sup>(1)</sup>** | **Percent** | **Number** | **Number<sup>(2)</sup>** | **Percent** |
|  ARC Group International Ltd.<sup>(3)(4)</sup> | 267857 | 3.7% | 2267857 | 2267857 | 24% |

---

____________

(1) Includes the Commitment Shares, but excludes from the number of Ordinary Shares beneficially owned prior to the offering all of the Ordinary Shares that the Selling Shareholder may be required to purchase pursuant to a valid Advance Notice delivered to the Selling Shareholder under the Purchase Agreement, because the issuance of such shares is solely at our discretion and is subject to conditions contained in the Purchase Agreement, the satisfaction of which are entirely outside of the Selling Shareholder's control, including the registration statement that includes this prospectus becoming and remaining effective.

(2) Assumes the sale of all Ordinary Shares being offered pursuant to this prospectus. Depending on the price per share at which we sell our Ordinary Shares to the Selling Shareholder pursuant to the Purchase Agreement, we may need to sell to the Selling Shareholder under the Purchase Agreement more of our Ordinary Shares than are offered under this prospectus in order to receive aggregate gross proceeds equal to the $30.0 million total commitment under the Purchase Agreement. If we choose to do so and otherwise satisfy the conditions in the Purchase Agreement, we must first register for resale under the Securities Act such additional shares. The number of Ordinary Shares ultimately offered for resale by the Selling Shareholder is dependent upon the number of Ordinary Shares we sell to the Selling Shareholder under the Purchase Agreement.

(3) The business address of the Selling Shareholder International Ltd. is 10 East 53<sup>rd</sup> St, Suite 3001, New York, NY 10022.

(4) Pursuant to the Purchase Agreement, the Selling Shareholder is not permitted to purchase nor acquire Ordinary Shares of the Company under the Purchase Agreement that would result in it beneficially owning in excess of 9.99% of the Ordinary Shares outstanding then outstanding at the time of any proposed sale pursuant to the Purchase Agreement.

[**Table of Contents**](#TOC001)

#### Description of ORDINARY SHARES
*The following description is a summary of our amended articles of association and Israeli corporate law regarding our Ordinary Shares. The following description may not contain all of the information that is important to you, and we therefore refer you to our amended articles of association, a copy of which is filed with the SEC as an exhibit to the registration statement of which this prospectus is a part.*

#### General
Our authorized and registered share capital is NIS 864,000,000 divided into 18,000,000 Ordinary Shares of a nominal (par) value of NIS 48.0 each. As of January 29, 2026, an aggregate of 7,288,359 Ordinary Shares were issued and outstanding.

#### Memorandum and Articles of Association
*Registration Number and Purposes of the Company*

Our registration number with the Israeli Registrar of Companies is 51-425981-1. Our purpose as set forth in our amended articles of association is to engage in any lawful activity.

*Voting Rights*

All Ordinary Shares have identical voting and other rights in all respects.

*Transfer of Shares*

Our fully paid Ordinary Shares are issued in registered form and may be freely transferred under our amended articles of association, unless the transfer is restricted or prohibited by another instrument, applicable law or the rules of a stock exchange on which the shares are listed for trade. The Ordinary Shares in this offering are non-assessable (except as such non-assessability may be affected by Section 181 of the Israeli Companies Law and by Articles 14 and 16 of our amended articles of association). Our board of directors undertakes that it will not seek to make calls on or forfeit the shares offered hereby at any time if the nominal amount per share has not been paid. We also undertake to include on the agenda for our next annual general meeting of shareholders a proposal to amend our amended articles of association to re-designate the Ordinary Shares as no-par value shares, subject to applicable law and shareholder approval. The ownership or voting of our Ordinary Shares by non-residents of Israel is not restricted in any way by our amended articles of association or the laws of the State of Israel, except for ownership by nationals of some countries that are, or have been, in a state of war with Israel, according to applicable Israeli law's requirements.

Our board of directors may, to the extent it deems necessary in its discretion, close the register of shareholders of registration of transfers of shares for a period determined by the Board of Directors, and no registrations of transfers of shares shall be made by us during any such period during which the register of shareholders is so closed. We shall notify shareholders with respect to such suspension of registration in such manner as shall be determined by our Board of Directors.

*Election of Directors*

Under our amended articles of association, our board of directors must consist of not less than four but no more than eleven directors, including (if any) external directors (within the meaning of the Israeli Companies Law, 1999, or the "Israeli Companies Law"). Pursuant to our amended articles of association, each of our directors will be appointed by a simple majority vote of holders of our voting shares, participating and voting at an annual general meeting of our shareholders (subject to the special approval requirements under the Israeli Companies Law for the election of external directors, if any). Our Ordinary Shares do not have cumulative voting rights for the election of directors.

Each director (other than external directors, if any) will hold office until the next annual general meeting following the annual general meeting at which they were elected and until his or her successor is elected and qualified, or until the occurrence of certain events, in accordance with the Israeli Companies Law and our amended articles of association, including his or her earlier resignation, death or removal by a vote of the majority of the voting power of our shareholders at a general meeting or until his or her office expires by operation of law. In addition, our amended

[**Table of Contents**](#TOC001)

articles of association allow our board of directors to appoint directors (other than external directors) to fill vacancies on the board of directors to serve for a term of office equal to the remaining period of the term of office of the directors(s) whose office(s) have been vacated.

*Dividend and Liquidation Rights*

We may declare a dividend to be paid to the holders of our Ordinary Shares in proportion to their respective shareholdings. Under the Israeli Companies Law, dividend distributions are determined by the board of directors and do not require the approval of the shareholders of a company unless the company's articles of association provide otherwise. Our amended articles of association do not require shareholder approval of a dividend distribution and provide that dividend distributions may be determined by our board of directors.

Pursuant to the Israeli Companies Law, we may declare and pay dividends only if, upon the determination of our board of directors, there is no reasonable concern that the distribution will prevent us from being able to meet the terms of our existing and foreseeable obligations as they become due. Under the Israeli Companies Law, the distribution amount is further limited to the greater of retained earnings or earnings generated over the two most recent years legally available for distribution according to our then last reviewed or audited financial statements (less the amount of previously distributed dividends, if not reduced from the earnings), provided that the date of the financial statements is not more than six months prior to the date of distribution. In the event that we do not have retained earnings or earnings generated over the two most recent years legally available for distribution, we must seek the approval of the court in order to distribute a dividend. The court may approve our request if it is convinced that there is no reasonable concern that the payment of a dividend will prevent us from satisfying our existing and foreseeable obligations as they become due.

In the event of our liquidation, after satisfaction of liabilities to creditors, our assets will be distributed to the holders of our Ordinary Shares in proportion to the nominal value of their shareholdings. This right, as well as the right to receive dividends, may be affected by the grant of preferential dividend or distribution rights to the holders of a class of shares with preferential rights that may be authorized in the future.

*Exchange Controls*

There are currently no Israeli currency control restrictions on remittances of dividends on our Ordinary Shares, proceeds from the sale of the shares or interest or other payments to non-residents of Israel, except for shareholders who are subjects of countries that are, or have been, in a state of war with Israel.

*Shareholder Meetings*

Under Israeli law, we are required to hold an annual general meeting of our shareholders once every calendar year that must be held no later than 15 months after the date of the previous annual general meeting. All meetings other than the annual general meeting of shareholders are referred to in our amended articles of association as special general meetings. Our board of directors may call special general meetings whenever it sees fit, at such time and place, within or outside of Israel, as it may determine. In addition, the Israeli Companies Law provides that our board of directors is required to convene a special general meeting upon the written request of (i) any two of our directors or one-quarter of the serving members of our board of directors; or (ii) one or more shareholders holding, in the aggregate, either (a) 5% or more of our outstanding shares and 1% of our outstanding voting power or (b) 5% or more of our outstanding voting power.

Furthermore, the Israeli Companies Law requires that resolutions regarding the following matters be approved by our shareholders at a general meeting:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• amendments to our articles of association;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• appointment, terms of service and termination of service of our auditors;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• appointment of external directors;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• approval of certain related party transactions;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• increases or reductions of our authorized share capital;

[**Table of Contents**](#TOC001)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• mergers; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the exercise of our board of director's powers by a general meeting, if our board of directors is unable to exercise its powers and the exercise of any of its powers is essential for our proper management.

Subject to the provisions of the Israeli Companies Law and regulations promulgated thereunder, shareholders entitled to participate and vote at general meetings are the shareholders of record on a date to be decided by the board of directors, which, as a company listed on an exchange outside Israel, may be between four and 40 days prior to the date of the meeting.

The Israeli Companies Law requires that a notice of any annual general meeting or special general meeting be provided to shareholders at least 21 days prior to the meeting and if the agenda of the meeting includes, among other things, the appointment or removal of directors, the approval of transactions with office holders or interested or related parties, an approval of a merger or the approval of the compensation policy, notice must be provided at least 35 days prior to the meeting.

Under the Israeli Companies Law, our shareholders are not permitted to take action via written consent in lieu of a meeting.

*Voting rights*

#### Quorum Requirements
Pursuant to our amended articles of association, holders of our Ordinary Shares have one vote for each ordinary share held on all matters submitted to a vote before the shareholders at a general meeting. The quorum required for general meetings of our shareholders is at least two shareholders present in person, by proxy or written ballot, who hold or represent between them at least 25% of the total outstanding voting rights (or if a higher percentage is required by law, such higher percentage), within half an hour of the time fixed for the commencement of the meeting. A meeting adjourned for lack of a quorum is adjourned either to the same day in the following week at the same time and place or to such day, time and place as specified in the notice of the meeting or to such day, time and place as the chairman of the general meeting shall determine. At the reconvened meeting, at least two shareholders present in person or by proxy shall constitute a lawful quorum, unless the meeting of shareholders was convened at the demand of shareholders, in which case, the quorum shall be the presence of one or more shareholders holding at least 5% of our issued share capital and at least one percent of the voting power of our shares, or one or more shareholders with at least 5% of the voting power of our shares.

#### Vote Requirements
Our amended articles of association provide that all resolutions of our shareholders require a simple majority vote, unless otherwise required by the Israeli Companies Law or by our amended articles of association. Under the Israeli Companies Law, certain actions require a special majority, including: (i) approval of an extraordinary transaction with a controlling shareholder or in which the controlling shareholder has a personal interest and the terms of employment or other engagement of the controlling shareholder or a relative of the controlling shareholder (even if not extraordinary), requiring the approval described in Item 6C "Directors, Senior Management and Employees — Board Practices — Approval of Related Party Transactions under Israeli Law — Disclosure of Personal Interests of Controlling Shareholders and Approval of Certain Transactions" in the 2024 Annual Report; (ii) approval of a compensation policy, requiring the approval described in Item 6C "Directors, Senior Management and Employees — Board Practices — Compensation Committee and Compensation Policy" in the 2024 Annual Report; and (iii) approval of executive officer compensation inconsistent with our office holder compensation policy or the compensation of our chief executive officer (subject to limited exceptions), requiring the approval described in Item 6C "Directors, Senior Management and Employees — Board Practices — Approval of Related Party Transactions under Israeli Law — Disclosure of Personal Interests of an Office Holder and Approval of Certain Transactions" in the 2024 Annual Report.

In addition, under the Israeli Companies Law the appointment of external directors requires the approval of a majority vote of the shares present and voting on the matter, provided that either: (i) such majority includes a majority of the shares held by all shareholders who are non-controlling shareholders and shareholders who do not have a personal interest in the election of the external director (other than a personal interest not deriving from a relationship

[**Table of Contents**](#TOC001)

with a controlling shareholder) that are voted at the meeting, excluding abstentions; or (ii) the total number of shares held by shareholders who are non-controlling shareholders and shareholders who do not have a personal interest in the election of the external director (other than a personal interest not derived from a relationship with a controlling shareholder) voted against the election of the external director does not exceed 2% of the aggregate voting rights in the company.

Furthermore, under the Israeli Companies Law the authorization of the chairman of the board to assume the role or responsibilities of the chief executive officer, or the authorization of the chief executive officer or his or her relative thereof to assume the role or responsibilities of the chairman of the board, for periods of no longer than three years each, is subject to receipt of the approval of a majority of the shares voting on the matter, provided that either (i) included in such majority are at least two-thirds of the shares of shareholders who are non-controlling shareholders and shareholders who do not have a personal interest in the resolution that are voted at the meeting on the matter (excluding any abstentions); or (ii) the total number of shares of shareholders specified in clause (i) who voted against the resolution does not exceed 2% of the voting rights in the company.

Another exception to the simple majority vote requirement is a resolution for the voluntary winding up, or an approval of a scheme of arrangement or reorganization, of the company pursuant to Section 350 of the Israeli Companies Law, which requires the approval of holders of 75% of the voting rights represented at the meeting and voting on the resolution.

*Access to Corporate Records*

Under the Israeli Companies Law, shareholders are provided access to: minutes of the general meetings of our shareholders; our shareholders register and principal shareholders register, articles of association and financial statements; and any document that we are required by law to file publicly with the Israeli Companies Registrar or the Israel Securities Authority. In addition, shareholders may request to be provided with any document in the company's possession related to an action or transaction requiring shareholder approval under the related party transaction provisions of the Israeli Companies Law. We may deny this request if we believe it has not been made in good faith or if such denial is necessary to protect our interest or protect a trade secret or patent.

*Modification of Class Rights*

Under the Israeli Companies Law and our amended articles of association, the rights attached to any class of shares, such as voting, liquidation and dividend rights, may be modified or cancelled by adoption of a resolution by the holders of a majority of all shares as one class, without any required separate resolution of any class of shares, or otherwise in accordance with the rights attached to such class of shares, as set forth in our amended articles of association.

*Acquisitions under Israeli Law*

#### Full Tender Offer
A person wishing to acquire shares of an Israeli public company, and who would as a result hold over 90% of the target company's voting rights or issued and outstanding share capital or a certain class of shares of the company, is required by the Israeli Companies Law to make a tender offer to all of the company's shareholders (or all of the shareholders who hold shares of the relevant class , if applicable) for the purchase of all of the issued and outstanding shares of the company (or all of the issued and outstanding shares of that class, if applicable). If the shareholders who do not accept the offer hold less than 5% of the issued and outstanding share capital of the company or of the applicable class, and more than half of the shareholders who do not have a personal interest in the offer accept the offer, all of the shares that the acquirer offered to purchase will be transferred to the acquirer by operation of law. However, a tender offer will also be accepted if the shareholders who do not accept the offer hold less than 2% of the issued and outstanding share capital of the company or of the applicable class of shares.

Upon a successful completion of such a full tender offer, any shareholder that was an offeree in such tender offer, whether such shareholder accepted the tender offer or not, may, within six months from the date of acceptance of the tender offer, petition an Israeli court to determine whether the tender offer was for less than fair value and that

[**Table of Contents**](#TOC001)

the fair value should be paid as determined by the court. However, under certain conditions, the offeror may include in the terms of the tender offer that an offeree who accepted the offer will not be entitled to petition the Israeli court as described above.

If (a) the shareholders who did not respond or accept the tender offer hold at least 5% of the issued and outstanding share capital of the company, or of the applicable class, and/or the shareholders who accept the offer constitute less than a majority of the offerees that do not have a personal interest in the acceptance of the tender offer, or (b) the shareholders who did not accept the tender offer hold 2% or more of the issued and outstanding share capital of the company (or of the applicable class), the acquirer may not acquire shares of the company that will increase its holdings to more than 90% of the company's issued and outstanding share capital or of the applicable class from shareholders who accepted the tender offer.

#### Special Tender Offer
The Israeli Companies Law provides that an acquisition of shares of an Israeli public company must be made by means of a special tender offer if as a result of the acquisition the purchaser would become a holder of 25% or more of the voting rights in the company, if there is no other shareholder that holds 25% or more of the voting rights in the company, subject to exceptions. Similarly, the Israeli Companies Law provides that an acquisition of shares in an Israeli public company must be made by means of a special tender offer if as a result of the acquisition the purchaser would become a holder of more than 45% of the voting rights in the company, if there is no other shareholder of the company who holds more than 45% of the voting rights in the company, subject to certain exceptions. No tender offer is required if the acquisition of shares: (i) occurs in the context of a private placement, that was approved by the company's shareholders and whose purpose is to give the acquirer at least 25% of the voting rights in the company if there is no person who holds 25% or more of the voting rights in the company, or as a private placement whose purpose is to give the acquirer 45% of the voting rights in the company, if there is no person who holds 45% of the voting rights in the company; (ii) was from a holder of 25% or more of the voting rights in the company following which the purchaser will hold 25% or more of the voting rights in the company; or (iii) was from a holder of more than 45% of the voting rights in the company following which the purchaser will hold more than 45% of the voting rights in the company.

A special tender offer must be extended to all shareholders of a company (but the offeror is not required to purchase shares representing more than 5% of the voting power attached to the company's outstanding shares, regardless of how many shares are tendered by shareholders). A special tender offer may be consummated only if (i) at least 5% of the voting power attached to the company's outstanding shares will be acquired by the offeror; and (ii) the number of shares tendered in the offer exceeds the number of shares whose holders objected to the offer (excluding the purchaser, its controlling shareholders, holders of 25% or more of the voting rights in the company or any person having a personal interest in the acceptance of the tender offer, or anyone on their behalf, including any such person's relatives and entities under their control). If a special tender offer is accepted, then the purchaser or any person or entity controlling it, at the time of the offer, and any person or entity under common control with the purchaser or such controlling person or entity may not make a subsequent tender offer for the purchase of shares of the target company and may not enter into a merger with the target company for a period of one year from the date of the offer, unless the purchaser or such person or entity undertook to effect such an offer or merger in the initial special tender offer.

#### Merger
The Israeli Companies Law permits merger transactions if approved by each party's board of directors and, unless certain requirements described under the Israeli Companies Law are met, by a majority vote of each party's shares, and, in the case of the target company, a majority vote of each class of its shares, voted on the proposed merger at a shareholders meeting. The board of directors of a merging company may not approve the merger if it determines that there exists a reasonable concern that, as a result of the merger, the surviving company will be unable to satisfy the obligations of the merging entities.

For purposes of the shareholder vote of a merging company whose shares are held by the other merging company or a person or entity holding 25% or more of any of the means of control of the other merging entity, unless a court rules otherwise, the merger will not be deemed approved if a majority of the votes of shares voting on the matter at the shareholders meeting (excluding abstentions) that are held by parties other than the other party to the merger, or by any other person or entity who holds 25% or more of the voting rights or the right to appoint 25% or more of the directors

[**Table of Contents**](#TOC001)

of the other party, or any one on their behalf including their relatives or corporations controlled by any of them, vote against the merger. If, however, the merger involves a merger with a company's own controlling shareholder or if the controlling shareholder has a personal interest in the merger, then the merger is instead subject to the same Special Majority approval that governs all extraordinary transactions with controlling shareholders (as described in Item 6C "Directors, Senior Management and Employees — Board Practices — Approval of Related Party Transactions under Israeli Law — Disclosure of Personal Interests of Controlling Shareholders and Approval of Certain Transactions" in the 2024 Annual Report).

If the transaction would have been approved by the shareholders of a merging company but for the separate approval of each class or the exclusion of the votes of certain shareholders as provided above, a court may still approve the merger upon the request of holders of at least 25% of the voting rights of a company, if the court holds that the merger is fair and reasonable, taking into account the valuation of the merging companies and the consideration offered to the shareholders.

Upon the request of a creditor of either party to the proposed merger, the court may delay or prevent the merger if it concludes that there exists a reasonable concern that, as a result of the merger, the surviving company will be unable to satisfy the obligations of the merging entities and may further give instructions to secure the rights of creditors.

In addition, a merger may not be consummated unless at least 50 days have passed from the date on which a proposal for approval of the merger was filed by each party with the Israeli Registrar of Companies and at least 30 days have passed from the date on which the merger was approved by the shareholders of each party.

#### Anti-Takeover Measures under Israeli Law
The Israeli Companies Law allows us to create and issue shares having rights different from those attached to our Ordinary Shares, including shares providing certain preferred rights with respect to voting, distributions or other matters and shares having preemptive rights. No preferred shares are currently authorized under our amended articles of association. In the future, if we do authorize, create and issue a specific class of preferred shares, such class of shares, depending on the specific rights that may be attached to it, may have the ability to frustrate or prevent a takeover or otherwise prevent our shareholders from realizing a potential premium over the market value of their Ordinary Shares. The authorization and designation of a class of preferred shares will require an amendment to our amended articles of association, which requires the prior approval of the holders of a majority of the voting power attached to our issued and outstanding shares at a general meeting. The convening of the meeting, the shareholders entitled to participate, and the majority vote required to be obtained at such a meeting will be subject to the requirements set forth in the Israeli Companies Law and our amended articles of association as described above in "— Voting Rights."

*Borrowing Powers*

Pursuant to the Israeli Companies Law and our amended articles of association, our board of directors may exercise all powers and take all actions that are not required under law or under our amended articles of association to be exercised or taken by our shareholders, including the power to borrow money for company purposes.

*Changes in Capital*

Our amended articles of association enable us to increase or reduce our share capital. Any such changes are subject to the provisions of the Israeli Companies Law and must be approved by a resolution duly passed by our shareholders at a general meeting by voting on such change in the capital. In addition, transactions that have the effect of reducing capital, such as the declaration and payment of dividends in the absence of sufficient retained earnings or profits, require the approval of both our board of directors and an Israeli court.

[**Table of Contents**](#TOC001)

#### Plan of Distribution
On December 17, 2025, we entered into the Purchase Agreement with the Selling Shareholder. The Purchase Agreement provides that, upon the terms and subject to the conditions set forth therein, the Selling Shareholder is committed to purchase up to $30.0 million of our Ordinary Shares over a three-year commitment period. Pursuant to the Purchase Agreement, we may request Advances in an Advance Notice delivered to the Selling Shareholder on any trading day, in an amount up to the lesser of (i) 75% of the average of the daily value traded of the Ordinary Shares on the ten trading days immediately preceding the date an Advance Notice is delivered, and (ii) $5.0 million, subject to satisfaction of the conditions in the Purchase Agreement. The Ordinary Shares that may be offered pursuant to this prospectus would be purchased by the Selling Shareholder from time to time at a price equal to 95% of the lowest of the three daily VWAPs following an Advance Notice as set forth in the Purchase Agreement and would be subject to certain limitations. While any Advance is pending, we may deliver a second Advance Notice specifying a number of Ordinary Shares mutually agreed upon which will begin another Advance. The purchase price of the Ordinary Shares in such Advance will be equal to 100% of the lowest intraday sale price of the Ordinary Shares on the same day the second Advance Notice is received, or the immediately following trading day if the second Advance Notice is received after 8:30 am Eastern Time, subject to mutual consent between the Selling Shareholder and us.

As consideration for the Selling Shareholder's purchase commitment of up to $30.0 million of our Ordinary Shares, we have agreed to direct our transfer agent to issue to the Selling Shareholder the Commitment Shares having an aggregate dollar value equal to 1.5% of the Total Commitment Amount, which Commitment Shares were deemed fully earned on the execution date of the Purchase Agreement.

The Ordinary Shares offered by this prospectus are being offered by the Selling Shareholder. The Selling Shareholder and any broker-dealers or agents that are involved in selling the Ordinary Shares may be deemed to be "underwriters" within the meaning of Section 2(a)(11) of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers or agents and any profit on the resale of the Ordinary Shares purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act. The Selling Shareholder has informed the Company that it does not have any written or oral agreement or understanding, directly or indirectly, with any person to distribute the Ordinary Shares. We have agreed in the Purchase Agreement to provide customary indemnification to ARC Group.

It is possible that our Ordinary Shares may be sold from time to time by ARC Group in one or more of the following manners:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• ordinary brokerage transactions and transactions in which the broker solicits purchasers;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• a block trade in which the broker or dealer so engaged will attempt to sell the shares as agent, but may position and resell a portion of the block as principal to facilitate the transaction;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• to a broker-dealer as principal and resale by the broker-dealer for its account;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• privately negotiated transactions;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• in transactions through broker-dealers that agree with the Selling Shareholder to sell a specified number of such securities at a stipulated price per security;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• through the writing or settlement of options or other hedging transactions, either through an options exchange or otherwise;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• a combination of any such methods of sale; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• any other method permitted pursuant to applicable law.

The Selling Shareholder may also sell securities under Rule 144 or any other exemption from registration under the Securities Act, if available, rather than this prospectus.

The Selling Shareholder has agreed that, during the term of the Purchase Agreement, it shall not engage in any short sales or hedging transactions with respect to our Ordinary Shares, provided that upon receipt of an advance notice, the Selling Shareholder may sell Ordinary Shares that it is obligated to purchase under such advance notice prior to taking possession of such Ordinary Shares or other Ordinary Shares issued or sold by the Company to the Selling Shareholder pursuant to the Purchase Agreement which have been continuously held as a long position.

[**Table of Contents**](#TOC001)

The Selling Shareholder and any unaffiliated broker-dealer will be subject to liability under the federal securities laws and must comply with the requirements of the Exchange Act of 1934, as amended, or the Exchange Act, including without limitation, Rule 10b-5 and Regulation M under the Exchange Act. These rules and regulations may limit the timing of purchases and sales of Ordinary Shares by the Selling Shareholder or any unaffiliated broker-dealer. Under these rules and regulations, the Selling Shareholder and any unaffiliated broker-dealer:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• may not engage in any stabilization activity in connection with our securities;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• must furnish each broker which offers our Ordinary Shares covered by the prospectus and any accompanying prospectus supplement that are a part of this registration statement with the number of copies of such prospectus and accompanying prospectus supplement which are required by each broker; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• may not bid for or purchase any of our securities or attempt to induce any person to purchase any of our securities other than as permitted under the Exchange Act.

These restrictions may affect the marketability of the Ordinary Shares by the Selling Shareholder and any unaffiliated broker-dealer.

The Selling Shareholder will pay all brokerage fees and commissions and similar expenses in connection with the offer and sale of the Ordinary Shares by the Selling Shareholder pursuant to this prospectus. We have paid the Selling Shareholder's legal fees in an amount of $50,000 related to the offer and sale of such Ordinary Shares. We will pay the expenses incident to the registration under the Securities Act of the offer and sale of the Ordinary Shares covered by this prospectus by the Selling Shareholder. We will bear all expenses incident to the registration of the Ordinary Shares covered by this prospectus, including legal, accounting, and filing fees.

[**Table of Contents**](#TOC001)

#### Expenses
Set forth below is an itemization of the total expenses expected to be incurred by us in connection with the offer and sale of the securities. With the exception of the SEC registration fee, all amounts are estimates:

---

| | |
|:---|:---|
|  SEC registration fee | $473 |
|  Printer fees and expenses | $15000 |
|  Legal fees and expenses | $200000 |
|  Accounting and professional fees and expenses | $100000 |
|  Miscellaneous | $40000 |
|  Total | $355473 |

---

[**Table of Contents**](#TOC001)

#### Legal Matters
Certain legal matters regarding the securities offered hereby under U.S. federal securities law will be passed upon for us by Paul Hastings LLP, Washington, DC. Certain legal matters with respect to the securities offered hereby under Israeli law will be passed upon for us by RIMÔN PC, New York, New York.

#### Experts
The consolidated financial statements of Check-Cap, as of December 31, 2022 and for the year then ended, have been audited by Brightman Almagor Zohar & Co., a firm in the Deloitte global network and an independent registered public accounting firm, as set forth in their report thereon, and are incorporated by reference herein in reliance upon such report given their authority of such firm as expert in accounting and auditing.

The consolidated financial statements of Check-Cap as of December 31, 2023 and for the year then ended are incorporated by reference herein in reliance upon the report of Fahn Kanne & Co, independent registered public accountants, upon the authority of said firm as expert in accounting and auditing.

The consolidated financial statements of Check-Cap, as of December 31, 2024 and for the year then ended, have been audited by RBSM LLP, an independent registered public accounting firm, as set forth in their report thereon, and are incorporated by reference herein in reliance upon such report given on the authority of such firm as expert in accounting and auditing.

The financial statements of MBody AI, as of December 31, 2024 and for the year then ended, have been audited by BCRG Group, an independent registered public accounting firm, as set forth in their report thereon, and are incorporated by reference herein in reliance upon such report given on the authority of such firm as expert in accounting and auditing.

The financial statements of MBody AI, as of June 30, 2025 and for the six months then ended, have been audited by BCRG Group, an independent registered public accounting firm, as set forth in their report thereon, and are incorporated by reference herein in reliance upon such report given on the authority of such firm as expert in accounting and auditing.

[**Table of Contents**](#TOC001)

#### Enforceability of Civil Liabilities
We are incorporated under the laws of the State of Israel. Service of process upon us and upon our directors and officers and the Israeli experts named in the registration statement of which this prospectus forms a part, a substantial majority of whom reside outside of the United States, may be difficult to obtain within the United States. Furthermore, because substantially all of our assets and a majority of our directors and officers are located outside of the United States, any judgment obtained in the United States against us or any of our directors and officers may not be collectible within the United States.

We have been informed by our legal counsel in Israel, RIMÔN PC, that it may be difficult to assert U.S. securities law claims in original actions instituted in Israel. Israeli courts may refuse to hear a claim based on an alleged violation of U.S. securities laws reasoning Israel is not the most appropriate forum to bring such a claim. In Israeli courts, the content of applicable U.S. law must be proved as a fact which can be a time-consuming and costly process and certain matters of procedure will also be governed by Israeli law.

Subject to specified time limitations and legal procedures, Israeli courts may enforce a U.S. judgment in a civil matter which, subject to certain exceptions, is non-appealable, including judgments based upon the civil liability provisions of the Securities Act and the Exchange Act and including a monetary or compensatory judgment in a non-civil matter, provided that among other things:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the judgment was rendered by a court which was, according to the laws of the state of the court, competent to render the judgment;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the obligation imposed by the judgment is enforceable according to the rules relating to the enforceability of judgments in Israel and the substance of the judgment is not contrary to public policy; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the judgment is executory in the state in which it was given.

Even if these conditions are met, an Israeli court will not declare a foreign civil judgment enforceable if:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the judgment was given in a state whose laws do not provide for the enforcement of judgments of Israeli courts (subject to exceptional cases);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the enforcement of the judgment is likely to prejudice the sovereignty or security of the State of Israel;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the judgment was obtained by fraud;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the opportunity given to the defendant to bring its arguments and evidence before the court was not reasonable in the opinion of the Israeli court;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the judgment was rendered by a court not competent to render it according to the laws of private international law as they apply in Israel;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the judgment is contradictory to another judgment that was given in the same matter between the same parties and that is still valid; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• at the time the action was brought in the foreign court, a lawsuit in the same matter and between the same parties was pending before a court or tribunal in Israel.

If a foreign judgment is enforced by an Israeli court, it generally will be payable in Israeli currency, which can then be converted into non-Israeli currency and transferred out of Israel. The usual practice in an action before an Israeli court to recover an amount in a non-Israeli currency is for the Israeli court to issue a judgment for the equivalent amount in Israeli currency at the rate of exchange in force on the date of the judgment, but the judgment debtor may make payment in foreign currency. Pending collection, the amount of the judgment of an Israeli court stated in Israeli currency ordinarily will be linked to the Israeli consumer price index plus interest at the annual statutory rate set by Israeli regulations prevailing at the time. Judgment creditors must bear the risk of unfavorable exchange rates.

[**Table of Contents**](#TOC001)

#### Where You Can Find Additional Information
We have filed with the SEC a registration statement on Form F-1 under the Securities Act relating to this offering of our Ordinary Shares. This prospectus does not contain all of the information contained in the registration statement. The rules and regulations of the SEC allow us to omit certain information from this prospectus that is included in the registration statement. Statements made in this prospectus concerning the contents of any contract, agreement or other document are summaries of all material information about the documents summarized, but are not complete descriptions of all terms of these documents. If we filed any of these documents as an exhibit to the registration statement, you may read the document itself for a complete description of its terms. The SEC maintains an Internet website that contains reports and other information regarding issuers that file electronically with the SEC. Our filings with the SEC are also available to the public through the SEC's website at *www.sec.gov*.

We are subject to the information reporting requirements of the Exchange Act that are applicable to foreign private issuers, and under those requirements are filing reports with the SEC. Those other reports or other information may be inspected without charge at the locations described above. As a foreign private issuer, we are exempt from the rules under the Exchange Act related to the furnishing and content of proxy statements, and our officers, directors and principal shareholders are exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange Act. In addition, we are not required under the Exchange Act to file annual, quarterly and current reports and financial statements with the SEC as frequently or as promptly as U.S. companies whose securities are registered under the Exchange Act. However, we are required to file with the SEC, within 120 days after the end of each fiscal year, or such applicable time as required by the SEC, an annual report on Form 20-F containing financial statements audited by an independent registered public accounting firm, and will submit to the SEC, on Form 6-K, unaudited interim financial information.

We maintain a corporate website at *www.check*-cap*.com*. Information contained on, or that can be accessed through, our website does not constitute a part of this prospectus. We have included our website address in this prospectus solely as an inactive textual reference. We will post on our website any materials required to be so posted on such website under applicable corporate or securities laws and regulations, including, posting any XBRL interactive financial data required to be filed with the SEC and any notices of general meetings of our shareholders.

[**Table of Contents**](#TOC001)

#### Incorporation of Certain Information by Reference
The SEC allows us to incorporate by reference information into this document. This means that we can disclose important information to you by referring you to another document filed separately with the SEC. The information incorporated by reference is considered to be a part of this document, except for any information superseded by information that is included directly in this prospectus or incorporated by reference subsequent to the date of this prospectus.

We incorporate by reference the following documents or information that we have filed with the SEC:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our Annual Report on [Form 20-F](http://www.sec.gov/Archives/edgar/data/1610590/000121390025080891/ea0253469-20f_check.htm) for the year ended December 31, 2024, filed with the SEC on August 27, 2025;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our Reports of Foreign Private Issuer on Form 6-K filed on [September 5, 2025](http://www.sec.gov/Archives/edgar/data/1610590/000121390025085071/ea0256194-6k_checkcap.htm), [September 12, 2025](http://www.sec.gov/Archives/edgar/data/1610590/000121390025087248/ea0257177-6k_check.htm), [October 16, 2025](http://www.sec.gov/Archives/edgar/data/1610590/000121390025099645/ea0261544-6k_check.htm), [November 4, 2025](http://www.sec.gov/Archives/edgar/data/1610590/000121390025106253/ea0264017-6k_check.htm), [November 10, 2025](http://www.sec.gov/Archives/edgar/data/1610590/000121390025107908/ea0264754-6k_check.htm), [November 17, 2025](http://www.sec.gov/Archives/edgar/data/1610590/000121390025111294/ea0265951-6k_check.htm), [December 1, 2025](http://www.sec.gov/Archives/edgar/data/1610590/000121390025116292/ea0267820-6k_checkcap.htm), [December 22, 2025](http://www.sec.gov/Archives/edgar/data/1610590/000121390025124171/ea0270535-6k_checkcap.htm), [December 30, 2025](http://www.sec.gov/Archives/edgar/data/1610590/000121390025126347/ea0269934-6k_check.htm), [January 23, 2026](http://www.sec.gov/Archives/edgar/data/1610590/000121390026006934/ea0273867-6k_check.htm),[January 26, 2026](http://www.sec.gov/Archives/edgar/data/1610590/000121390026007478/ea0274052-6k_checkcap.htm) and [<u>January</u> <u>30, 2026</u>](http://www.sec.gov/Archives/edgar/data/1610590/000121390026010290/ea0274731-6k_checkcap.htm); and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the description of our Ordinary Shares contained in our [Form F-3](http://www.sec.gov/Archives/edgar/data/1610590/000117891322000252/zk2227124.htm) filed on January 28, 2022 (File No. 333-262401), including any amendments or reports filed for the purpose of updating such description.

We will provide you without charge, upon your written or oral request, a copy of any of the documents incorporated by reference in this prospectus, other than exhibits to such documents which are not specifically incorporated by reference into such documents. Please direct your written or telephone requests to us at: Check-Cap Ltd., 29 Abba Hushi Avenue, Isfiya, 3009000, Mount Carmel, Israel, Tel: +1 (647) 892-9516.

[**Table of Contents**](#TOC001)

#### Up to 2,267,857 Ordinary Shares

#### Check-Cap Ltd.
**__________________________________________**

#### PROSPECTUS
**__________________________________________**

, 2026

------

[**Table of Contents**](#TOC001)

#### Part II<br>Information Not Required in Prospectus

#### Item 6. Indemnification of Directors, Officers and Employees
Under the Companies Law, a company may not exculpate an office holder from liability for a breach of the duty of loyalty. An Israeli company may exculpate an office holder in advance from liability to the Company, in whole or in part, for damages caused to the Company as a result of a breach of duty of care but only if a provision authorizing such exculpation is included in its articles of association. Our Articles of Association contain such a provision. An Israeli company may not exculpate a director in advance from liability arising out of a breach of the director's duty of care in a prohibited dividend or distribution to shareholders.

An Israeli company may indemnify an office holder in respect of the following liabilities and expenses incurred for acts performed as an office holder, either in advance of an event or following an event provided a provision authorizing such indemnification is contained in its articles of association:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• a financial liability imposed on him or her in favor of another person pursuant to a judgment, including a settlement or arbitrator's award approved by a court. However, if an undertaking to indemnify an office holder with respect to such liability is provided in advance, then such an undertaking must be limited to events which, in the opinion of the board of directors, can be foreseen based on the Company's activities when the undertaking to indemnify is given, and to an amount or according to criteria determined by the board of directors as reasonable under the circumstances, and such undertaking shall detail the abovementioned events and amount or criteria;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• reasonable litigation expenses, including legal fees, incurred by the office holder (a) as a result of an investigation or proceeding instituted against him or her by an authority authorized to conduct such investigation or proceeding, provided that (i) no indictment was filed against such office holder as a result of such investigation or proceeding; and (ii) no financial liability, such as a criminal penalty, was imposed upon him or her as a substitute for the criminal proceeding as a result of such investigation or proceeding or, if such financial liability was imposed, it was imposed with respect to an offense that does not require proof of criminal intent; and (b) in connection with a monetary sanction;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• reasonable litigation expenses, including legal fees, incurred by the office holder or imposed by a court (i) in proceedings instituted against him or her by the Company, on its behalf or by a third party, or (ii) in connection with criminal proceedings in which the office holder was acquitted, or (iii) as a result of a conviction for a crime that does not require proof of criminal intent; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• expenses, including reasonable litigation expenses and legal fees, incurred by an office holder in relation to an administrative proceeding instituted against such office holder, or certain compensation payments made to an injured party imposed on an office holder by an administrative proceeding, pursuant to certain provisions of the Israeli Securities Law.

An Israeli company may insure an office holder against the following liabilities incurred for acts performed as an office holder if and to the extent provided in the Company's articles of association:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• a breach of the duty of loyalty to the Company, to the extent that the office holder acted in good faith and had a reasonable basis to believe that the act would not prejudice the Company;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• a breach of the duty of care to the Company or to a third party, including a breach arising out of the negligent conduct of the office holder;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• a financial liability imposed on the office holder in favor of a third party;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• a financial liability imposed on the office holder in favor of a third party harmed by a breach in an administrative proceeding; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• expenses, including reasonable litigation expenses and legal fees, incurred by the office holder as a result of an administrative proceeding instituted against him or her, pursuant to certain provisions of the Israeli Securities Law.

[**Table of Contents**](#TOC001)

An Israeli company may not indemnify or insure an office holder against any of the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• a breach of the duty of loyalty, except to the extent that the office holder acted in good faith and had a reasonable basis to believe that the act would not prejudice the Company;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• a breach of duty of care committed intentionally or recklessly, excluding a breach arising out of the negligent conduct of the office holder;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• an act or omission committed with intent to derive illegal personal benefit; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• a fine, monetary sanction or forfeit levied against the office holder.

Under the Israeli Companies Law, exculpation, indemnification and insurance of office holders must be approved by the compensation committee, the board of directors (and, with respect to directors and the chief executive officer, by the shareholders).

Our Articles of Association allow us to exculpate, indemnify and insure our office holders for any liability imposed on them as a consequence of an act (including any omission) which was performed by virtue of being an office holder. Our office holders are currently covered by a directors and officers' liability insurance policy.

We have entered into agreements with each of our directors and executive officers exculpating them in advance from liability to us for damages caused to us as a result of a breach of duty of care and undertaking to indemnify them. This exculpation and indemnification is limited both in terms of amount and coverage, and it covers certain amounts regarding administrative proceedings insurable or indemnifiable under the Companies Law and our Articles of Association.

In the opinion of the SEC, however, indemnification of directors and office holders for liabilities arising under the Securities Act, is against public policy and therefore unenforceable.

There is no pending litigation or proceeding against any of our office holders as to which indemnification is being sought.

#### Item 7. Recent Sales of Unregistered Securities
Set forth below are the sales of all securities by the Company since January 2023, which were not registered under the Securities Act. The Company believes that each of such issuances was exempt from registration under the Securities Act in reliance on Section 4(a)(2) of the Securities Act, and/or Regulation D under the Securities Act.

On September 15, 2025, the Company issued 1,169,596 Ordinary Shares to Parea LLC pursuant to an Asset Purchase Agreement with Parea LLC. On January 21, 2026, the Company issued 267,857 Ordinary Shares to the Selling Shareholder as a commitment fee pursuant to the Purchase Agreement.

#### Item 8. Exhibits and Financial Statement Schedules

#### Exhibits:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  **Exhibit No.** | **Exhibit Description** | **Form** | **File No.** | **Exhibit <br>No.** | **Filing Date** |
|  2.1\* | [Business Combination Agreement between Check-Cap Ltd. and Nobul AI Corp. dated March 25, 2024](http://www.sec.gov/Archives/edgar/data/1610590/000121390024026835/ea020276201ex99-1_checkcap.htm) | 6-K | 001-36848 | 99.1 | March 28, 2024 |
|  2.2\* | [Agreement and Plan of Merger, dated September 12, 2025, by and among Check-Cap Ltd., CC Merger Sub Inc. and MBody AI.](http://www.sec.gov/Archives/edgar/data/1610590/000121390025087248/ea025717701ex99-2_check.htm#b_001) | 6-K | 001-36848 | 99.4 | September 12, 2025 |
|  3.1\* | [Amended and Restated Articles of Association of the Registrant](http://www.sec.gov/Archives/edgar/data/1610590/000117891323001275/exhibit_1-1.htm) | 20-F | 001-36848 | 1.1 | March 31, 2023 |
|  4.1\* | [Form of Registrant's Ordinary Share Warrant Certificate](http://www.sec.gov/Archives/edgar/data/1610590/000117891315000446/exhibit_4-1.htm) | F-1 | 333-201250 | 4.1 | February 18, 2015 |
|  4.2\* | [Form of Warrant Agreement dated as of February 24, 2015 between Check-Cap Ltd. and American Stock Transfer & Trust Company LLC, as Warrant Agent](http://www.sec.gov/Archives/edgar/data/1610590/000117891315000567/exhibit_4-6.htm) | F-1 | 333-201250 | 4.6 | February 17, 2015 |

---

[**Table of Contents**](#TOC001)

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  **Exhibit No.** | **Exhibit Description** | **Form** | **File No.** | **Exhibit <br>No.** | **Filing Date** |
|  4.3\* | [Amendment No.1 dated as of June 24, 2015, to Warrant Agreement dated as of February 24, 2015 between Check-Cap Ltd. and American Stock Transfer & Trust Company LLC, as Warrant Agent](http://www.sec.gov/Archives/edgar/data/1610590/000117891315002104/exhibit_4-1.htm) | 6-K | 001-36848 | 4.1 | June 24, 2015 |
|  4.4\* | [Form of Ordinary Shares Warrant Certificate issued pursuant to a certain Credit Line Agreement dated as of August 20, 2014](http://www.sec.gov/Archives/edgar/data/1610590/000117891317003232/exhibit_4-1.htm) | 6-K | 001-36848 | 4.1 | November 22, 2017 |
|  4.5\* | [Forms of Ordinary Shares Warrant Certificate issued to the Pontifax entities](http://www.sec.gov/Archives/edgar/data/1610590/000117891314003928/exhibit_10-15.htm) | F-1 | 333-201250 | 10.15 | February 18, 2015 |
|  4.6\* | [Form of Series C Warrant](http://www.sec.gov/Archives/edgar/data/1610590/000117891318001272/exhibit_4-14.htm) | F-1 | 333-224139 | 4.14 | April 25, 2018 |
|  4.7\* | [Form of Warrant Agent Agreement between Check-Cap Ltd. and American Stock Transfer & Trust Company LLC, as Warrant Agent](http://www.sec.gov/Archives/edgar/data/1610590/000117891318001272/exhibit_4-15.htm) | F-1 | 333-224139 | 4.15 | April 25, 2018 |
|  4.8\* | [Form of February 2019 Series D Warrant](http://www.sec.gov/Archives/edgar/data/1610590/000117891319000303/exhibit_4-1.htm) | 6-K | 001-36848 | 4.1 | February 6, 2019 |
|  4.9\* | [Form of the February 2019 Placement Agent Warrant](http://www.sec.gov/Archives/edgar/data/1610590/000117891319000303/exhibit_4-3.htm) | 6-K | 001-36848 | 4.3 | February 6, 2019 |
|  4.10\* | [2006 Unit Option Plan and Amendments thereto](http://www.sec.gov/Archives/edgar/data/1610590/000117891314003928/exhibit_10-1.htm) | F-1 | 333-201250 | 10.1 | February 18, 2015 |
|  4.11\* | [Form of Series C-1 preferred shares purchase warrant](http://www.sec.gov/Archives/edgar/data/1610590/000117891314003928/exhibit_10-4.htm) | F-1 | 001-38041 | 10.4 | February 18, 2015 |
|  4.12\* | [Forms of Series C-2 preferred shares purchase warrant](http://www.sec.gov/Archives/edgar/data/1610590/000117891314003928/exhibit_10-5.htm) | F-1 | 001-38041 | 10.5 | February 18, 2015 |
|  4.13\* | [Form of Warrant issued by Check-Cap Ltd. on April 22, 2020](http://www.sec.gov/Archives/edgar/data/1610590/000117891320001161/exhiibit_10-2.htm) | 6-K | 001-36848 | 10.2 | April 22, 2020 |
|  4.14\* | [Form of Warrant issued by Check-Cap Ltd. on May 4, 2020](http://www.sec.gov/Archives/edgar/data/1610590/000117891320001286/exhibit_10-2.htm) | 6-K | 001-36848 | 10.2 | May 4, 2020 |
|  4.15\* | [Form of Warrant issued by Check-Cap Ltd. on May 13, 2020](http://www.sec.gov/Archives/edgar/data/1610590/000117891320001436/exhibit_10-2.htm) | 6-K | 001-36848 | 10.2 | May 12, 2020 |
|  4.16\* | [Form of Warrant issued by Check-Cap Ltd. on July 27, 2020](http://www.sec.gov/Archives/edgar/data/1610590/000117891320002081/exhibit_10-3.htm) | 6-K | 001-36848 | 10.3 | July 24, 2020 |
|  4.17\* | [Form of Warrant issued by Check-Cap Ltd. on July 2, 2021](http://www.sec.gov/Archives/edgar/data/1610590/000117891321002209/exhibit_10-2.htm) | 6-K | 001-36848 | 10.2 | July 2, 2021 |
|  4.18\* | [Form of Warrant issued by Check-Cap Ltd. on March 3, 2022](http://www.sec.gov/Archives/edgar/data/1610590/000117891322000913/exhibit_10-2.htm) | 6-K | 001-36848 | 10.2 | March 3, 2022 |
|  4.19\* | [Form of Placement Agent Warrant issued by Check-Cap Ltd. on April 22, 2020](http://www.sec.gov/Archives/edgar/data/1610590/000117891320001553/exhibit_10-5.htm) | F-1 | 333-238532 | 10.5 | May 20, 2020 |
|  4.20\* | [Form of Placement Agent Warrant issued by Check-Cap Ltd. on May 4, 2020](http://www.sec.gov/Archives/edgar/data/1610590/000117891320001553/exhibit_10-6.htm) | F-1 | 333-238532 | 10.6 | May 20, 2020 |
|  4.21\* | [Form of Placement Agent Warrant issued by Check-Cap Ltd. on May 13, 2020](http://www.sec.gov/Archives/edgar/data/1610590/000117891320001553/exhibit_10-7.htm) | F-1 | 333-238532 | 10.7 | May 20, 2020 |
|  4.22\* | [Form of Placement Agent Warrant issued by Check-Cap Ltd. on July 27, 2020](http://www.sec.gov/Archives/edgar/data/1610590/000117891320002081/exhibit_10-2.htm) | 6-K | 001-36848 | 10.2 | July 24, 2020 |
|  4.23\* | [Form of Placement Agent Warrant issued by Check-Cap Ltd. on July 2, 2021](http://www.sec.gov/Archives/edgar/data/1610590/000117891321002209/exhibit_10-3.htm) | 6-K | 001-36848 | 10.3 | July 2, 2021 |
|  4.24\* | [Form of Placement Agent Warrant issued by Check-Cap Ltd. on March 3, 2022](http://www.sec.gov/Archives/edgar/data/1610590/000117891322000913/exhibit_10-3.htm) | 6-K | 001-36848 | 10.3 | March 3, 2022 |
|  5.1& | [Opinion of RIMÔN PC](ea027460901ex5-1_checkcap.htm) |  |  |  |  |
|  10.1\* | [Asset Transfer Agreement, dated as of May 31, 2009 by and between Check-Cap Ltd. and Check-Cap LLC](http://www.sec.gov/Archives/edgar/data/1610590/000117891314003928/exhibit_10-10.htm) | F-1 | 333-201250 | 10.10 | February 18, 2015 |
|  10.2\* | [The Agreement for ASIC Design and Development dated November 26, 2009 by and between Check-Cap Ltd. and Politechnico di Milano](http://www.sec.gov/Archives/edgar/data/1610590/000117891314003928/exhibit_10-11.htm) | F-1 | 333-201250 | 10.11 | February 18, 2015 |

---

[**Table of Contents**](#TOC001)

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  **Exhibit No.** | **Exhibit Description** | **Form** | **File No.** | **Exhibit <br>No.** | **Filing Date** |
|  10.3\* | [Form of Indemnification Agreement](http://www.sec.gov/Archives/edgar/data/1610590/000117891314003928/exhibit_10-12.htm) | F-1 | 333-201250 | 10.12 | February 18, 2015 |
|  10.4\* | [Compensation Policy for Executive Officers and Directors](http://www.sec.gov/Archives/edgar/data/1610590/000117891320002868/exhibit_99-1.htm) | 6-K | 001-36848 | 99.1 | October 21, 2020 |
|  10.5\* | [Underwriting Agreement, dated as of May 4, 2018, by and between Check-Cap Ltd. and H.C. Wainwright & Co., LLC](http://www.sec.gov/Archives/edgar/data/1610590/000117891318001462/exhibit_1-1.htm) | 6-K | 001-36848 | 1.1 | May 4, 2018 |
|  10.6\* | [Form of Securities Purchase Agreement dated as of February 4, 2019 by and between Check-Cap Ltd. and the Purchasers named therein](http://www.sec.gov/Archives/edgar/data/1610590/000117891319000303/exhibit_10-1.htm) | 6-K | 001-36848 | 10.1 | February 6, 2019 |
|  10.7\* | [Form of Securities Purchase Agreement dated as of December 19, 2019 by and between Check-Cap Ltd. and the Purchasers named therein](http://www.sec.gov/Archives/edgar/data/1610590/000117891320000745/exhibit_4-15.htm) | 20-F | 001-36848 | 4.15 | March 6, 2020 |
|  10.8\* | [Form of Securities Purchase Agreement dated as of April 20, 2020 by and between Check-Cap Ltd. and the Purchasers signatory thereto](http://www.sec.gov/Archives/edgar/data/1610590/000117891320001161/exhibit_10-1.htm) | 6-K | 001-36848 | 10.1 | April 22, 2020 |
|  10.9\* | [Form of Securities Purchase Agreement dated as of April 30, 2020 by and between Check-Cap Ltd. and the Purchasers signatory thereto](http://www.sec.gov/Archives/edgar/data/1610590/000117891320001286/exhibit_10-1.htm) | 6-K | 001-36848 | 10.1 | May 4, 2020 |
|  10.10\* | [Form of Securities Purchase Agreement dated as of May 8, 2020 by and between Check-Cap Ltd. and the Purchasers signatory thereto](http://www.sec.gov/Archives/edgar/data/1610590/000117891320001436/exhibit_10-1.htm) | 6-K | 001-36848 | 10.1 | May 12, 2020 |
|  10.11\* | [Form of Securities Purchase Agreement dated as of June 30, 2021 by and between Check-Cap Ltd. and the Purchasers signatory thereto](http://www.sec.gov/Archives/edgar/data/1610590/000117891321002209/exhibit_10-1.htm) | 6-K | 001-36848 | 10.1 | July 2, 2021 |
|  10.12\* | [Form of Warrant Exercise Agreement dated as of July 23, 2020 by and between Check-Cap Ltd. and the Purchasers signatory thereto](http://www.sec.gov/Archives/edgar/data/1610590/000117891320002081/exhibit_10-1.htm) | 6-K | 001-36848 | 10.1 | July 24, 2020 |
|  10.13\* | [Form of Securities Purchase Agreement dated as of March 1, 2022 by and between Check-Cap Ltd. and the Purchasers signatory thereto](http://www.sec.gov/Archives/edgar/data/1610590/000117891322000913/exhibit_10-1.htm) | 6-K | 001-36848 | 10.1 | March 3, 2022 |
|  10.14\* | [Form of Warrant Amendment Agreement dated as of March 1, 2022 by and between Check-Cap Ltd. and the Purchasers signatory thereto](http://www.sec.gov/Archives/edgar/data/1610590/000117891322001429/exhibit_4-22.htm) | 20-F | 001-36848 | 4.22 | April 6, 2022 |
|  10.15\* | [Exclusive License Agreement between the Company and the Curators of the University Of Missouri, dated February 26, 2021](http://www.sec.gov/Archives/edgar/data/1610590/000117891321001100/exhibit_4-28.htm) | 20-F | 001-36848 | 4.28 | March 18, 2021 |
|  10.16\* | [Loan Agreement, by and between Check-Cap Ltd. and Nobul AI Corp., dated July 28, 2024](http://www.sec.gov/Archives/edgar/data/1610590/000121390025080891/ea025346901ex4-33_check.htm) | 20-F | 001-36848 | 4.33 | August 27, 2025 |
|  10.17\* | [Loan Agreement, by and between Check-Cap Ltd. and Nobul AI Corp., dated December 23, 2024](http://www.sec.gov/Archives/edgar/data/1610590/000121390025080891/ea025346901ex4-34_check.htm) | 20-F | 001-36848 | 4.34 | August 27, 2025 |
|  10.18\* | [Loan Agreement, by and between Check-Cap Ltd. and Nobul AI Corp., dated July 2, 2025](http://www.sec.gov/Archives/edgar/data/1610590/000121390025080891/ea025346901ex4-35_check.htm) | 20-F | 001-36848 | 4.35 | August 27, 2025 |
|  10.19\* | [Loan Agreement, by and between Check-Cap Ltd. and Nobul AI Corp., dated July 3, 2025](http://www.sec.gov/Archives/edgar/data/1610590/000121390025080891/ea025346901ex4-36_check.htm) | 20-F | 001-36848 | 4.36 | August 27, 2025 |
|  10.20& | [Purchase Agreement, dated December 17, 2025, between ARC Group International Ltd. and the Company](ea027460901ex10-20_checkcap.htm) |  |  |  |  |
|  21.1\* | [List of Subsidiaries](http://www.sec.gov/Archives/edgar/data/1610590/000117891316004712/exhibit_8-1.htm) | 20-F | 001- 36848 | 8.1 | March 15, 2016 |
|  23.1& | [Consent of Brightman Almagor Zohar & Co., independent registered public accounting firm](ea027460901ex23-1_checkcap.htm) |  |  |  |  |
|  23.2& | [Consent of RBSM LLP, independent registered public accounting firm](ea027460901ex23-2_checkcap.htm) |  |  |  |  |

---

[**Table of Contents**](#TOC001)

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  **Exhibit No.** | **Exhibit Description** | **Form** | **File No.** | **Exhibit <br>No.** | **Filing Date** |
|  23.3& | [Consent of Fahn Kanne & Co., independent registered public accounting firm](ea027460901ex23-3_checkcap.htm) |  |  |  |  |
|  23.4& | [Consent of BCRG Group, independent registered public accounting firm](ea027460901ex23-4_checkcap.htm) |  |  |  |  |
|  24.1& | [Power of Attorney (included on signature page of this Registration Statement).](#T15) |  |  |  |  |
|  107& | [Calculation of Registration Fee Table](ea027460901ex-fee_checkcap.htm) |  |  |  |  |

---

____________

\* Previously filed.

& Filed herewith.

#### Item 9. Undertakings
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The undersigned Registrant hereby undertakes:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i. To include any prospectus required by section 10(a)(3) of the Securities Act of 1933;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ii. To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post- effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the "Calculation of Registration Fee" table in the effective registration statement;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;iii. To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) That for the purpose of determining any liability under the Securities Act of 1933, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and this offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4) To file a post-effective amendment to the registration statement to include any financial statements required by Item 8.A. of Form 20-F at the start of any delayed offering or throughout a continuous offering. Financial statements and information otherwise required by Section 10(a)(3) of the Act need not be furnished, provided that the registrant includes in the prospectus, by means of a post-effective amendment, financial statements required pursuant to this paragraph (a)(4) and other information necessary to ensure that all other information in the prospectus is at least as current as the date of those financial statements. Notwithstanding the foregoing, with respect to registration statements on Form F-3, a post-effective amendment need not be filed to include financial statements and information required by Section 10(a)(3) of the Act or Item 8.A of Form 20-F if such financial statements and information are contained in periodic reports filed with or furnished to the Commission by the registrant pursuant to section 13 or section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the Form F-3.

[**Table of Contents**](#TOC001)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) The undersigned registrant hereby undertakes that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) That for purposes of determining any liability under the Securities Act of 1933, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4), or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) That for the purpose of determining any liability under the Securities Act of 1933, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

[**Table of Contents**](#TOC001)

#### SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form F-1 and has duly caused this registration statement on Form F-1 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Toronto, Ontario, Canada on January 30, 2026.

---

| | |
|:---|:---|
|  **CHECK**-CAP **LTD.** | **CHECK**-CAP **LTD.** |
|  By: | /s/ David Lontini  |
|  | David Lontini |
|  | Interim Chief Executive Officer |

---

#### POWER OF ATTORNEY
The undersigned officers and directors of Check-Cap Ltd. hereby constitute and appoint David Lontini as our true and lawful attorney-in-fact and agent to take any actions to enable the Company to comply with the Securities Act, and any rules, regulations and requirements of the SEC, in connection with this registration statement on Form F-1, including the power and authority to sign for us in our names in the capacities indicated below any and all further amendments to this registration statement and any other registration statement filed pursuant to the provisions of Rule 462 under the Securities Act.

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
|  **Signature** | **Title** | **Date** |
|  /s/ David Lontini | Chairman and Interim Chief Executive Officer | January 30, 2026 |
|  David Lontini | (Principal Executive Officer) |  |
|  /s/ Alan Lewis | Chief Financial Officer (Principal Financial | January 30, 2026 |
|  Alan Lewis | Officer and Principal Accounting Officer) |  |
|  /s/ Carlos Cheung | Director | January 30, 2026 |
|  Carlos Cheung |  |  |
|  /s/ Michael Hutton | Director | January 30, 2026 |
|  Michael Hutton |  |  |
|  /s/ Daniel Kokiw | Director | January 30, 2026 |
|  Daniel Kokiw |  |  |

---

[**Table of Contents**](#TOC001)

#### SIGNATURE OF AUTHORIZED REPRESENTATIVE IN THE UNITED STATES
Pursuant to the Securities Act of 1933, as amended, the undersigned, Puglisi & Associates, the duly authorized representative in the United States of Check-Cap Ltd., has signed this registration statement on January 30, 2026.

---

| | |
|:---|:---|
|  Puglisi & Associates | Puglisi & Associates |
|  By: | /s/ Donald J. Puglisi  |
|  | Donald J Puglisi  |
|  | Managing Director  |

---

## Exhibit 5.1

**Exhibit 5.1**

![](ex5-1_001.jpg)

January 30, 2026

<u>VIA ELECTRONIC TRANSMISSION</u>

Check-Cap Ltd.

29 Abba Hushi

Avenue

P.O. Box 1271

Isfiya, 3009000

Mount Carmel,

Israel

Re: <u>Check-Cap Ltd.; Form F-1 Registration Statement</u>

Ladies and Gentlemen:

We have acted as counsel to Check-Cap Ltd. (the "Company") in connection with the Company's registration statement on Form F-1 (such registration statement as amended or supplemented from time to time, the "Registration Statement"), as originally filed with the U.S. Securities and Exchange Commission on January 30, 2026, as thereafter amended and supplemented, relating to the registration under the U.S. Securities Act of 1933, as amended, of the offer and sale of up to 2,267,857 ordinary shares of the Company by ARC Group International Ltd. ("Arc"), which may be issued to Arc from time to time upon the exercise of the Company's right to put such shares to Arc pursuant to the Purchase Agreement, dated as of December 17, 2025, by and between the Company and Arc (the "Purchase Agreement").

We have examined the originals, photocopies, certified copies or other evidence of such records of the Company, certificates of officers of the Company and public officials, and other documents as we have deemed relevant and necessary as a basis for the opinion hereinafter expressed. In such examination, we have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as certified copies or photocopies and the authenticity of the originals of such documents.

Based on our examination mentioned above, we are of the opinion that the ordinary shares being sold by the Company pursuant to the Purchase Agreement have been duly authorized, and when issued in the manner described in the Registration Statement, will be validly issued, fully paid, and non-assessable (except as such non-assessability may be affected by Section 181 of the Israeli Companies Law and by Articles 14 and 16 of the Company's Articles of Association).

We hereby consent to the filing of this opinion as Exhibit 5.1 to the Registration Statement and to the reference to our firm under "Legal Matters" in the Registration Statement. In giving the foregoing consent, we do not hereby admit that we are in the category of persons whose consent is required under Section 7 of the Act, or the rules and regulations of the Securities and Exchange Commission.

Very truly yours,

*/s/ Rimon PC*

**RIMON, P.C, I www.RIMONLAW.COM (800) 930.7271 info@rimonlaw.com**

## Exhibit 10.20

**Exhibit 10.20**

**PURCHASE AGREEMENT**

**THIS PURCHASE AGREEMENT** (this "<u>Agreement</u>"), dated as of December 17, 2025, is made by and between ARC Group International Ltd. (the "<u>Investor</u>"), and Check-Cap Ltd., a company organized under the laws of the State of Israel (the "<u>Company</u>").

**WHEREAS**, the Company's ordinary shares, par value NIS 48.00 per share (the "<u>Ordinary Shares</u>"), are listed for trading on The Nasdaq Capital Market under the symbol "CHEK";

**WHEREAS**, the parties desire that, upon the terms and subject to the conditions contained herein, the Company shall have the right to issue and sell to the Investor, from time to time as provided herein, and the Investor shall purchase from the Company, up to USD $30,000,000 of Ordinary Shares (the "<u>Shares</u>"); and

**WHEREAS**, the offer and sale of the Shares issuable hereunder will be made in reliance upon Section 4(a)(2) under the Securities Act of 1933, as amended (the "<u>Securities Act</u>"), and the rules and regulations promulgated thereunder, or upon such other exemption from the registration requirements of the Securities Act as may be available with respect to any or all of the transactions to be made hereunder.

**NOW, THEREFORE**, in consideration of the foregoing and the mutual representations, warranties, covenants, and agreements herein contained, for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties, intending to be legally bound hereby, agree as follows:

**Article I**<br> **CERTAIN DEFINITIONS**

"<u>Advance</u>" shall mean the portion of the Commitment Amount requested by the Company in an Advance Notice (Drawdown 1) or Advance Notice (Drawdown 2), as applicable.

"<u>Advance Date</u>" shall mean the date of the delivery of the Shares issuable in respect of the applicable Advance Notice.

"<u>Advance Halt</u>" shall have the meaning set forth in Section 2.05(d).

"<u>Advance Notice</u>" shall mean, collectively, an Advance Notice (Drawdown 1) and Advance Notice (Drawdown 2).

"<u>Advance Notice (Drawdown 1)</u>" shall mean a written notice in the form of <u>Exhibit A</u> attached hereto to the Investor executed by an officer of the Company or other authorized representative of the Company identified on Schedule 1 hereto and setting forth the amount of an Advance that the Company desires to issue and sell to the Investor while no other Advance is ongoing pursuant to any Advance Notice.

"<u>Advance Notice (Drawdown 2)</u>" shall mean a written notice in the form of <u>Exhibit A</u> attached hereto to the Investor executed by an officer of the Company or other authorized representative of the Company identified on Schedule 1 hereto and setting forth the amount of an Advance that the Company desires to issue and sell to the Investor prior to the Settlement Date of any ongoing Advance pursuant to a valid Advance Notice.

"<u>Advance Notice Confirmation</u>" shall have the meaning set forth in Section 2.03(a).

"<u>Advance Notice Date</u>" shall mean each date the Company delivers (in accordance with Section 2.03 of this Agreement) to the Investor an Advance Notice, as applicable, subject to the terms of this Agreement.

"<u>Affiliate</u>" shall have the meaning set forth in Section 3.07.

"<u>Agreement</u>" shall have the meaning set forth in the preamble of this Agreement.

"<u>Applicable Laws</u>" shall mean all applicable laws, statutes, rules, regulations, orders, executive orders, directives, policies, guidelines and codes having the force of law, whether local, national, or international, as amended from time to time, including without limitation (i) all applicable laws that relate to money laundering, terrorist financing, financial record keeping and reporting, (ii) all applicable laws that relate to anti-bribery, anti-corruption, books and records and internal controls, including the United States Foreign Corrupt Practices Act of 1977, and (iii) any Sanctions laws.

"<u>Bankruptcy Law</u>" means Title 11, U.S. Code, or any similar federal, state or similar laws for the relief of debtors.

"<u>Black Out Period</u>" shall have the meaning set forth in Section 6.02.

"<u>Board of Directors</u>" means the Board of Directors of the Company.

"<u>Buy-In</u>" shall have the meaning set forth in Section 2.06.

"<u>Buy-In Price</u>" shall have the meaning set forth in Section 2.06.

"<u>Closing</u>" shall have the meaning set forth in Section 2.05.

"<u>Closing Price</u>" means (i) if this Agreement is fully executed during market hours (before the close of the regular session at 4:00 P.M. Eastern Time) on a Trading Day, the previous Trading Day's closing price of the Ordinary Shares (as reflected on Nasdaq.com), (ii) if this Agreement is fully executed after market hours (on or after the close of the regular session at 4:00 P.M. Eastern Time) on a Trading Day, that Trading Day's closing price of the Ordinary Shares (as reflected on Nasdaq.com), or (iii) if this Agreement is fully executed on a day that is not a Trading Day, the previous Trading Day's closing price of the Ordinary Shares (as reflected on Nasdaq.com).

"<u>Commitment Amount</u>" shall mean USD $30,000,000 of Ordinary Shares.

"<u>Commitment Fee Shares</u>" shall have the meaning set forth in Section 13.04.

"<u>Commitment Period</u>" shall mean the period commencing on the date hereof and expiring upon the date that is 36 months from the date hereof, unless earlier terminated in accordance with Section 11.02.

"<u>Ordinary Shares Equivalents</u>" means any securities of the Company which entitle the holder thereof to acquire at any time shares of Ordinary Shares, including, without limitation, any debt, preferred shares, rights, options, warrants or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, shares of Ordinary Shares.

"<u>Company</u>" shall have the meaning set forth in the preamble of this Agreement.

"<u>Company Indemnitees</u>" shall have the meaning set forth in Section 5.02.

"<u>Condition Satisfaction Date</u>" shall have the meaning set forth in Section 7.01

"<u>Confidential Information</u>" means all confidential, proprietary or non-public information, documentation or data (whether written, oral or electronic communications) regarding the Company or any of its affiliates received by a Purchaser or its Representatives, in each case, regardless of whether or not such information, documentation or data is marked or otherwise identified as "confidential". Confidential Information also includes information of third parties where the Company or its affiliates have an obligation of confidentiality with respect to such information. Confidential Information will not, however, include information which (a) is or becomes publicly available other than as a result of a disclosure by a Purchaser or its Representatives in violation of this Agreement, (b) is or becomes available to a Purchaser or any of its Representatives on a non-confidential basis from a third-party or (c) is or has been independently developed by a Purchaser and/or its Representatives without use of or reference to any Confidential Information.

"<u>Custodian</u>" means any receiver, trustee, assignee, liquidator or similar official under any Bankruptcy Law.

"<u>Daily Value Traded</u>" means the product obtained by multiplying the daily trading volume of the Ordinary Shares on the Principal Market or Trading Market, as applicable, during regular trading hours as reported by Bloomberg L.P., by the VWAP for such Trading Day. For the avoidance of doubt, the daily trading volume shall include all trades on the Principal Market or Trading Market during regular trading hours.

"<u>DTC</u>" means the Depository Trust Company.

"<u>DWAC Shares</u>" means the Shares acquired or purchased by the Investor pursuant to this Agreement (a) that the Investor has resold in a manner described under the caption "Plan of Distribution" in the Registration Statement and otherwise in compliance with this Agreement before the delivery of the Transfer Agent Confirmation regarding the resale of such Shares in accordance with this Agreement, and (b) about which the Investor has (i) delivered to the Company and the transfer agent to the Company (A) the Transfer Agent Confirmation relating to such Shares and (B) a customary representation letter from the Investor, and, if requested by the transfer agent, its broker, confirming, among other things, the resale of such Shares in the manner described in clause (a) of this definition of DWAC Shares (including confirmation of compliance with any relevant prospectus delivery requirements), and (ii) delivered to the transfer agent instructions for the delivery of such Shares to the account with DTC of the Investor's designated broker-dealer as specified in the Transfer Agent Deliverables, which Shares will be in the hands of the persons who purchase such or Shares from the Investor in the manner described in clause (a) of this definition of DWAC Shares, freely tradable and transferable without restriction on resale and without stop transfer instructions maintained against the transfer thereof.

"<u>Effective Date</u>" means the date a Registration Statement is declared effective.

"<u>Effectiveness Deadline</u>" shall have the meaning set forth in Section 6.01(a).

"<u>Exchange Act</u>" shall mean the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

"<u>Filing Deadline</u>" shall have the meaning set forth in Section 6.01(a).

"<u>Exchange Cap</u>" has the meaning set forth in Section 2.09.

"<u>Indemnified Liabilities</u>" shall have the meaning set forth in Section 5.01.

"<u>Initial Registration Statement</u>" shall have the meaning set forth in Section 6.01(a).

"<u>Investor</u>" shall have the meaning set forth in the preamble of this Agreement.

"<u>Investor Indemnitees</u>" shall have the meaning set forth in Section 5.01.

"<u>Material Adverse Effect</u>" shall mean any event, occurrence or condition that has had or would reasonably be expected to have (i) a material adverse effect on the legality, validity or enforceability of this Agreement or the transactions contemplated herein, (ii) a material adverse effect on the results of operations, assets, business or condition (financial or otherwise) of the Company, taken as a whole, or (iii) a material adverse effect on the Company's ability to perform in any material respect on a timely basis its obligations under this Agreement.

"<u>Material Outside Event</u>" shall have the meaning set forth in Section 6.08.

"<u>Maximum Advance Amount</u>" shall be, an amount equal to lesser of (i) 75% of the average of the Daily Value Traded of the Ordinary Shares over the 10 Trading Days immediately preceding the date an Advance Notice is delivered, or (ii) $5,000,000; provided, however, that the parties hereto may modify the aforementioned conditions by mutual prior written consent.

"<u>Merger</u>" shall mean the merger described in the Agreement and Plan of Merger entered into as of September 12, 2025, by and among MBody AI Corp., a Nevada corporation, the Company, and CC Merger Sub Inc., a Nevada corporation and a direct, wholly owned subsidiary of the Company.

"<u>OFAC</u>" shall mean the U.S. Department of Treasury's Office of Foreign Asset Control.

"<u>Ordinary Shares</u>" shall have the meaning set forth in the recitals of this Agreement.

"<u>Ownership Limitation</u>" shall have the meaning set forth in Section 2.04(a).

"<u>Person</u>" shall mean an individual, a corporation, a partnership, a limited liability company, a trust or other entity or organization, including a government or political subdivision or an agency or instrumentality thereof.

"<u>Plan of Distribution</u>" shall mean the section of a Registration Statement disclosing the plan of distribution of the Ordinary Shares.

"<u>Pricing Period</u>" shall mean, in respect of any Advance, the three (3) Trading Days commencing on the first full Trading Day following the delivery of the Shares in respect of the applicable Advance Notice.

"<u>Principal Market</u>" shall mean either The Nasdaq Capital Market; provided however, that in the event the Ordinary Shares are ever listed or traded on the Nasdaq Global Select Market, the Nasdaq Global Market, the New York Stock Exchange, or the NYSE American, then the "Principal Market" shall mean such other market or exchange on which the Ordinary Shares are then listed or traded to the extent such other market or exchange is the principal trading market or exchange for the Ordinary Shares.

"<u>Purchase Price</u>" shall mean, collectively, the Purchase Price (Drawdown 1) and Purchase Price (Drawdown 2).

"Purchase Price (Drawdown 1)" shall mean 95% of the lowest closing VWAP of the Ordinary Shares during the applicable Pricing Period related to an Advance Notice (Drawdown 1).

"Purchase Price (Drawdown 2)" shall mean 100% of the lowest intraday sale price of the Ordinary Shares on the same Trading Day on which an Advance Notice (Drawdown 2) is received, or, if such Advance Notice (Drawdown 2) is received after 8:30 a.m. Eastern Time, on the immediately following Trading Day.

"<u>Registrable Securities</u>" shall mean (i) the Commitment Fee Shares, (ii) the Shares, and (iii) any other Company securities issued or issuable with respect to any of the foregoing by way of exchange, stock dividend or stock split or in connection with a combination of shares, recapitalization, merger, consolidation or other reorganization or otherwise.

"<u>Registration Limitation</u>" shall have the meaning set forth in Section 2.04(b).

"<u>Registration Statement</u>" shall mean a registration statement on Form F-1 or Form F-3 or on such other form promulgated by the SEC for which the Company then qualifies and which counsel for the Company shall deem appropriate, and which form shall be available for the registration of the resale by the Investor of the Registrable Securities under the Securities Act.

"<u>Regulation D</u>" shall mean the provisions of Regulation D promulgated under the Securities Act.

"<u>Required Delivery Date</u>" means any date on which the Company or its transfer agent is required to deliver Ordinary Shares to Investor hereunder.

"<u>Rule 144 Holding Period</u>" means six months from the date of issuance of any Ordinary Shares issuable hereunder or such date as shall be required to comply with Rule 144 of the Securities Act.

"<u>Sanctions</u>" means any sanctions administered or enforced by OFAC, the U.S. State Department, the United Nations Security Council, the European Union, His Majesty's Treasury, or other relevant sanctions authority.

"<u>Sanctions Programs</u>" means any OFAC economic sanction program (including, without limitation, programs related to Crimea, Cuba, Iran, North Korea, Sudan and Syria).

"<u>SEC</u>" shall mean the U.S. Securities and Exchange Commission.

"<u>SEC Documents</u>" shall have the meaning set forth in Section 4.04.

"<u>Securities Act</u>" shall have the meaning set forth in the recitals of this Agreement.

"<u>Settlement Date</u>" shall mean the 3rd Trading Day after expiration of the applicable Pricing Period for each Advance or if the Investor shall not have sold all of the shares of Ordinary Shares in respect of such Advance the Trading Day following the date the Investor shall have sold all of the shares in respect of such Advance.

"<u>Settlement Document</u>" shall have the meaning set forth in Section 2.05(a).

"<u>Shares</u>" shall mean the shares of Ordinary Shares to be issued to the Investor from time to time hereunder pursuant to an Advance.

"<u>Trading Day</u>" shall mean any day during which the Principal Market or Trading Market shall be open for business.

"<u>Trading Market</u>" shall mean the New York Stock Exchange, the NYSE American LLC, the Nasdaq Global Select Market, the Nasdaq Global Market, the Nasdaq Capital Market, the Nasdaq Global Market Composite, the NYSE Euronext, OTCQX, OTCQB, OTCID, Pink Limited Market, whichever is at the time the principal trading exchange or market for the Ordinary Shares.

"<u>Transaction Documents</u>" shall have the meaning set forth in Section 4.02.

"<u>Transfer Agent Confirmation</u>" means a written confirmation sent by the Investor to the transfer agent that sets forth the number of DWAC Shares that have been resold, and the date(s) of such resales.

"<u>Transfer Agent Deliverables</u>" shall have the meaning set forth in Section 2.03(b).

"<u>VWAP</u>" means, for any Trading Day, the daily volume weighted average price of the Ordinary Shares for such Trading Day on the Principal Market or Trading Market from 9:30 a.m. Eastern Time through 4:00 p.m. Eastern Time, excluding the opening price and the closing price; provided, however, that upon the occurrence of an Advance Halt due to a Material Outside Event, the VWAP calculation shall terminate as of the effective time of the Material Outside Event.

**Article II**

**ADVANCES**

**Section 2.01 Advances; Mechanics.** Subject to the terms and conditions of this Agreement (including, without limitation, the provisions of Article VII hereof), the Company, at its sole and exclusive option, may issue and sell to the Investor, and the Investor shall purchase from the Company, Ordinary Shares on the terms set forth herein.

**Section 2.02 Advance Notice.** At any time during the Commitment Period, the Company may require the Investor to purchase Ordinary Shares by delivering an Advance Notice to the Investor, subject to the conditions set forth in Section 7.01, and in accordance with the following provisions:

&nbsp;&nbsp;&nbsp;&nbsp;a. The Company shall, in its sole discretion, select the amount of the Advance, not to exceed the Maximum
Advance Amount, it desires to issue and sell to the Investor in each Advance Notice and the time it desires to deliver each Advance Notice;
provided that the Company and the Investor can mutually agree in respect of any particular Advance to increase the amount of such Advance
up to 500% of the Maximum Advance Amount prior to the settlement of an ongoing Advance.

&nbsp;&nbsp;&nbsp;&nbsp;b. There shall be no mandatory minimum Advances and no non-usages fee for not utilizing the Commitment Amount or any part thereof.

&nbsp;&nbsp;&nbsp;&nbsp;c. The Advance Notice shall be valid upon delivery to Investor in accordance with <u>Exhibit C</u>.

&nbsp;&nbsp;&nbsp;&nbsp;d. Notwithstanding anything in this Agreement to the contrary:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i. In the event no Advance is ongoing pursuant to a valid Advance Notice at the time the Company delivers
an Advance Notice to the Investor, (i) such Advance Notice shall be deemed and treated as an Advance Notice (Drawdown 1), and (ii) the
Purchase Price applicable to such Advance shall be the Purchase Price (Drawdown 1).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ii. In the event the Company delivers an Advance Notice to the Investor on or prior to the Settlement Date
of an ongoing Advance, (i) such subsequent Advance Notice shall be deemed and treated as an Advance Notice (Drawdown 2), and (ii) the
Purchase Price applicable to such subsequent Advance shall be the Purchase Price (Drawdown 2).

**Section 2.03 Date of Delivery of Advance Notice; Issuance of Shares.** 

&nbsp;&nbsp;&nbsp;&nbsp;a. An Advance Notice shall be deemed delivered on the day it is received by the Investor if such notice is
received by email prior to 8:30 a.m. Eastern Time (or later if waived by the Investor in its sole discretion) in accordance with the instructions
set forth on <u>Exhibit C</u>. Following the receipt of such Advance Notice the Investor shall promptly provide the Company with a confirmation
of its receipt of such Advance Notice, which receipt may be in the form of an email (each, an " <u>Advance Notice Confirmation</u> ").

&nbsp;&nbsp;&nbsp;&nbsp;b. Promptly after receipt of the Advance Notice with respect to each Advance (and, in any event, not later
than three Trading Days after such receipt), the Company will, or will cause its transfer agent to, issue in the Investor's name
in a DRS account or accounts at the transfer agent all the Shares purchased by Investor pursuant to such Advance. Such Shares shall constitute
"restricted securities" as such term is defined in Rule 144(a)(3) under the Securities Act and the certificate or book-entry
statement representing such Shares shall bear the restrictive legend under the Securities Act set forth in Section 9.1(iii). Notwithstanding
the foregoing, if the Investor is to resell the Shares in a manner described under the caption "Plan of Distribution" in the
Registration Statement and otherwise in compliance with this Agreement prior to the delivery by the Investor to the Company of the appliable
Advance Notice Confirmation, the Investor shall concurrently with the delivery by the Investor to the Company of such Advance Notice Confirmation
deliver to the transfer agent the items set forth in clause (b) of the definition of DWAC Shares with respect to such resold Shares and
such other items as the transfer agent may reasonably request (collectively, the " <u>Transfer Agent Deliverables</u> "). With
respect to Shares to be resold by the Investor as described in the preceding sentence and as to which the Investor has timely delivered
the Transfer Agent Deliverables with respect to such Shares, such securities shall be delivered and credited by the transfer agent using
the Fast Automated Securities Transfer (FAST) Program maintained by DTC (or any similar program hereafter adopted by DTC performing substantially
the same function) to the account with DTC of the Investor's designated Broker-Dealer as specified in the Transfer Agent Deliverables
with respect to such securities at the time such securities would otherwise have been required to be delivered to the Investor in accordance
with this Agreement, which securities (x) shall only be used by the Investor's Broker-Dealer to deliver such securities to DTC for
the purpose of settling the Investor's share delivery obligations with respect to the sale of such Shares, which may include delivery
to other accounts of such Broker-Dealer and inclusion in the number of Shares delivered by that Broker-Dealer in "net settling"
that Broker-Dealer's trading of Shares, including its positions with the Broker-Dealers of the respective persons who purchase such
securities from the Investor, and (y) shall remain "restricted securities" as such term is defined in Rule 144(a)(3) under
the Securities Act until so delivered. The Company and the Investor acknowledge that such Shares credited to the account with DTC of the
Investor's designated Broker-Dealer shall be eligible for transfer to the third-party purchasers of such Shares or their respective
Broker-Dealers as DWAC Shares. No fractional shares shall be issued, and any fractional amounts shall be rounded to the next higher whole
number of shares. Any portion of the aggregate Purchase Price for Shares issued pursuant to an Advance that is not paid by the Investor
when due shall constitute a 'call' (or an amount payable at a fixed time) in respect of such Shares for purposes of Articles
14 and 16 of the Company's Articles of Association. Without limiting any other remedies available to the Company, the Company shall
be entitled to exercise all rights available under Articles 14 and 16 of its Articles of Association in respect of any such unpaid amounts,
including the right to charge interest and to forfeit the relevant Shares.

&nbsp;&nbsp;&nbsp;&nbsp;c. Each Advance Notice may specify a minimum acceptable price (the " <u>Floor Price</u> ") for
the applicable Advance. If, during the Pricing Period, the VWAP of the Ordinary Shares is below the Floor Price, the Investor shall not
be obligated to purchase, and the Company shall not be obligated to deliver, any Shares at prices below the Floor Price, and the amount
of the Advance shall be automatically reduced to exclude such Shares without penalty.

**Section 2.04 Advance Limitations**. Regardless of the amount of an Advance requested by the Company in the Advance Notice, the final amount of an Advance pursuant to an Advance Notice shall be reduced in accordance with each of the following limitations:

&nbsp;&nbsp;&nbsp;&nbsp;a. <u>Ownership Limitation; Commitment Amount</u>. In no event shall the number of Shares issuable to the
Investor pursuant to an Advance cause the aggregate number of shares of Ordinary Shares beneficially owned (as calculated pursuant to
Section 13(d) of the Exchange Act) by the Investor and its affiliates as a result of previous issuances and sales of Shares to Investor
under this Agreement to exceed 9.99% of the then issued and outstanding shares of Ordinary Shares (the " <u>Ownership Limitation</u> ").
In connection with each Advance Notice delivered by the Company, any portion of an Advance that would (i) cause the Investor to exceed
the Ownership Limitation, or (ii) cause the aggregate number of Shares issued and sold to the Investor hereunder to exceed the Commitment
Amount shall automatically be withdrawn with no further action required by the Company, and such Advance Notice shall be deemed automatically
modified to reduce the amount of the Advance requested by an amount equal to such withdrawn portion; provided that in the event of any
such automatic withdrawal and automatic modification, Investor will promptly notify the Company of such event.

&nbsp;&nbsp;&nbsp;&nbsp;b. <u>Registration Limitation</u>. In no event shall an Advance exceed the amount registered under the Registration
Statement then in effect (the " <u>Registration Limitation</u> ") or the Exchange Cap to the extent applicable. In connection
with each Advance Notice, any portion of an Advance that would exceed the Registration Limitation or Exchange Cap shall automatically
be withdrawn with no further action required by the Company and such Advance Notice shall be deemed automatically modified to reduce the
aggregate amount of the requested Advance by an amount equal to such withdrawn portion in respect of each Advance Notice; provided that
in the event of any such automatic withdrawal and automatic modification, Investor will promptly notify the Company of such event.

&nbsp;&nbsp;&nbsp;&nbsp;c. Notwithstanding any other provision in this Agreement, the Company and the Investor acknowledge and agree
that upon the Investor's receipt of a valid Advance Notice the parties shall be deemed to have entered into an unconditional contract
binding on both parties for the purchase and sale of Ordinary Shares pursuant to such Advance Notice in accordance with the terms of this
Agreement and, subject to Applicable Law and Section 3.08 (Trading Activities), subject to ‎Section 6.18, and subject to the Floor
Price condition set forth in Section 2.03(c), the Investor may sell Ordinary Shares during the Pricing Period.

**Section 2.05 Closings**. The closing of each Advance and each sale and purchase of Shares related to each Advance (each, a "<u>Closing</u>") shall take place on the applicable Settlement Date in accordance with the procedures set forth below. The parties acknowledge that the Purchase Price is not known at the time the Advance Notice is delivered (at which time the Investor is irrevocably bound) but shall be determined on each Closing based on the daily prices of the Ordinary Shares that are the inputs to the determination of the Purchase Price as set forth further below. In connection with each Closing, and subject to <u>Section 2.02.d</u> of this Agreement, the Company and the Investor shall fulfill each of its obligations as set forth below:

&nbsp;&nbsp;&nbsp;&nbsp;a. On the Settlement Date in respect of an Advance, the Investor shall deliver to the Company a written document,
in the form attached hereto as <u>Exhibit B</u> (each a " <u>Settlement Document</u> "), setting forth the final number of Shares
to be purchased by the Investor (taking into account any adjustments pursuant to <u>Section 2.04</u>), the applicable Purchase Price,
the aggregate proceeds to be paid by the Investor to the Company, and a report by Bloomberg, L.P. indicating the VWAP of the Ordinary
Shares for each of the Trading Days during the applicable Pricing Period (or, if not reported on Bloomberg, L.P., another reporting service
reasonably agreed to by the parties), in each case in accordance with the terms and conditions of this Agreement. The Investor shall pay
to the Company the aggregate Purchase Price of the Shares (as set forth in the Settlement Document) in cash in immediately available funds
to an account designated by the Company in writing, and transmit notification to the Company that such funds transfer has been requested.

&nbsp;&nbsp;&nbsp;&nbsp;b. Notwithstanding anything to the contrary in this Agreement, if on any day during the Pricing Period (i)
the Company notifies Investor that a Material Outside Event set forth in Section 6.08(i) through (v) has occurred or if the Material Outside
Event set forth in Sections 6.08(vi) or (vii) shall have occurred, or (ii) the Company notifies the Investor of a Black Out Period, the
parties agree that the pending Advance shall end (the " <u>Advance Halt</u> ") and the final number of Shares to be purchased
by the Investor at the Closing for such Advance shall be equal to the number of Shares sold by the Investor during the applicable Pricing
Period prior to the notification from the Company of a Material Outside Event or Black Out Period.

&nbsp;&nbsp;&nbsp;&nbsp;c. On or prior to the Settlement Date, each of the Company and the Investor shall deliver to the other all
documents, instruments and writings expressly required to be delivered by either of them pursuant to this Agreement in order to implement
and effect the transactions contemplated herein.

**Section 2.06 Intentionally Omitted**.

**Section 2.07 Return of Surplus**. If the value of the Shares delivered to the Investor causes the Company to exceed the Commitment Amount, then the Investor shall return to the Company the surplus amount of Shares associated with such Advance.

**Section 2.08 Completion of Resale Pursuant to the Registration Statement**. After the Investor has purchased the full Commitment Amount and has completed the subsequent resale of the full Commitment Amount pursuant to the Registration Statement, the Investor will notify the Company that all subsequent resales are completed and the Company will be under no further obligation to maintain the effectiveness of the Registration Statement.

**Section 2.09 Exchange Cap**. Notwithstanding anything to the contrary in this Agreement, the Company shall not effect any sales under this Agreement and the Investor shall not have the obligation to purchase Ordinary Shares under this Agreement to the extent (but only to the extent) that after giving effect to such purchase and sale the aggregate number of Ordinary Shares issued under this Agreement (including all of the Registrable Securities) would exceed 19.99% of the issued and outstanding shares of Ordinary Shares as of the date of this Agreement (the "<u>Exchange Cap</u>"); provided, however, that, the Exchange Cap will not apply (i) if the Company obtains the requisite stockholder approval for issuances in excess of the Exchange Cap or (ii) if, and only to the extent, that The Nasdaq Stock Market ("<u>Nasdaq</u>") grants an exception to permit shares of Ordinary Shares to be sold in excess of the Exchange Cap pursuant to Nasdaq Listing Rule 5635(f) without stockholder approval.

**Article III**

**REPRESENTATIONS AND WARRANTIES OF INVESTOR**

Investor hereby represents and warrants to, and agrees with, the Company that the following are true and correct as of the date hereof and as of each Advance Notice Date and each Advance Date:

**Section 3.01 Organization and Authorization**. The Investor is duly organized, validly existing and in good standing under the laws of its jurisdiction of organization and has all requisite power and authority to execute, deliver and perform this Agreement, including all transactions contemplated hereby. The decision to invest and the execution and delivery of this Agreement by the Investor, the performance by the Investor of its obligations hereunder and the consummation by the Investor of the transactions contemplated hereby have been duly authorized and require no other proceedings on the part of the Investor. The undersigned has the right, power and authority to execute and deliver this Agreement and all other instruments on behalf of the Investor or its shareholders. This Agreement has been duly executed and delivered by the Investor and, assuming the execution and delivery hereof and acceptance thereof by the Company, will constitute the legal, valid and binding obligations of the Investor, enforceable against the Investor in accordance with its terms.

**Section 3.02 Evaluation of Risks**. The Investor has such knowledge and experience in financial, tax and business matters as to be capable of evaluating the merits and risks of, and bearing the economic risks entailed by, an investment in the Ordinary Shares of the Company and of protecting its interests in connection with the transactions contemplated hereby. The Investor acknowledges and agrees that its investment in the Company involves a high degree of risk, and that the Investor may lose all or a part of its investment.

**Section 3.03 No Legal, Investment or Tax Advice from the Company**. The Investor acknowledges that it had the opportunity to review this Agreement and the transactions contemplated by this Agreement with its own legal counsel and investment and tax advisors. The Investor is relying solely on such counsel and advisors and not on any statements or representations of the Company or any of the Company's representatives or agents for legal, tax, investment or other advice with respect to the Investor's acquisition of Ordinary Shares hereunder, the transactions contemplated by this Agreement or the laws of any jurisdiction, and the Investor acknowledges that the Investor may lose all or a part of its investment.

**Section 3.04 Investment Purpose**. The Investor is acquiring the Ordinary Shares for its own account, for investment purposes and not with a view towards, or for resale in connection with, the public sale or distribution thereof, except pursuant to sales registered under or exempt from the registration requirements of the Securities Act; provided, however, that by making the representations herein, the Investor does not agree, or make any representation or warranty, to hold any of the Ordinary Shares for any minimum or other specific term and reserves the right to dispose of the Ordinary Shares at any time in accordance with, or pursuant to, a registration statement filed pursuant to this Agreement or an applicable exemption under the Securities Act. The Investor does not presently have any agreement or understanding, directly or indirectly, with any Person to sell or distribute any of the Shares. The Investor acknowledges that it will be disclosed as an "underwriter" and a "selling stockholder" in each Registration Statement and in any prospectus contained therein.

**Section 3.05. Accredited Investor**. The Investor is an "Accredited Investor" as that term is defined in Rule 501(a)(3) of Regulation D.

**Section 3.06 Information**. The Investor and its advisors (and its counsel), if any, have been furnished with all materials relating to the business, finances and operations of the Company and information the Investor deemed material to making an informed investment decision. The Investor and its advisors (and its counsel), if any, have been afforded the opportunity to ask questions of the Company and its management and have received answers to such questions. Neither such inquiries nor any other due diligence investigations conducted by such Investor or its advisors (and its counsel), if any, or its representatives shall modify, amend or affect the Investor's right to rely on the Company's representations and warranties contained in this Agreement. The Investor acknowledges and agrees that the Company has not made to the Investor, and the Investor acknowledges and agrees it has not relied upon, any representations and warranties of the Company, its employees or any third party other than the representations and warranties of the Company contained in this Agreement. The Investor understands that its investment involves a high degree of risk. The Investor has sought such accounting, legal and tax advice, as it has considered necessary to make an informed investment decision with respect to the transactions contemplated hereby. The Investor acknowledges that it has reviewed or has access to the SEC Filings, including, without limitation, the Company's Annual Report on Form 20-F for the fiscal year ended December 31, 2024, filed with the SEC on August 27, 2025 (the "Annual Report"), and the Company's Current Reports on Form 6-K filed with the SEC since the filing of the Annual Report, including the risk factors contained therein.

**Section 3.07 Not an Affiliate**. The Investor is not an officer, director or a person that directly, or indirectly through one or more intermediaries, controls or is controlled by, or is under common control with the Company or any "affiliate" of the Company (as that term is defined in Rule 405 promulgated under the Securities Act).

**Section 3.08 Trading Activities**. The Investor's trading activities with respect to the Ordinary Shares shall be in compliance with all applicable federal and state securities laws, rules and regulations and the rules and regulations of the Principal Market or Trading Market. Neither the Investor nor its affiliates has any open short position in the Ordinary Shares, nor has the Investor entered into any hedging transaction that establishes a net short position with respect to the Ordinary Shares, and the Investor agrees that it shall not, and that it will cause its affiliates not to, engage in any short sales or hedging transactions with respect to the Ordinary Shares during the terms of this Agreement; provided that the Company acknowledges and agrees that upon receipt of an Advance Notice the Investor has the right to sell (a) the Shares to be issued to the Investor pursuant to the Advance Notice prior to receiving such Shares, or (b) other shares of Ordinary Shares issued or sold by the Company to Investor pursuant to this Agreement and which the Company has continuously held as a long position.

**Section 3.09 General Solicitation**. Neither the Investor, nor any of its affiliates, nor any person acting on its or their behalf, has engaged or will engage in any form of general solicitation or general advertising (within the meaning of Regulation D) in connection with any offer or sale of the Ordinary Shares by the Investor.

**Section 3.10 Reliance o<u>n Exemptions</u>.** The Investor understands that the Shares are being offered and sold to it in reliance on specific exemptions from the registration requirements of United States federal and state securities laws and that the Company is relying in part upon the truth and accuracy of, and the Investor's compliance with, the representations, warranties, agreements, acknowledgments and understandings of the Investor set forth herein in order to determine that the offering qualifies for such exemptions and to comply with applicable securities laws.

**Section 3.11 <u>Resale of Shares</u>**. The Investor represents, warrants and covenants that it will resell the Shares only pursuant to (i) a Registration Statement in which the resale of such Shares is registered under the Securities Act, in a manner described under the caption "Plan of Distribution" in such Registration Statement, and in a manner in material compliance with all applicable federal and state securities laws, rules and regulations, or (ii) pursuant to an exception or exemption from the registration provisions of the Securities Act.

**Article IV**<br> **REPRESENTATIONS AND WARRANTIES OF THE COMPANY**

Except as set forth in the SEC Documents, or in the Disclosure Schedules, which Disclosure Schedules shall be deemed a part hereof and shall qualify any representation or warranty otherwise made herein to the extent of the disclosure contained in the corresponding section of the Disclosure Schedules or in another Section of the Disclosure Schedules, to the extent that it is reasonably apparent on the face of such disclosure that such disclosure is applicable to such Section, the Company represents and warrants to the Investor that, as of the date hereof and each Advance Notice Date (other than representations and warranties which address matters only as of a certain date, which shall be true and correct as written as of such certain date), that:

**Section 4.01 Organization and Qualification**. The Company is an entity duly organized and validly existing under the laws of its state of organization or incorporation, and has the requisite power and authority to own its properties and to carry on its business as now being conducted. The Company is duly qualified to do business and is in good standing (to the extent applicable) in every jurisdiction in which the nature of the business conducted by it makes such qualification necessary, except to the extent that the failure to be so qualified or be in good standing would not have a Material Adverse Effect.

**Section 4.02 Authorization, Enforcement, Compliance with Other Instruments**. The Company has the requisite corporate power and authority to enter into and perform its obligations under this Agreement and the other Transaction Documents and to issue the Shares in accordance with the terms hereof and thereof. The execution and delivery by the Company of this Agreement and the other Transaction Documents, and the consummation by the Company of the transactions contemplated hereby and thereby (including, without limitation, the issuance of the Shares) have been or (with respect to consummation) will be duly authorized by the Board of Directors and no further consent or authorization will be required by the Company, its Board of Directors or its stockholders (except as otherwise contemplated by this Agreement). This Agreement and the other Transaction Documents to which it is a party have been (or, when executed and delivered, will be) duly executed and delivered by the Company and, assuming the execution and delivery thereof and acceptance by the Investor, constitute (or, when duly executed and delivered, will be) the legal, valid and binding obligations of the Company, enforceable against the Company in accordance with their respective terms, except as such enforceability may be limited by general principles of equity or applicable bankruptcy, insolvency, reorganization, moratorium, liquidation or other laws relating to, or affecting generally, the enforcement of applicable creditors' rights and remedies and except as rights to indemnification and to contribution may be limited by federal or state securities law. "<u>Transaction Documents</u>" means, collectively, this Agreement and each of the other agreements and instruments entered into or delivered by any of the parties hereto in connection with the transactions contemplated hereby and thereby, as may be amended from time to time.

**Section 4.03 No Conflict**. The execution, delivery and performance of the Transaction Documents by the Company and the consummation by the Company of the transactions contemplated hereby and thereby (including, without limitation, the issuance of the Shares) will not (i) result in a violation of the certificate of incorporation or other organizational documents of the Company (with respect to consummation, as the same may be amended from time to time prior to the date on which any of the transactions contemplated hereby are consummated), (ii) conflict with, or constitute a default (or an event which with notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument to which the Company is a party, or (iii) result in a violation of any law, rule, regulation, order, judgment or decree (including federal and state securities laws and regulations) applicable to the Company or by which any property or asset of the Company is bound or affected except, in the case of clause (ii) or (iii) above, to the extent such violations or conflicts would not reasonably be expected to have a Material Adverse Effect.

**Section 4.04 SEC Documents; Financial Statements**. The Company has filed all reports, schedules, forms, statements and other documents required to be filed by it with the SEC pursuant to the Exchange Act for the two years preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such material) (all of the foregoing filed within the past two years preceding the date hereof or amended after the date hereof, or filed after the date hereof, and all exhibits included therein and financial statements and schedules thereto and documents incorporated by reference therein, and all registration statements filed by the Company under the Securities Act, being hereinafter referred to as the "<u>SEC Documents</u>"). The Company has made available to the Investor through the SEC's website at http://www.sec.gov, true and complete copies of the SEC Documents, and none of the SEC Documents, when viewed as a whole as of the date hereof, contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. As of their respective dates (or, with respect to any filing that has been amended or superseded, the date of such amendment or superseding filing), the SEC Documents complied in all material respects with the requirements of the Exchange Act or the Securities Act, as applicable, and the rules and regulations of the SEC promulgated thereunder applicable to the SEC Documents, except as may be otherwise noted in the SEC Documents. As of their respective dates (or, with respect to any financial statements that have been amended or superseded, the date of such amended or superseding financial statements), the financial statements of the Company included in the SEC Documents complied as to form in all material respects with applicable accounting requirements and the published rules and regulations of the SEC with respect thereto. Such financial statements have been prepared in accordance with generally accepted accounting principles, consistently applied, during the periods involved (except (i) as may be otherwise indicated in such financial statements or the notes thereto, or (ii) in the case of unaudited interim statements, to the extent they may exclude footnotes or may be condensed or summary statements) and fairly present in all material respects the financial position of the Company as of the respective dates thereof and the results of its operations and cash flows for the periods then ended (subject, in the case of unaudited statements, to normal year-end audit adjustments).

**Section 4.05 Equity Capitalization**. As of the date hereof, the authorized capital of the Company consists of 18,000,000 Ordinary Shares, of which, 7,020,502 Ordinary Shares are issued and outstanding

**Section 4.06 Intellectual Property Rights**. The Company owns or possesses adequate rights or licenses to use all trademarks, trade names, service marks, service mark registrations, service names, patents, patent rights, copyrights, inventions, licenses, approvals, governmental authorizations, trade secrets and rights, if any, necessary to conduct their respective businesses as now conducted, except as would not cause a Material Adverse Effect. The Company has not received written notice of any infringement by the Company of trademark, trade name rights, patents, patent rights, copyrights, inventions, licenses, service names, service marks, service mark registrations, or trade secrets. To the knowledge of the Company, there is no claim, action or proceeding being made or brought against, or to the Company's knowledge, being threatened against the Company regarding any material trademark, trade name, patents, patent rights, invention, copyright, license, service names, service marks, service mark registrations, trade secret or other infringement; and the Company is not aware of any facts or circumstances which might give rise to any of the foregoing.

**Section 4.07 Employee Relations**. The Company is not involved in any labor dispute nor, to the knowledge of the Company, is any such dispute threatened, in each case which is reasonably likely to cause a Material Adverse Effect.

**Section 4.08 Title**. Except as would not cause a Material Adverse Effect, the Company has indefeasible fee simple or leasehold title to its properties and assets owned by it, free and clear of any pledge, lien, security interest, encumbrance, claim or equitable interest. Any real property and facilities held under lease by the Company are held by them under valid, subsisting and enforceable leases with such exceptions as are not material and do not interfere with the use made and proposed to be made of such property and buildings by the Company.

**Section 4.09 Reserved**.

**Section 4.10 Insurance**. The Company is insured by insurers of recognized financial responsibility against such losses and risks and in such amounts as management of the Company believes to be prudent and customary in the businesses in which the Company is engaged. The Company has no reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business at a cost that would not have a Material Adverse Effect.

**Section 4.11 Regulatory Permits**. Except as would not cause a Material Adverse Effect, the Company possesses all certificates, authorizations and permits issued by the appropriate federal, state or foreign regulatory authorities necessary to own their respective businesses, and the Company has not received any written notice of proceedings relating to the revocation or modification of any such certificate, authorization or permits.

**Section 4.12 Internal Accounting Controls**. Except as set forth in the SEC Documents, the Company maintains a system of internal accounting controls sufficient to provide reasonable assurance that (i) transactions are executed in accordance with management's general or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with generally accepted accounting principles and to maintain asset accountability, (iii) access to assets is permitted only in accordance with management's general or specific authorization, and (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences, and management is not aware of any material weaknesses that are not disclosed in the SEC Documents as and when required.

**Section 4.13 Absence of Litigation**. Except as set forth in the SEC Documents, there is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending against or affecting the Company, or the Ordinary Shares, wherein an unfavorable decision, ruling or finding would have a Material Adverse Effect.

**Section 4.14 Subsidiaries**. Except as set forth in the SEC Documents, as of the date hereof, the Company does not own or control, directly or indirectly, any interest in any other corporation, partnership, association or other business entity.

**Section 4.15 Tax Status**. Except as would not have a Material Adverse Effect, or except as set forth in the SEC Documents, the Company (i) has timely made or filed all foreign, federal and state income and all other tax returns, reports and declarations required by any jurisdiction to which it is subject, (ii) has timely paid all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due on such returns, reports and declarations, except those being contested in good faith and (iii) has set aside on its books provision reasonably adequate for the payment of all taxes for periods subsequent to the periods to which such returns, reports or declarations apply. The Company has not received written notification of any unpaid taxes in any material amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company know of no basis for any such claim where failure to pay would cause a Material Adverse Effect.

**Section 4.16 Certain Transactions**. Except as (i) set forth in the SEC Documents or (ii) not required to be disclosed pursuant to Applicable Law (including, for the avoidance of doubt, not yet required to be disclosed at the relevant time), none of the officers or directors of the Company is presently a party to any transaction with the Company (other than for services as employees, officers and directors), including any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to or from, or otherwise requiring payments to or from any officer or director, or to the knowledge of the Company, any corporation, partnership, trust or other entity in which any officer or director has a substantial interest or is an officer, director, trustee or partner.

**Section 4.17 Reserved**.

**Section 4.18 Dilution**. The Company is aware and acknowledges that the issuance of the Shares hereunder could cause dilution to existing stockholders and could significantly increase the outstanding number of Ordinary Shares.

**Section 4.19 Acknowledgment Regarding Investor's Purchase of Shares**. The Company acknowledges and agrees that the Investor is acting solely in the capacity of an arm's length investor with respect to this Agreement and the transactions contemplated hereunder. The Company further acknowledges that the Investor is not acting as a financial advisor or fiduciary of the Company (or in any similar capacity) with respect to this Agreement and the transactions contemplated hereunder and any advice given by the Investor or any of its representatives or agents in connection with this Agreement and the transactions contemplated hereunder is merely incidental to the Investor's purchase of the Shares hereunder. The Company is aware and acknowledges that it shall not be able to request Advances under this Agreement if the Registration Statement is not effective or if any issuances of Shares pursuant to any Advances would violate any rules of the Principal Market or Trading Market.

**Section 4.20 Sanctions Matters**. Neither the Company nor, to the Company's knowledge, any director, officer, agent, employee or affiliate of the Company is a Person that is, or is owned or controlled by a Person that is on the list of Specially Designated Nationals and Blocked Persons maintained by OFAC from time to time:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. the subject of any Sanctions; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. has a place of business in, or is operating, organized, resident or doing business in a country or territory
that is, or whose government is, the subject of Sanctions Programs (including without limitation Crimea, Cuba, Iran, North Korea, Sudan
and Syria).

**Section 4.21 DTC Eligibility**. The Company, through the transfer agent, currently participates in the DTC Fast Automated Securities Transfer (FAST) Program and the Ordinary Shares can be transferred electronically to third parties via the DTC Fast Automated Securities Transfer (FAST) Program.

**Article V**<br> **INDEMNIFICATION**

**Section 5.01 Indemnification by the Company**. In consideration of the Investor's execution and delivery of this Agreement, and in addition to all of the Company's other obligations under this Agreement, to the extent permitted by law, the Company shall defend, protect, indemnify and hold harmless the Investor, its investment manager, and each of their respective officers, directors, managers, members, partners, employees and agents (including, without limitation, those retained in connection with the transactions contemplated by this Agreement) and each person who controls the Investor within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act (collectively, the "<u>Investor Indemnitees</u>") from and against any and all actions, causes of action, suits, claims, losses, costs, penalties, fees, liabilities and damages, and reasonable and documented expenses in connection therewith (irrespective of whether any such Investor Indemnitee is a party to the action for which indemnification hereunder is sought), and including reasonable attorneys' fees and disbursements (the "<u>Indemnified Liabilities</u>"), incurred by the Investor Indemnitees or any of them as a result of, or arising out of, or relating to (a) any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement for the registration of the Shares as originally filed or in any amendment thereof, or in any related prospectus, or in any amendment thereof or supplement thereto, or arise out of or are based upon the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading; <u>provided</u>, <u>however</u>, that the Company will not be liable in any such case to the extent that any such loss, claim, damage or liability arises out of or is based upon any such untrue statement or alleged untrue statement or omission or alleged omission made therein in reliance upon and in conformity with written information furnished to the Company by or on behalf of the Investor specifically for inclusion therein; (b) any material misrepresentation or breach of any material representation or material warranty made by the Company in this Agreement or any other certificate, instrument or document contemplated hereby or thereby; or (c) any material breach of any material covenant, material agreement or material obligation of the Company contained in this Agreement or any other certificate, instrument or document contemplated hereby or thereby; provided, however, that the Company will not be liable in any such case to the extent that any such loss, claim, damage or liability is the direct result of the fraud, gross negligence or intentional misconduct of the Investor (as determined by a final non-appealable judgment of court having jurisdiction over such matter). To the extent that the foregoing undertaking by the Company may be unenforceable under Applicable Law, the Company shall make the maximum contribution to the payment and satisfaction of each of the Indemnified Liabilities, which is permissible under Applicable Law.

**Section 5.02 Notice of Claim**. Promptly after receipt by an Investor Indemnitee or Company Indemnitee of notice of the commencement of any action or proceeding (including any governmental action or proceeding) involving an Indemnified Liability, such Investor Indemnitee or Company Indemnitee, as applicable, shall, if a claim for an Indemnified Liability in respect thereof is to be made against any indemnifying party under this Article V, deliver to the indemnifying party a written notice of the commencement thereof; but the failure to so notify the indemnifying party will not relieve it of liability under this Article V except to the extent the indemnifying party is prejudiced by such failure. The indemnifying party shall have the right to participate in, and, to the extent the indemnifying party so desires, jointly with any other indemnifying party similarly noticed, to assume control of the defense thereof with counsel mutually reasonably satisfactory to the indemnifying party and the Investor Indemnitee or Company Indemnitee, as the case may be; provided, however, that an Investor Indemnitee or Company Indemnitee shall have the right to retain its own counsel with the actual and reasonable third party fees and expenses of not more than one counsel for such Investor Indemnitee or Company Indemnitee to be paid by the indemnifying party, if, in the reasonable opinion of counsel retained by the indemnifying party, the representation by such counsel of the Investor Indemnitee or Company Indemnitee and the indemnifying party would be inappropriate due to actual or potential differing interests between such Investor Indemnitee or Company Indemnitee and any other party represented by such counsel in such proceeding. The Investor Indemnitee or Company Indemnitee shall cooperate fully with the indemnifying party in connection with any negotiation or defense of any such action or claim by the indemnifying party and shall furnish to the indemnifying party all information reasonably available to the Investor Indemnitee or Company Indemnitee which relates to such action or claim. The indemnifying party shall keep the Investor Indemnitee or Company Indemnitee reasonably apprised as to the status of the defense or any settlement negotiations with respect thereto. No indemnifying party shall be liable for any settlement of any action, claim or proceeding effected without its prior written consent, provided, however, that the indemnifying party shall not unreasonably withhold, delay or condition its consent. No indemnifying party shall, without the prior written consent of the Investor Indemnitee or Company Indemnitee, consent to entry of any judgment or enter into any settlement or other compromise which does not include as an unconditional term thereof the giving by the claimant or plaintiff to such Investor Indemnitee or Company Indemnitee of a release from all liability in respect to such claim or litigation. Following indemnification as provided for hereunder, the indemnifying party shall be subrogated to all rights of the Investor Indemnitee or Company Indemnitee with respect to all third parties, firms or corporations relating to the matter for which indemnification has been made. The indemnification required by this Article V shall be made by periodic payments of the amount thereof during the course of the investigation or defense, as and when bills are received and payment therefor is due, subject to receipt by the indemnifying party of an undertaking to repay any amounts that such party is ultimately not entitled to receive as indemnification pursuant to this Agreement.

**Section 5.03 Remedies**. The remedies provided for in this Article V are not exclusive and shall not limit any right or remedy which may be available to any indemnified person at law or equity. The obligations of the parties to indemnify or make contribution under this Article V shall survive expiration or termination of this Agreement.

**Section 5.04 Limitation of Liability**. Notwithstanding the foregoing, no party shall be entitled to recover from the other party for punitive, indirect, incidental or consequential damages.

**Article VI**<br> **COVENANTS**

**Section 6.01 Registration Statement**.

&nbsp;&nbsp;&nbsp;&nbsp;a. <u>Filing of a Registration Statement</u>. As soon as reasonably possible following the date hereof (the
" <u>Filing Deadline</u> "), the Company shall have prepared and filed with the SEC, a Registration Statement for the resale
by the Investor of Registrable Securities (the " <u>Initial Registration Statement</u> ") and shall file one or more additional
Registration Statements for the resale by Investor of Registrable Securities if necessary. The Company shall use its best efforts to have
such Registration Statement declared effective as soon as reasonably possible following the initial filing of the Initial Registration
Statement (the " <u>Effectiveness Deadline</u> "). The Company acknowledges and agrees that it shall not have the ability to
request any Advances until the effectiveness of a Registration Statement registering the applicable Registrable Securities for resale
by the Investor.

&nbsp;&nbsp;&nbsp;&nbsp;b. <u>Maintaining a Registration Statement</u>. After the Effectiveness Date, the Company shall use commercially
reasonable efforts to maintain the effectiveness of any Registration Statement that has been declared effective at all times during the
Commitment Period, provided, however, that if the Company has received notification pursuant to Section 2.08 that the Investor has completed
resales pursuant to the Registration Statement for the full Commitment Amount, then the Company shall be under no further obligation to
maintain the effectiveness of the Registration Statement. Notwithstanding anything to the contrary contained in this Agreement, the Company
shall use commercially reasonable efforts to ensure that, when filed, each Registration Statement (including, without limitation, all
amendments and supplements thereto) and the prospectus (including, without limitation, all amendments and supplements thereto) used in
connection with such Registration Statement shall not contain any untrue statement of a material fact or omit to state a material fact
required to be stated therein, or necessary to make the statements therein (in the case of prospectuses, in the light of the circumstances
in which they were made) not misleading. During the Commitment Period, the Company shall notify the Investor promptly if (i) the Registration
Statement shall cease to be effective under the Securities Act, (ii) the Ordinary Shares shall cease to be authorized for listing on the
Principal Market or Trading Market, (iii) the Ordinary Shares ceases to be registered under Section 12(b) or Section 12(g) of the Exchange
Act or (iv) the Company fails to file in a timely manner all reports and other documents required of it as a reporting company under the
Exchange Act.

&nbsp;&nbsp;&nbsp;&nbsp;c. <u>Filing Procedures</u>. Not less than one Trading Day prior to the filing of a Registration Statement
and not less than one Trading Day prior to the filing of any related amendments and supplements to any Registration Statement (except
for any amendments or supplements caused by the filing of any annual reports on Form 20-F, reports on Form 6-K, and any similar or successor
reports), the Company shall furnish to the Investor copies of all such documents proposed to be filed, which documents (other than those
filed pursuant to Rule 424 promulgated under the Securities Act) will be subject to the reasonable and prompt review of the Investor (in
each of which cases, if such document contains material non-public information as consented to by the Investor pursuant to Section 6.15,
the information provided to Investor will be kept strictly confidential until filed and treated as subject to Section 6.08). The Investor
shall furnish comments on a Registration Statement and any related amendment and supplement to a Registration Statement to the Company
within 24 hours of the receipt thereof. If the Investor fails to provide comments to the Company within such 24-hour period, then the
Registration Statement, related amendment or related supplement, as applicable, shall be deemed accepted by the Investor in the form originally
delivered by the Company to the Investor.

&nbsp;&nbsp;&nbsp;&nbsp;d. <u>Delivery of Final Documents</u>. The Company shall furnish to the Investor without charge, (i) at least
one copy of each Registration Statement as declared effective by the SEC and any amendment(s) thereto, including financial statements
and schedules, all documents incorporated therein by reference, all exhibits and each preliminary prospectus, (ii) at the request of the
Investor, at least one copy of the final prospectus included in such Registration Statement and all amendments and supplements thereto
(or such other number of copies as the Investor may reasonably request) and (iii) such other documents as the Investor may reasonably
request from time to time in order to facilitate the disposition of the Ordinary Shares owned by the Investor pursuant to a Registration
Statement. Filing of the foregoing with the SEC via its EDGAR system shall satisfy the requirements of this section.

&nbsp;&nbsp;&nbsp;&nbsp;e. <u>Amendments and Other Filings</u>. The Company shall use commercially reasonable efforts to (i) prepare
and file with the SEC such amendments (including post-effective amendments) and supplements to a Registration Statement and the related
prospectus used in connection with such Registration Statement, which prospectus is to be filed pursuant to Rule 424 promulgated under
the Securities Act, as may be necessary to keep such Registration Statement effective at all times during the Commitment Period, and prepare
and file with the SEC such additional Registration Statements in order to register for resale under the Securities Act all of the Registrable
Securities; (ii) cause the related prospectus to be amended or supplemented by any required prospectus supplement (subject to the terms
of this Agreement), and as so supplemented or amended to be filed pursuant to Rule 424 promulgated under the Securities Act; (iii) provide
the Investor copies of all correspondence from and to the SEC relating to a Registration Statement (provided that the Company may excise
any information contained therein which would constitute material non-public information), and (iv) comply with the provisions of the
Securities Act with respect to the disposition of all the Shares covered by such Registration Statement until such time as all of such
Shares shall have been disposed of in accordance with the intended methods of disposition by the seller or sellers thereof as set forth
in such Registration Statement. In the case of amendments and supplements to a Registration Statement which are required to be filed pursuant
to this Agreement (including pursuant to this Section 6.01(e)) by reason of the Company's filing a report on Form 20-F, Form 6-K,
or any analogous report under the Exchange Act, the Company shall use commercially reasonable efforts to file such report in a prospectus
supplement filed pursuant to Rule 424 promulgated under the Securities Act to incorporate such filing into the Registration Statement,
if applicable, or shall file such amendments or supplements with the SEC either on the day on which the Exchange Act report is filed which
created the requirement for the Company to amend or supplement the Registration Statement, if feasible, or otherwise promptly thereafter.

&nbsp;&nbsp;&nbsp;&nbsp;f. <u>Blue-Sky</u>. The Company shall use its commercially reasonable efforts to, if required by Applicable
Law, (i) register and qualify the Shares covered by a Registration Statement under such other securities or "blue sky" laws
of such jurisdictions in the United States as the Investor reasonably requests, (ii) prepare and file in those jurisdictions, such amendments
(including post-effective amendments) and supplements to such registrations and qualifications as may be necessary to maintain the effectiveness
thereof during the Commitment Period, (iii) take such other actions as may be necessary to maintain such registrations and qualifications
in effect at all times during the Commitment Period, and (iv) take all other actions reasonably necessary or advisable to qualify the
Shares for sale in such jurisdictions; provided, however, that the Company shall not be required in connection therewith or as a condition
thereto to (w) make any change to its certificate of incorporation or bylaws, (x) qualify to do business in any jurisdiction where it
would not otherwise be required to qualify but for this Section 6.01(f), (y) subject itself to general taxation in any such jurisdiction,
or (z) file a general consent to service of process in any such jurisdiction. The Company shall promptly notify the Investor of the receipt
by the Company of any notification with respect to the suspension of the registration or qualification of any of the Shares for sale under
the securities or "blue sky" laws of any jurisdiction in the United States or its receipt of actual notice of the initiation
or threat of any proceeding for such purpose.

**Section 6.02 Suspension of Registration Statement**.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. <u>Establishment of a Black Out Period</u>. During the Commitment Period, the Company may from time to
time suspend the use of the Registration Statement by written notice to the Investor in the event that the Company determines in its sole
discretion in good faith that such suspension is necessary to (A) delay the disclosure of material nonpublic information concerning the
Company, the disclosure of which at the time is not, in the good faith opinion of the Company, in the best interests of the Company or
(B) amend or supplement the Registration Statement or prospectus so that such Registration Statement or prospectus shall not include an
untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements
therein, in light of the circumstances under which they were made, not misleading (a " <u>Black Out Period</u> "). With respect
to any updated registration statement or post-effective amendment to the registration statement, such blackout period shall continue until
such time as the registration statement or post-effective amendment thereto has been filed and declared effective by the SEC.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. <u>No Sales by Investor During the Black Out Period</u>. During such Black Out Period, the Investor agrees
not to sell any Ordinary Shares of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c. <u>Limitations on the Black Out Period</u>. The Company shall not impose any Black Out Period that is
longer than 60 days or in a manner that is more restrictive (including, without limitation, as to duration) than the comparable restrictions
that the Company may impose on transfers of the Company's equity securities by its directors and senior executive officers. In addition,
the Company shall not deliver any Advance Notice during any Black Out Period. If the public announcement of such material, nonpublic information
is made during a Black Out Period, the Black Out Period shall terminate immediately after such announcement, and the Company shall immediately
notify the Investor of the termination of the Black Out Period.

**Section 6.03 Listing of the Ordinary Shares**. As of each Advance Date, the Shares to be sold by the Company from time to time hereunder will have been registered under Section 12(b) of the Exchange Act and approved for listing on the Principal Market or other Trading Market, subject to official notice of issuance.

**Section 6.04 Opinion of Counsel**. Prior to the date of the delivery by the Company of the first Advance Notice, the Investor shall have received an opinion from the Company's Israeli counsel in form and substance reasonably satisfactory to the Investor.

**Section 6.05 Exchange Act Registration**. The Company will use commercially reasonable efforts to file in a timely manner all reports and other documents required of it as a reporting company under the Exchange Act and will not take any action or file any document (whether or not permitted by Exchange Act or the rules thereunder) to terminate or suspend its reporting and filing obligations under the Exchange Act.

**Section 6.06 Transfer Agent Instructions**. So long as there is a Registration Statement in effect for this transaction, the Company shall (if required by the transfer agent for the Ordinary Shares) cause legal counsel for the Company to deliver to the transfer agent for the Ordinary Shares (with a copy to the Investor) instructions to issue Ordinary Shares to the Investor free of restrictive legends upon each Advance if the delivery of such instructions are consistent with Applicable Law and the Investor has provided the Transfer Agent Deliverables with respect to such Ordinary Shares required by this Agreement.

**Section 6.07 Corporate Existence**. The Company will use commercially reasonable efforts to preserve and continue the corporate existence of the Company during the Commitment Period.

**Section 6.08 Notice of Certain Events Affecting Registration; Suspension of Right to Make an Advance**. The Company will promptly notify the Investor, and confirm in writing, upon its becoming aware of the occurrence of any of the following events in respect of a Registration Statement or related prospectus relating to an offering of Ordinary Shares (in each of which cases the information provided to Investor will be kept strictly confidential): (i) except for requests made in connection with SEC or other Federal or state governmental authority investigations disclosed in the SEC Documents, receipt of any request for additional information by the SEC or any other Federal or state governmental authority during the period of effectiveness of the Registration Statement or any request for amendments or supplements to the Registration Statement or related prospectus; (ii) the issuance by the SEC or any other Federal governmental authority of any stop order suspending the effectiveness of the Registration Statement or the initiation of any proceedings for that purpose; (iii) receipt of any notification with respect to the suspension of the qualification or exemption from qualification of any of the Ordinary Shares for sale in any jurisdiction or the initiation or written threat of any proceeding for such purpose; (iv) the happening of any event that makes any statement made in the Registration Statement or related prospectus or any document incorporated or deemed to be incorporated therein by reference untrue in any material respect or that requires the making of any changes in the Registration Statement, related prospectus or documents so that, in the case of the Registration Statement, it will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein not misleading, and that in the case of the related prospectus, it will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading, or of the necessity to amend the Registration Statement or supplement a related prospectus to comply with the Securities Act or any other law; and (v) the Company's reasonable determination that a post-effective amendment to the Registration Statement would be appropriate; in which case the Company will prepare and promptly make available to the Investor any such supplement or amendment to the related prospectus. The Company shall not deliver to the Investor any Advance Notice, and the Company shall not sell any Shares pursuant to any Advance Notice (other than as required pursuant to Section 2.05(b)), during the continuation of any of the foregoing events in clauses (i) through (v) above, or in the event that (vi) there shall be no bid for the Ordinary Shares on the Principal Market or Trading Market for a period of 15 consecutive minutes at any time during the applicable Pricing Period or (vii) there shall be a "trading halt" or circuit breaker" event with respect to the Ordinary Shares on the Principal Market or Trading Market during the applicable Pricing Period (each of the events described in the immediately preceding clauses (i) through (vii), inclusive, a "<u>Material Outside Event</u>").

**Section 6.09 Consolidation**. If an Advance Notice has been delivered to the Investor, then the Company shall not effect any consolidation of the Company with or into, or a transfer of all or substantially all the assets of the Company to another entity before the transaction contemplated in such Advance Notice has been closed in accordance with Section 2.03 hereof, and all Shares issuable in connection with such Advance have been received by the Investor.

**Section 6.10 Change of Domicile**. If, at any time during the Commitment Period, the Company's jurisdiction of incorporation or domicile is changed (including, without limitation, as a result of any merger, continuation, reorganization or similar transaction), the Company and the Investor shall promptly cooperate in good faith to enter into such amendments to this Agreement and the other Transaction Documents as may be reasonably necessary to (a) update any references in this Agreement and the other Transaction Documents to the Company's jurisdiction of incorporation or domicile and related terms and concepts, and (b) ensure that this Agreement and the other Transaction Documents remain valid, binding and enforceable and otherwise in compliance with the governing law of the Company's new jurisdiction of incorporation or domicile. No amendment entered into pursuant to this Section 6.10 shall, individually or in the aggregate, materially and adversely affect the rights, benefits or remedies of the Investor under this Agreement or any other Transaction Document, except to the extent required in order to comply with Applicable Law.

**Section 6.11 Israeli Law Limitations on Advances**. Notwithstanding anything to the contrary contained in this Agreement, the parties acknowledge and agree that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) the number of Shares issuable pursuant to any Advance Notice shall not exceed the maximum number of Shares that may be issued by the Company to the Investor pursuant to such Advance Notice under applicable Israeli law then in effect; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) the Purchase Price applicable to any Advance shall in no event be less than the minimum price per Share that the Company is permitted to receive for the issuance of the Shares under applicable Israeli law then in effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) If, with respect to any Advance Notice, (i) the number of Shares otherwise issuable hereunder would exceed such maximum number of Shares permitted to be issued under applicable Israeli law, or (ii) the Purchase Price otherwise determined hereunder would be less than such minimum price per Share permitted under applicable Israeli law, then, in each case, the number of Shares issuable pursuant to such Advance Notice and/or the amount of such Advance shall be automatically reduced (or the applicable Advance Notice shall be deemed automatically modified) to the extent necessary to comply with such requirements, without any further action on the part of either party. For the avoidance of doubt, nothing in this Section 6.11 shall obligate the Investor to purchase any Shares that cannot be validly issued in compliance with applicable Israeli law.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Notwithstanding anything to the contrary contained in the Company's Articles of Association or applicable Israeli law, the Company hereby covenants and agrees that, with respect to any Ordinary Shares issued pursuant to this Agreement, the Board of Directors shall not make, and the Company shall not demand, enforce or collect, any call or other payment in respect of the nominal (par) value of such Shares in excess of the Purchase Price actually paid for such Shares pursuant to this Agreement, and such Shares shall be deemed fully paid and non-assessable upon issuance for all purposes.

**Section 6.12 Issuance of Ordinary Shares**. The issuance and sale of Ordinary Shares hereunder shall be made in accordance with the provisions and requirements of Section 4(a)(2) of the Securities Act or Regulation D under the Securities Act and any applicable state securities law.

**Section 6.13 Market Activities**. The Company will not, directly or indirectly, take any action designed to cause or result in, or that constitutes or might reasonably be expected to constitute, the stabilization or manipulation of the price of any security of the Company under Regulation M of the Exchange Act, with the exception of any open market purchases made within the safe harbor provided by Rule 10b-18 under the Exchange Act.

**Section 6.14 Expenses**. The Company, whether or not the transactions contemplated hereunder are consummated or this Agreement is terminated, will pay all expenses incident to the performance of its obligations hereunder, including but not limited to (i) the preparation, printing and filing of the Registration Statement and each amendment and supplement thereto, of each prospectus and of each amendment and supplement thereto; (ii) the preparation, issuance and delivery of any Shares issued pursuant to this Agreement, (iii) all reasonable fees and disbursements of the Company's counsel, accountants and other advisors, (iv) the qualification of the Shares under securities laws in accordance with the provisions of this Agreement, including filing fees in connection therewith, (v) the printing and delivery of copies of any prospectus and any amendments or supplements thereto, (vi) the fees and expenses incurred in connection with the listing or qualification of the Shares for trading on the Principal Market or Trading Market, or (vii) filing fees of the SEC and the Principal Market or Trading Market.

**Section 6.15 Material Non-Public Information**. The Company shall not, and the Company shall cause each of its and their respective officers, directors, employees and agents not to, provide the Investor with any material, non-public information regarding the Company without the express prior written consent of the Investor (which may be granted or withheld in the Investor's sole discretion and must include an agreement to keep such information confidential until publicly disclosed or 45 days have passed); it being understood that the mere notification of Investor required pursuant to Section 6.08(iv) hereof shall not in and of itself be deemed to be material non-public information. Notwithstanding anything contained in this Agreement to the contrary, the Company expressly agrees that it shall use its commercially reasonable efforts to publicly disclose, no later than 45 days following the date hereof, but in any event prior to delivering the first Advance Notice hereunder, any information communicated to the Investor by or, to the knowledge of the Company, on behalf of the Company in connection with the transactions contemplated herein, which, following the date hereof would, if not so disclosed, constitute material, non-public information regarding the Company.

**Section 6.16 Advance Notice Limitation**. The Company shall not deliver an Advance Notice if a stockholder meeting or corporate action date, or the record date for any stockholder meeting or any corporate action, would fall during the period beginning two Trading Days prior to the date of delivery of such Advance Notice and ending two Trading Days following the Closing of such Advance.

**Section 6.17 Use of Proceeds**. The Company will use the proceeds from the sale of the Ordinary Shares hereunder for working capital and other general corporate purposes or, if different, in a manner consistent with the application thereof described in the Registration Statement. Neither the Company will, directly or indirectly, use the proceeds of the transactions contemplated herein, or lend, contribute, facilitate or otherwise make available such proceeds to any Person (i) to fund, either directly or indirectly, any activities or business of or with any Person that is identified on the list of Specially Designated Nationals and Blocker Persons maintained by OFAC, or in any country or territory, that, at the time of such funding, is, or whose government is, the subject of Sanctions or Sanctions Programs, or (ii) in any other manner that will result in a violation of Sanctions.

**Section 6.18 Compliance with Laws**. The Company and the Investor shall comply in all material respects with all Applicable Laws.

**Section 6.19 Aggregation**. From and after the date of this Agreement, neither the Company, nor or any of its affiliates will, and the Company shall use its commercially reasonable efforts to ensure that no Person acting on their behalf will, directly or indirectly, make any offers or sales of any security or solicit any offers to buy any security, under circumstances that would cause this offering of the Ordinary Shares by the Company to the Investor to be aggregated with other offerings by the Company in a manner that would require stockholder approval pursuant to the rules of the Principal Market or Trading Market on which any of the securities of the Company are listed or designated, unless stockholder approval is obtained before the closing of such subsequent transaction in accordance with the rules of such Principal Market or Trading Market.

**Section 6.20 Other Transactions**. The Company shall not enter into, announce or recommend to its stockholders any agreement, plan, arrangement or transaction in or of which the terms thereof would restrict, materially delay, conflict with or impair the ability or right of the Company to perform its obligations under the Transaction Documents, including, without limitation, the obligation of the Company to deliver the Shares to the Investor in accordance with the terms of the Transaction Documents. For the avoidance of doubt, nothing in this Section 6.20 shall restrict or impair the Company's ability to conduct any "at the market offering" (as defined in Rule 415 under the Securities Act) or complete the transactions contemplated by the Merger.

**Section 6.21 Integration**. From and after the date of this Agreement, neither the Company, nor or any of its affiliates will, and the Company shall use its commercially reasonable efforts to ensure that no Person acting on their behalf will, directly or indirectly, make any offers or sales of any security or solicit any offers to buy any security, under circumstances that when combined with the offering of securities hereunder would require registration of the offer and sale of any of the securities under the Securities Act prior to the issuance of securities hereunder.

**Section 6.22 (Reserved.)**

**Section 6.23 DTC**. The Company shall take all commercially reasonable action required to ensure that its Ordinary Shares can be transferred electronically as DWAC Shares if the Transfer Agent Deliverables with respect to such Ordinary Shares have been provided by the Investor.

**Section 6.24 Confidential Information**. Each party hereto agrees not to disclose any Confidential Information of the other party to any third party and shall not use the Confidential Information for any purpose other than in connection with, or in furtherance of, the transactions contemplated hereby in full compliance with applicable securities laws; provided, however that a party may disclose Confidential Information that is required by law to be disclosed by the receiving party, provided that the receiving party gives the disclosing party prompt written notice of such requirement prior to such disclosure and assistance in obtaining an order protecting the information from public disclosure. Each party hereto acknowledges that the Confidential Information shall remain the property of the disclosing party and agrees that it shall take all reasonable measures to protect the secrecy of any Confidential Information disclosed by the other party.

**Section 6.25 Prohibition of Short Sales and Hedging Transactions**. The Investor agrees that beginning on the date of this Agreement and ending on the date of termination of this Agreement as provided in Section 11, the Investor and its agents, representatives and affiliates shall not in any manner whatsoever enter into or effect, directly or indirectly, any (i) "short sale" (as such term is defined in Rule 200 of Regulation SHO of the Exchange Act) of the Ordinary Shares (excluding transactions properly marked "short exempt") or (ii) hedging transaction, which establishes a net short position with respect to the Ordinary Shares; provided that the Company acknowledges and agrees that upon receipt of an Advance Notice the Investor has the right to sell (a) the Shares to be issued to the Investor pursuant to such Advance Notice prior to receiving such Shares, or (b) other Ordinary Shares issued or sold by the Company to the Investor pursuant to this Agreement and which the Investor has continuously held as a long position.

**Section 6.26 Use of Name**. The Company shall not, directly or indirectly, use the names "Arc Group International", "Arc Group", or "Arc", or any derivations thereof, or logos associated with these names, as the case may be, in any manner or take any action that may imply any relationship with the Investor or any of its affiliates without the prior written consent of the Investor, provided, however, the Investor hereby consents to all lawful uses of these names in the prospectus, statement and other materials that are required by applicable laws or pursuant to the disclosure requirements of the SEC or any state securities authority.

**Article VII**<br> **CONDITIONS FOR DELIVERY OF ADVANCE NOTICE**

**Section 7.01 Conditions Precedent to the Right of the Company to Deliver an Advance Notice**. The right of the Company to deliver an Advance Notice and the obligations of the Investor hereunder with respect to an Advance is subject to the satisfaction by the Company, on each Advance Notice Date (a "<u>Condition Satisfaction Date</u>"), of each of the following conditions:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. <u>Accuracy of the Company's Representations and Warranties</u>. The representations and warranties
of the Company in this Agreement shall be true and correct in all material respects.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. <u>Registration of the Ordinary Shares with the SEC</u>. There is an effective Registration Statement
pursuant to which the Investor is permitted to utilize the prospectus thereunder to resell all of the Registrable Securities. The Company
shall have filed with the SEC all reports, notices and other documents required under the Exchange Act and applicable SEC regulations
during the twelve-month period immediately preceding the applicable Condition Satisfaction Date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c. <u>Authority</u>. The Company shall have obtained all permits and qualifications required by any applicable
state for the offer and sale of all the Shares issuable pursuant to such Advance Notice, or shall have the availability of exemptions
therefrom. The sale and issuance of such Ordinary Shares shall be legally permitted by all laws and regulations to which the Company is
subject.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d. <u>No Material Outside Event or Material Adverse Effect</u>. No Material Outside Event or Material Adverse
Effect shall have occurred and be continuing.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;e. <u>Performance by the Company</u>. Unless waived in advance by the Investor, the Company shall have performed,
satisfied and complied in all material respects with all covenants, agreements and conditions required by this Agreement to be performed,
satisfied or complied with by the Company at or prior the applicable Condition Satisfaction Date including, without limitation, the delivery
of all Ordinary Shares issuable pursuant to all previously delivered Advance Notices and the issuance of all Commitment Fee Shares previously
required to be issued to Investor (for the avoidance of doubt, if the Company shall have performed, satisfied and complied in all material
respects with all covenants, agreements and conditions required by this Agreement at the time of the applicable Condition Satisfaction
Date, but did not comply with any timing requirement set forth herein, then this condition shall be deemed satisfied unless the Investor
is materially prejudiced by the failure of the Company to comply with any such timing requirement). When so requested, and following such
Rule 144 Holding Period and delivery of any required documents from the Investor, the Company will ensure that its legal counsel provides
the Investor with a Rule 144 legal opinion regarding the Commitment Fee Shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;f. <u>No Injunction</u>. No statute, rule, regulation, executive order, decree, ruling or injunction shall
have been enacted, entered, promulgated or endorsed by any court or governmental authority of competent jurisdiction that prohibits or
directly, materially and adversely affects any of the transactions contemplated by this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;g. <u>No Suspension of Trading in or Delisting of the Ordinary Shares</u>. The Ordinary Shares is quoted
for trading on the Principal Market or a Trading Market and all of the Shares issuable pursuant to such Advance Notice will be listed
or quoted for trading on the Principal Market or a Trading Market.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;h. <u>Authorized</u>. There shall be a sufficient number of authorized but unissued and otherwise unreserved
shares of Ordinary Shares for the issuance of all of the Shares issuable pursuant to such Advance Notice.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i. <u>Executed Advance Notice</u>. The representations contained in the applicable Advance Notice shall be
true and correct in all material respects as of the applicable Condition Satisfaction Date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;j. <u>Consecutive Advance Notices</u>. Except with respect to the first Advance Notice, the Pricing Period
for all prior Advances has been completed.

Furthermore, the Company shall not have the right to deliver an Advance Notice to the Investor if any of the following shall occur:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;k. the Company breaches any representation or warranty in any material respect, or breaches any covenant
or other term or condition under any Transaction Document in any material respect, and except in the case of a breach of a covenant which
is reasonably curable, only if such breach continues for a period of at least three (3) consecutive Trading Days;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;l. if any Person commences a proceeding against the Company pursuant to or within the meaning of any Bankruptcy
Law for so long as such proceeding is not dismissed;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;m. if the Company is at any time insolvent, or, pursuant to or within the meaning of any Bankruptcy Law,
(i) commences a voluntary case, (ii) consents to the entry of an order for relief against it in an involuntary case, (iii) consents to
the appointment of a Custodian of it or for all or substantially all of its property, (iv) makes a general assignment for the benefit
of its creditors or (v) the Company is generally unable to pay its debts as the same become due;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;n. a court of competent jurisdiction enters an order or decree under any Bankruptcy Law that (i) is for relief
against the Company in an involuntary case, (ii) appoints a Custodian of the Company or for all or substantially all of its property,
or (iii) orders the liquidation of the Company for so long as such order, decree or similar action remains in effect;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o. if at any time the Company is not eligible or is unable to transfer its Shares to Investor, including,
without limitation, electronically through DTC's Deposit/Withdrawal At Custodian system; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;p. the Shares shall not have been approved by the Investor's prime broker or designated clearing firm
for deposit to its account with the Depository Trust Company system.

**Article VIII**<br> **NON-DISCLOSURE OF NON-PUBLIC INFORMATION**

The Company covenants and agrees that, other than as expressly required by Section 6.08 hereof or, with the Investor's consent pursuant to Section 6.01(c) and 6.13, it shall refrain from disclosing, and shall cause its officers, directors, employees and agents to refrain from disclosing, any material non-public information (as determined under the Securities Act, the Exchange Act, or the rules and regulations of the SEC) directly or indirectly to the Investor or its affiliates, without also disseminating such information to the public, unless prior to disclosure of such information the Company identifies such information as being material non-public information and provides the Investor with the opportunity to accept or refuse to accept such material non-public information for review. Unless specifically agreed to in writing, in no event shall the Investor have a duty of confidentiality, or be deemed to have agreed to maintain information in confidence, with respect to the delivery of any Advance Notices.

**Article IX**<br> **NON-EXCLUSIVE AGREEMENT**

Notwithstanding anything contained herein, this Agreement and the rights awarded to the Investor hereunder are non-exclusive, and the Company may, at any time throughout the term of this Agreement and thereafter, if permitted by the terms of the Agreement, issue and allot, or undertake to issue and allot, any shares and/or securities and/or convertible notes, bonds, debentures, options to acquire shares or other securities and/or other facilities which may be converted into or replaced Ordinary Shares or other securities of the Company, and to extend, renew and/or recycle any bonds and/or debentures, and/or grant any rights with respect to its existing and/or future share capital.

**Article X**<br> **CHOICE OF LAW/JURISDICTION**

This Agreement shall be governed by and interpreted in accordance with the laws of the State of New York without regard to the principles of conflict of laws. The parties further agree that any action between them shall be heard in New York County, New York, and expressly consent to the jurisdiction and venue of the Supreme Court of New York, sitting in New York County, New York and the United States District Court of the Southern District of New York, sitting in New York, New York, for the adjudication of any civil action asserted pursuant to this Agreement.

**Article XI**<br> **ASSIGNMENT; TERMINATION**

**Section 11.01 Assignment**. Neither this Agreement nor any rights or obligations of the parties hereto may be assigned to any other Person.

**Section 11.02 Termination**.

&nbsp;&nbsp;&nbsp;&nbsp;a. Unless earlier terminated as provided hereunder, this Agreement shall terminate automatically on the earliest
of (i) the day that is the 36-month anniversary of the date hereof or (ii) the date on which the Investor shall have made payment of Advances
pursuant to this Agreement for Ordinary Shares equal to the Commitment Amount.

&nbsp;&nbsp;&nbsp;&nbsp;b. The Company may terminate this Agreement effective upon five (5) Trading Days' prior written notice
to the Investor; provided that (i) there are no outstanding Advance Notices, the Ordinary Shares in respect of which has yet to be issued,
and (ii) the Company has paid all amounts owed to the Investor pursuant to this Agreement including, without limitation, all Commitment
Fee Shares. This Agreement may be terminated at any time by the mutual written consent of the parties, effective as of the date of such
mutual written consent unless otherwise provided in such written consent.

&nbsp;&nbsp;&nbsp;&nbsp;c. Nothing in this Section 11.02 shall be deemed to release the Company or the Investor from any liability
for any breach under this Agreement, or to impair the rights of the Company and the Investor to compel specific performance by the other
party of its obligations under this Agreement. The indemnification provisions contained in Article V shall survive termination hereunder.

**Article XII**<br> **NOTICES**

Other than with respect to Advance Notices, which must be in writing and will be deemed delivered on the day set forth in Section 2.03 in accordance with <u>Exhibit C</u>, any notices, consents, waivers, or other communications required or permitted to be given under the terms of this Agreement must be in writing and will be deemed to have been delivered (i) upon receipt, when delivered personally; (ii) upon receipt, when sent by facsimile or e-mail if sent on a Trading Day, or, if not sent on a Trading Day, on the immediately following Trading Day; (iii) five (5) days after being sent by U.S. certified mail, return receipt requested, (iv) one (1) day after deposit with a nationally recognized overnight delivery service, in each case properly addressed to the party to receive the same. The addresses and facsimile numbers for such communications (except for Advance Notices which shall be delivered in accordance with <u>Exhibit A</u> hereof) shall be:

---

| | |
|:---|:---|
| If to the Company, to: | [\*\*\*]<br> [\*\*\*]<br> [\*\*\*]<br> [\*\*\*] |
| With a Copy (which shall not constitute notice or delivery of process) to:<br>| [\*\*\*]<br> [\*\*\*]<br> [\*\*\*]<br> [\*\*\*] |
| If to the Investor(s): | [\*\*\*]<br> [\*\*\*]<br> [\*\*\*]<br> [\*\*\*]<br> [\*\*\*]<br> [\*\*\*] |
| With a Copy (which shall not constitute notice or delivery of process) to: | [\*\*\*]<br> [\*\*\*]<br> [\*\*\*]<br> [\*\*\*]<br> [\*\*\*]<br> [\*\*\*]<br> [\*\*\*] |

---

Either party may change its information contained in this Article XII by delivering notice to the other party as set forth herein.

**Article XIII**<br> **MISCELLANEOUS**

**Section 13.01 Counterparts**. This Agreement may be executed in identical counterparts, both which shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party. Facsimile or other electronically scanned and delivered signatures, including by e-mail attachment, shall be deemed originals for all purposes of this Agreement.

**Section 13.02 Entire Agreement; Amendments**. This Agreement supersedes all other prior oral or written agreements between the Investor, the Company, their respective affiliates and persons acting on their behalf with respect to the matters discussed herein, and this Agreement contains the entire understanding of the parties with respect to the matters covered herein and, except as specifically set forth herein, neither the Company nor the Investor makes any representation, warranty, covenant or undertaking with respect to such matters. No provision of this Agreement may be waived or amended other than by an instrument in writing signed by the parties to this Agreement. The provisions of the existing confidentiality agreement between the Investor and the Company shall remain in force, except that all provisions therein dealing with the treatment of material non-public information are superseded by this Agreement.

**Section 13.03 Reporting Entity for the Ordinary Shares**. The reporting entity relied upon for the determination of the trading price or trading volume of the Ordinary Shares on any given Trading Day for the purposes of this Agreement shall be Bloomberg, L.P. or any successor thereto. The written mutual consent of the Investor and the Company shall be required to employ any other reporting entity.

**Section 13.04 Expenses; Commitment Fee**.

&nbsp;&nbsp;&nbsp;&nbsp;a. Each of the parties shall pay its own fees and expenses (including the fees of any attorneys, accountants,
appraisers or others engaged by such party) in connection with this Agreement and the transactions contemplated hereby, except that the
Company shall be responsible for all payment of Investor's legal fees (and will provide proof of any retainer payments and engagement
letters to the extent requested), which shall not exceed $40,000 in the aggregate, and Investor acknowledges and agrees that the Company
has already paid $10,000 of such aggregate amount.

&nbsp;&nbsp;&nbsp;&nbsp;b. In consideration for the parties mutual covenants and agreements contained herein and their respective
execution and delivery of this Agreement, upon the execution and delivery of this Agreement, the Company shall issue or cause to be issued
to the Investor as a commitment fee on the date hereof, such number of Ordinary Shares having an aggregate value of 1.5% of the Commitment
Amount (the "Commitment Fee Shares"). The number of Commitment Fee Shares issued shall (i) be equal to 1.5% of the Commitment
Amount divided by the lowest one-day VWAP during the five (5) Trading Days immediately preceding the entry into this Agreement, and (ii)
bear a standard restrictive legend. For the avoidance of doubt, (i) the Commitment Fee Shares shall be fully earned as of the Execution
Date, and the issuance of the Commitment Fee Shares is not contingent upon any other event or condition, (ii) the Company shall include
on the Registration Statement filed with the SEC (to the extent that one is filed), all of the Commitment Fee Shares, and (iii)
no cash payment is due by the Investor for the Commitment Fee Shares issued to it by the Company pursuant to the terms of this Agreement.
Within three (3) Trading Days of the Effective Date or the end of the Rule 144 Holding Period, whichever occurs first, the Company and
its counsel shall deliver an instruction letter and opinion of counsel allowing the Commitment Fee Shares to be freely transferable. The
Investor agrees that, when reselling the Commitment Fee Shares, it will not sell on any Trading Day a number of such Commitment Fee Shares
that exceeds 10% of the Daily Value Traded of the Ordinary Shares on such Trading Day.

**Section 13.05 Brokerage**. Except as set forth on <u>Schedule 13.05</u>, each of the parties hereto represents that it has had no dealings in connection with this transaction with any finder or broker who will demand payment of any fee or commission from the other party. The Company on the one hand, and the Investor, on the other hand, agree to indemnify the other against and hold the other harmless from any and all liabilities to any person claiming brokerage commissions or finder's fees on account of services purported to have been rendered on behalf of the indemnifying party in connection with this Agreement or the transactions contemplated hereby.

[***REMAINDER OF PAGE INTENTIONALLY LEFT BLANK***]

**IN WITNESS WHEREOF**, the parties hereto have caused this Purchase Agreement to be executed by the undersigned, thereunto duly authorized, as of the date first set forth above.

---

| | |
|:---|:---|
| **COMPANY**: | **COMPANY**: |
| **Check-Cap Ltd.** | **Check-Cap Ltd.** |
| By: | /s/ David Lontini |
| Name: | David Lontini |
| Title: | Interim CEO |
| **INVESTOR**: | **INVESTOR**: |
| **Arc Group International Ltd.** | **Arc Group International Ltd.** |
| By: | /s/ Abraham Cinta |
| Name: | Abraham Cinta |
| Title: | Chief Executive Officer |

---

[*Signature Page to Purchase Agreement*]

**<u>EXHIBIT A</u>**

**ADVANCE NOTICE**

Check-Cap Ltd.

Dated: ______________ Advance Notice Number: ____

The undersigned, _______________________, hereby certifies, with respect to the sale of ordinary shares, par value NIS 48.00 per share (the "<u>Ordinary Shares</u>"), of Check-Cap Ltd. (the "<u>Company</u>") issuable in connection with this Advance Notice, delivered pursuant to that certain Purchase Agreement, dated as of [__], 2025 (the "<u>Agreement</u>"), as follows:

1 The undersigned is the duly elected ______________ of the Company.

2 There are no fundamental changes to the information set forth in the Registration Statement which would require the Company to file a post-effective amendment to the Registration Statement.

3 All conditions to the delivery of this Advance Notice are satisfied as of the date hereof.

---

| | |
|:---|:---|
| 4 | The amount of Ordinary Shares issued in respect of such Advance is: |

---

5 The number of shares of Ordinary Shares of the Company issued and outstanding as of the date hereof is ___________.

6 The Pricing Period shall be three (3) Trading Days.

The undersigned has executed this Advance Notice as of the date first set forth above.

---

| |
|:---|
| **Check-Cap Ltd.** |
| By: |
| Name: |
| Title: |

---

**<u>EXHIBIT B</u>**

**FORM OF SETTLEMENT DOCUMENT**

**VIA EMAIL**

**CHECK-CAP LTD.**

Attn:

Email:

Subject:

Below please find the settlement information with respect to the Advance Notice Date of:

1. Amount of Advance requested in the Advance Notice

2. Time of Advance:

---

| |
|:---|
| Sincerely, |
| [**Arc Group International Ltd.]** |
| By: |
| Name: |
| Title: |

---

---

| |
|:---|
| **Agreed and Approved**: |
| **Check-Cap Ltd.** |
| By: |
| Name: |
| Title: |

---

**<u>EXHIBIT C</u>**

**VIA EMAIL**

Email:

Subject: ELOC: Check-Cap Ltd.

Advance Notice

Below please find the Advance Notice Date of:

1. Amount of Advance Shares:

2. Time of Advance:

**<u>SCHEDULE 1</u>**

**Authorized Representatives**

The following individuals may execute Advance Notices:

1. David Lontini

2. **<u>Disclosure Schedule 4.04 (Merger-Related Financial Information)</u>**

The Company has publicly announced and entered into an Agreement and Plan of Merger with MBody AI Corp. In connection with such transaction, the Company expects to file, certain historical financial statements of MBody AI Corp. and unaudited and/or audited pro forma combined financial information reflecting the proposed merger (the "Merger Financial Information").

Notwithstanding anything to the contrary in Section 4.04 of the Agreement, the representations and warranties set forth in Section 4.04 do not apply to the Merger Financial Information to the extent such information has not yet been filed with the SEC, is subject to completion, audit, review, adjustment, or amendment, or is otherwise permitted to be omitted, modified, or supplemented in accordance with applicable SEC rules and regulations.

The Company represents that any Merger Financial Information, when filed, will be prepared in accordance with applicable SEC requirements in all material respects.

**<u>Disclosure Schedule 13.05 (Brokerage)</u>**

[Parties to provide if necessary]

## Exhibit 23.1

**Exhibit 23.1**

![](ex23-1_001.jpg)

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

We consent to the incorporation by reference in this Registration Statement on Form F-1 of our report dated March 31, 2023, relating to the financial statements of Check-Cap Ltd. (the "Company") appearing in the Annual Report on Form 20-F of the Company for the year ended December 31, 2022. We also consent to the reference to us under the heading "Experts" in such Registration Statement.

/s/ Brightman Almagor Zohar & Co.

**Brightman Almagor Zohar & Co.** 

**Certified Public Accountants** 

**A Firm in the Deloitte Global Network** 

Tel Aviv, Israel

January 30, 2026

![](ex23-1_002.jpg)

## Exhibit 23.2

**Exhibit 23.2**

---

| | |
|:---|:---|
| ![](ex23-2_001.jpg) | ***New York Office:***<br>805 Third Avenue<br> 14<sup>th</sup> floor<br> New York, NY 10022<br> 212.838-5100<br>***www.rbsmllp.com*** |

---

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

We consent to the incorporation by reference in this Registration Statement on Form F-1 of Check-Cap Ltd. of our report dated August 26, 2025 (which contains an explanatory paragraph relating to the Company's ability to continue as a going concern as described in Note 2 to the consolidated financial statements), relating to the consolidated financial statements of Check-Cap Ltd. as of and for the year ended December 31, 2024 included in its Annual Report on Form 20-F for the year ended December 31, 2024.

We also consent to the reference to us under the heading "Experts" in such Registration Statement.

*/s/ **RBSM LLP***

New York, NY

January 30, 2026

New York, NY Washington DC Mumbai & Pune, India Boca Raton, FL

Houston, TX San Francisco, CA Las Vegas, NV Beijing, China Athens, Greece

Member: ANTEA International with affiliated offices worldwide

## Exhibit 23.3

**Exhibit 23.3**

![](ex23-3_001.jpg)

**Fahn Kanne & Co.**<br> Head Office<br> 32 Hamasger Street<br> Tel-Aviv 6721118, ISRAEL<br> PO Box 36172, 6136101<br>T +972 3 7106666<br> F +972 3 7106660<br> www.gtfk.co.il<br>

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

We have issued our report dated May 15, 2024 with respect to the consolidated financial statements of Check Cap Ltd. included in the Annual Report on Form 20-F for the year ended December 31, 2023, which are incorporated by reference in this Registration Statement. We consent to the incorporation by reference of the aforementioned report in this Registration Statement, and to the use of our name as it appears under the caption "Experts."

/s/ FAHN KANNE & CO. GRANT THORNTON ISRAEL

**FAHN KANNE & CO. GRANT THORNTON ISRAEL**

Tel Aviv, Israel

January 30, 2026

**Certified Public Accountants**

Fahn Kanne & Co. is the Israeli member firm of Grant Thornton International Ltd.

## Exhibit 23.4

**Exhibit 23.4**

---

| | |
|:---|:---|
| ![](ex23-4_001.jpg) | **200 Spectrum Center Drive, Suite 300**<br> **Irvine, CA 92618**<br> **(714) 234-5980**<br> **www.BCRGCPAS.com** |

---

**Consent of Independent Registered Public Accounting Firm**

We consent to the incorporation by reference in this Registration Statement on Form F-1 of Check-Cap Ltd. of our audit report dated November 12, 2025, relating to the financial statements of MBody AI Corp. as of December 31, 2024 and June 30, 2025, and for the periods from October 7, 2024 (date of formation) to December 31, 2024, and for the six months ended June 30, 2025, respectively.

We also consent to the reference to us as an expert under the heading "Experts" in such Registration Statement.

![](ex23-4_002.jpg)

Irvine, California

January 30, 2026

## Ex-Filing

?xml version='1.0' encoding='ASCII'? Filing Fee Exhibit

**Ex-Filing Fees**

**CALCULATION OF FILING FEE TABLES**

**F-1**

**CHECK-CAP LTD.**

**Table 1: Newly Registered and Carry Forward Securities**

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Line Item Type** | **Security Type** | **Security Class Title** | **Notes** | **Fee Calculation<br> Rule** | **Amount Registered** | **Proposed Maximum Offering<br> Price Per Unit** | **Maximum Aggregate Offering Price** | **Fee Rate** | **Amount of Registration Fee** |
| *Newly Registered Securities* | *Newly Registered Securities* | *Newly Registered Securities* | *Newly Registered Securities* | *Newly Registered Securities* | *Newly Registered Securities* | *Newly Registered Securities* | *Newly Registered Securities* | *Newly Registered Securities* | *Newly Registered Securities* |
| Fees to be Paid | Equity | Ordinary Shares, par value NIS 48.00 per share | (1) | Other | 2267857 | $1.51 | $3424464.07 | 0.0001381 | $473.00 |
| Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | $3424464.07 |  | 473.00 |
| Total Fees Previously Paid: | Total Fees Previously Paid: | Total Fees Previously Paid: | Total Fees Previously Paid: | Total Fees Previously Paid: | Total Fees Previously Paid: | Total Fees Previously Paid: |  |  | 0.00 |
| Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: |  |  | 0.00 |
| Net Fee Due: | Net Fee Due: | Net Fee Due: | Net Fee Due: | Net Fee Due: | Net Fee Due: | Net Fee Due: |  |  | $473.00 |

---

**__________________________________________ Offering Note(s)**

&nbsp;&nbsp;&nbsp;&nbsp;(1) Pursuant to Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), the ordinary shares being registered hereunder include such indeterminate number of ordinary shares as may be issuable with respect to the ordinary shares being registered hereunder as a result of stock splits, stock dividends or similar transactions. Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(c) of the Securities Act, on the basis of the average of the high and low prices for an ordinary share of the Registrant as reported on The Nasdaq Capital Market on January 23, 2026, which date is a date within five business days prior to the filing of this registration statement. The Registrant will not receive any proceeds from the sale of its ordinary shares by the selling stockholder. All of the ordinary shares are to be offered for resale by the selling stockholder named in the prospectus contained in this Registration Statement on Form F-1.